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HAPTER 1 
GENERAL INTRODUCTION 
AND AIMS OF THE STUDIES 
Chapter 1 
1.1 GENERAL INTRODUCTION 
Respiratory syncytial virus (RSV) is the most important cause of viral respiratory 
h'act infections in infants and yOlUlg children '. TI,e munber of infants which are 
atmually hospitalised with acute bronchiolitis in 111e Netherlands is depicted in Figure 
1.1. TIle virlls causes yearly outbreaks 'with a seasonal distribution 2,3. Nearly all 
children have been infected by the virus at least once by the age of two years '. 
1. 1. 1 VIROLOGICAL ASPECTS 
RSV is classified within the genus p"ellllloviridae of the family of paralllyxoviridae. 
Two major subtypes ofRSV (A and B) Catl be identified by the use of specific monoclonal 
antibodies 5.'. Both subtypes can circulate simultatleously or independently during an 
epidemic (Figme 1.2). TI,e proportion varies evety season and per geographic location, 
although a predominance of subtype A is usually noted 7.8. Dming an outbreak various 
atltigenically distinct strains can be fOlUld. Multiple evolutionaty lineages of RSV 
cocirculate globally during a single epidemic. For instance, an identical strain was 
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Figure 1.1 Nllmber of infallts youllger tlIml 12 months of age hospitalised with aC/lle bronchiolitis aCO-9 
diag1Iosis code 466.1) mId 1l1lmller of positive RSV isolates l,etweell 1988 alld 1998. TIle closed bars represent 
tlte Il11l1/ber of hospitalised illfmlls (data from SIGjlllformaticccl1fYllm voor de gezondlteidszorg), tlte cOl1tillllcd 
line represents the Il11111ber of positive RSV isolates (data kindly supplied by Dr. M.L. Heijl1en, National 
Illstitute of Public Health and the Environment (RWM), The Netherlands) 
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Figure 1.2 Distributioll of RSV subtypes A alld B ill all palicllts diagnosed betweell 1990 - 1998 at the 
Sophia ClIifdrell's Hospital, Rotterdam (data killdly supplied by A.H. Bralldelll)J[rg MD, Departmellt of 
Virology, LIniversity Hospital Rotterdam, Tlte Neflterlmlds) 
f01Uld in Hannover, Germany and Montevideo, Uruguay during the srune epidemic 9. 
Several investigators previously reported that subgroup A infections lead to a 1110re 
severe disease COlU'se 7,10-12. Hmvever, other groups could not confirnl a relationship 
between subtype and severity of disease 13-16, 
1,1,2 EPIDEMIOLOGY OF INFECTIONS BY RSV 
RSV infections are relatively uncommon dming the first month of life ", The clinical 
presentation of RSV infection Inay vary geographically, even ,,,,ithin one country or 
continent 18, ", The disease course of RSV infection is similar in tropical and developed 
countries 20, Epidelnics usually last five to sLx n10nths with the highest incidence 
dming the third or fourth month of the epidemic ", Not all infections by RSV result in 
lower resph'atory tract disease 22, The UHouston Family" study, carried out between 
1975 and 1980, demonstrated RSV associated lower respiratory tract disease in 21.6% 
of a cohort of children followed during their first year of life " In a hospitalised 
population RSV may be accolintable for up to 13% of the upper respiratory h'act 
infections and approximately 65% to 90% of the lower respiratory tract diseases 
(bronchiolitis and/ or pnemnonia) 23 Reinfections with RSV occur frequently and tend 
to be mild 24-26, The majority of RSV lower respiratory h'act disease occurs in infants 
13 
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YOlmger than 12 months of age with a peak incidence between the age of two and six 
Illonths 27, 
Age is a predictor for severity of RSV infection (Figure 1.3) 28, Severe LRT disease 
may occur especially in infants younger than six months of age ", Other risk factors 
include low socio-economic status, day-care attendance, smoking, low nlaternal 
antibody level, nmllber of siblings, overcrmvding, lllonth of birth, air humidity and 
outdoor telnperature 17,30-34. Lmv bil'thweight Inay be a risk factor, because it has been 
proposed that small airways predispose to bronchiolitis 35, Studies on the relationship 
between RSV infections in infancy and the development of atopy have generated 
conflicting data, Some groups suggest that there is no relationship between bronchiolitis 
in infancy and atopy; others have come to the opposite conclusion 3;, Breastfeeding 
Inay protect against RSV infection, but again controversy exists 36,37, 
Underlying conditions that may result in severe RSV infection include 
bronchopulmonary dysplasia (BPD), congenital heart disease (CHD) with 
hemodynamic consequenses i.e, left to right shunting, T-cell immunodeficiency and 
prelnaturlty 38-40. Especially infants with congenital heart disease and pulInonary 
hypertension may be at an increased risk for severe infections by RSV 39,41, ", 
Immunodeficiency, both acquired and congenital, results in increased viral shedding 
and increased Inorbidity 40,43, RSV-associated pneumonia was fotmd aInong patients 
50 
" 
45 
40 ! 
"I 
$ 30-: 
! 25 1 
i , 
z 
"I 
15 
10 
5 j 
o i o 
" 
3 5 6 9 10 
" 
Age In months 
Figure 1.3 Age distribution of illfants diagllosed wUIl RSV illfeelioll lletween 1992 - 1995 at lite Sopltia 
Children's Hospital. Rotterdam 
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with HIV-infection -H, Prernattu'e birth is associated with an increased necessity for 
supplemental oxygen, rnechanical ventilation and adnussion to the intensive care 
unit 45, 
1.1.3 CLINICAL MANIFESTATIONS OF INFECTIONS BY RSV 
The clinical spectrum of RSV-associated disease extends from mild upper 
respiratory tract involvernent to severe lower respiratory tract disease necessitating 
mechanical ventilation, and apnoea. Symptoms by RSV infection usually begin in the 
nasopharynx with coryza and nasal congestion. A low grade fever may be noticed. 
Approximately two to five days later infection may progress to involve the lower 
respiratory tract as shown by the development of cough, dys- and/ or tachypnoea and 
wheezing 46.". Physical examination may reveal tachypnoea, signs of rhinitis, cough, 
chest wall retractions, nasal flaring and seldomly fever. Wheezing may be noted even 
without the use of a stethoscope. On auscultation in- and/ or exspiratory crackles may 
be noted. Hypoxaemia due to a ventilation/perfusion mismatch with or without 
hypercapnia is frequently observed 41;'''. 
Apnoea may be the first clinical sign of RSV infection. The incidence of apnoea in 
hospitalised patients varies between 10% and 20% 49-52, RSV associated apnoea 
specifically occurs in yotmg infants and premature infants 49.51.53. The occurrence of 
apnoeic spells Inay necessitate rnechanical ventilation 53, 
The large majority of infections by RSV have a mild disease course in which neither 
hospitalisation nor the use of medication is indicated. In approxinlately 0.5% to 2% of 
all patients hospital admission is required 17.". The duration of hospitalisation for 
RSV infection varies extensively depending on the geographic area. For instance, in 
the United States and Australia, the mean duration of hospitalisation is four days, 
whereas children spend eight to 10 days in hospital in several European cotmtries ". 
Of all hospitalised patients with infections by RSV, intensive care admission is 
necessary in 15% to 35% 56. In approximately 7% to 21% of hospitalised patients 
mechanical ventilation is indicated because of respiratory distress, hyperapnia or 
recurrent apnoea 56.". Risk factors for mechanical ventilation include yotmg age and 
low weight 53.58. Neonatal RSV infection may follow an atypical course willi nonspecific 
signs 19. Bradycardia may the first presenting sign 59. 
The mortality of infants with RSV infection is low and estimated to be between 1 % 
and 3% in hospitalised children 23. High-risk children have an increased mortality 
rate: 5% - 8% for children with CHO and up to 13% for children with c1u·onic hmg 
disease (CLO) 42.53.60. 
RSV has also been identified as a nosocomial pathogen with infection rates vruying 
15 
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between 5% and 45% of the total munber of (hospitalised) RSV infections and leading 
to a more severe disease COlU'se 61--6-1, Infants at high risk for severe infections by RSV 
have a high hospitalisation rate and are at increased risk for severe nosocomial RSV 
infections 61,65. TIle risk of acquisition of a nosocomial I~SV infection increased with 
increasing stay in hospital for any lmderlying condition 61. Hospital staff are thought 
to be a l1lain vector for the transmission of RSV 66, Various strains Inay be fOlmd runong 
infants and children ·with a nosocOlnial infection. 
1.1.4 THE VALUE OF CHEST RADIOGRAPHY IN INFECTIONS BY RSV 
RSV infections are diagnosed 1l10Stly on clinical sylnptoIlls ·whereas virological 
confinnation is necessary in children adnlitted to the hospital in order to prevent 
nosocomial infections. The clinical cliagnosis of infections by RSV is based upon 
sylnpt0111S such as lvheezing, rales, tachypnoea ruld dyspnoea. In addition, chest 
radiography is often performed. The spectrum of findings on chest radiographs in 
RSV infection may vary from a normal cllest radiograph to atelectasis, hyperinflation 
or pulnlonary infiltrate (Figure 1.4) 67,68. Hmvever, there seems to be no correlation 
between the severity of RSV infection and the findings on chest radiographs ". TIle 
routine use of chest radiographs in the initial management of infections by RSV has 
been questioned 70. 
1.1.5 TREATMENT AND PREVENTION OF INFECTIONS BY RSV 
Treatment ofRSV bronchiolitis has been mainly supportive. Oxygen administration 
and nasogastric hlbe feeding are usually indicated for hospitalised infants. The use of 
Figure 1.4 Cltest radiographs of patients with respiratory syncytial vims ilifecUons showing hyperinflatioll 
(left) and atelectasis (right) (murtesy of F. Jallsen MD, departmellt of Radiology, Cafliarilla Hospital Eilldhovl'l1). 
16 
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bronchodilators, corticosteroids and the antiviral drug ribavirinhave been extensively 
investigated as will be discussed in Chapter 8 71,72,73, Preventive approaches include 
novel therapies such as passive inununisation with RSV-inununoglobulin (RSV-NIG) 
01' 11lonoclonal antibodies such as palivizUlnab n 75, Despite dratna tic effects in the 
'60s with a fonnalin inactived aluln precipitated vaccin, vaccin development is 
currently progressing rapidly and smne of the new vaccines such as subtmit vaccines 
or live attenuated cold passaged-tell/pemtlire sensitive vaccines hold great promise 76,77. 
1. 1,6 LONG TERM EFFECTS OF INFECTIONS BY RSV 
Pulmonary function testing in infants hospitalised with bronchiolitis may either 
reveal increased airway resistance or restrictive, parenchynlallung disease as found 
in RSV pneUlllOlua 78-81, In contrast to these observations, a recent controlled shidy 
including patients with mild/moderate severe RSV bronchiolitis failed to identify 
significant differences in puhnonmy function ", It has also been suggested that pre-
existing abnormalities in lung flmction may be fOlmd mnong clilldren with broncl1iolitis 
when compared to controls m1d that this difference in llmg itmction disappears between 
six and 12 months of age 83, Others observed no increased incidence of airway 
hyperreactivity or pulmonmy itmction eight to twelve years after mild broncluolitis in 
infm1cy 8.1. Bronclual hyperreactivity during RSV broncluolitis may occur 85, 
Bronchiolitis in infm1cy may result in obstructive pulmonmy disease during (em'ly) 
clilldhood 86, Over the years, numerous studies have been published on the relationslup 
between broncluolitis in infm1cy m1d long term morbidity. Wheezing episodes can 
occm up to eight to ten years after RSV broncluolitis in infm1cy 87, It has been suggested 
that RSV bronchiolitis in infm1cy may lead to astluna in later life 83, Two hypothesis 
have been proposed: i) a causal association - RSV induced lower respiratory h'act 
infection directly damages the IW1g leading to long-term morbidity - m1d ii) m1 inherent 
predisposition: RSV infects the predisposed host resulting in severe infection and 
long term morbidity with subsequent asthma 89, Controversy exists whether an atopic 
backgrOlmd is related to long-term morbidity by RSV 83,90, Some clhucal shldies failed 
to identify a relationslup between personal or family Ius tory of atopy m1d respiratory 
morbidity during childhood whereas others identified such a relationship 91.93, 
17 
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1.2 OUTliNE AND AIMS OF THE STUDIES 
This thesis describes the results of epidemiological and clinical studies on infections 
by RSV in infancy. TI,e studies were carried out in the Deparhnent ofPaediah'ics of the 
Sophia Children's Hospital, Rotterdam, a university children's hospital with both 
secondaty and tertiary health care functions. Chapter 2 provides an overview of 
clinical and pathophysiological aspects of RSV infections in yotmg children. 
Specific aims of the shtdies were: 
1. Study of the relationship between the clinical severity of RSV infection and 
subtypes A or B. This issue is addressed in chapter 3. 
2. Evaluation of characteristics of RSV-associated apnoea: identification of 
independent risk factors and assessment of the risk for recurrent apnoea and 
for mechanical ventilation once RSV -associated apnoea occurred. TIlese issues 
are addressed in chapter 4. 
3. To develop a prediction model for a normal chest radiograph based on clinical 
parameters in infants with infections by RSV (chapter 5). 
4. In chapter 6 a previously published model for the prediction of the duration of 
hospitalisation in RSV infections is evaluated and a new model is developed. 
5. In chapter 7 the number of nosocomial infections by RSV over the years and 
the association with morbidity at the Sophia Children's Hospital is shldied. 
FUl'thernlOl'el a revieV\' ofpl'eventive approaches which have to be be undertaken 
to reduce the mmlber of nosocomial RSV infections is presented. 
6. Chapter 8 reviews the therapeutic and preventive approaches in the treatment 
of infections by RSV. 
7. In a quantitative review the long term effects of RSV-bronchiolitis in infancy 
with a focus on the later development of recurrent wheezing/ astimla during 
childhood is evaluated in chapter 9. 
In chapter 10 the results of the previous studies are summarised. Also, 
recommendations for further research are given. Finally, the results of this thesis are 
summarised in Dutch (chapter 11). 
1.2 REFERENCES 
1. Glezen WP, Denny FvV. Epidemiology of acute lower respiratory tract disease in children. N 
Eng! J Mcd 1973;288:498-505 
2. Brandt CD, Kim HVv, Arrobio JA Jeffries BC, Wood SC, Chanock RM, et a1. Epidemiology of 
respiratory syncytial virus infection in Washington DC. HI: composite analysis of eleven 
consecutive yearly epidemicS. Am J Epidemiol 1973;98:355~364 
3. Kimpen JLL. Respiratory syncytial virus: immunology and immunopathogenesis. Thesis 
University Groningen, 1993 
4. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection ·with 
18 
General introduction and aims of the studies 
respiratory syncytial virus, Am J Dis Child 1986;140:543-546 
5. :~vlufson MA, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory 
syncytial virus. J Gen ViroI1985;66:2111-2124 
6. Anderson LJ, Hierholzer JC, Tsou C, Michael HR, Fernie BF, Stone Y, et a1. Antigenic 
characterisation of respiratory syncytial virus strains with monoclonal antibodies, J Infect Dis 
1985;151 :626-633 
7. Taylor CE, Morrow S, Scott M, YotUlg D, Toms GL. Comparative virulence of respiratory 
syncytial virus subgroups A and B. Lancet 1989;1:777-778 
8, Akerlind H, Norrby E, Occurence of respiratory syncytial virus subtypes A and B strains in 
Sweden, J Med Viral 1986;19:241-247 
9. Cane PA, .~ ... Iatthews DA, Pringle CR. Analysis of relatedness of subgroup A respiratory 
syncytial virus isolated worldwide, Virus Res 1992;25:15-22 
10. r..'IcConnochie KM, Hall CB, \Valsh EE, Roghmann KJ, Variation in severity of respiratory 
syncytial virus infections with subtype. J Pediatr 1990;117:52-62 
11. Hall CB, ·Walsh EE, Sdmabel KC, Long CE, McConnochie KM, Hildreth SW, et al. Occurrence 
of groups A and D of respiratory syncytial virus over 15 years: associated epidemiologic and 
clinical characteristics in hospitalised and ambulatory children. J Infect Dis 1990;162:1283-
1290 
12. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection 
is related to virus strain. J Infect Dis 1997;175:814-820 
13. Straliotto Sr..'I, Roitman B, Lima JB, Fischer GB, Siqueira MM. Respiratory syncytial virus 
(RSV) bronchiolitis: comparative study of RSV groups A and B infected children. Rev Soc 
Brasil Med Trop 1994;27:1-4 
14. McIntosh EDGM, De Silva LM, Oates RK Clinical severity of respiratory syncytial virus 
group A and B infection in SydneYi Australia. Pediatr Infect Dis J 1993;12:815-819 
15. Stark JM, Fatemi SH, Amini SB, Huang 'IT. Occurrence of respiratory syncytial virus subtypes 
in hospitalised children in Cleveland, Ohio from 1985 to 1988. Pediatr Pulmonol 1991;11:98-
102 
16, Homsleth A, Klug B, Nir M, Johansen], Hansen KS, Christensen LS, et al. Severity of respiratory 
syncytial virus disease related to type and genotype of virus and to cytokine values in 
nasopharyngeal secretions. Pediatr Infect Dis J 1998;17:1114-1121 
17. Hall CB, Kopelman AE, Douglas RG Jr, Geiman JM, Meagher MP. Neonatal respiratory 
syncytial virus infection. N Engl J Med 1979;300:393-396 
18, Wang EEL, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, et a1. Pediatric 
Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission 
and management variation in patients hospitalised with respiratory syncytial viral lower 
respiratory tract infection. J Pediatr 1996;129:390-395 
19. Brandenburg AH, Jeannet PY, Steensel-Moll HA van, Ott A, Rothbarth PhH, Wtmderli W, et 
a1. Local variability in respiratory syncytial virus disease severity. Arch Dis Child 1997;77:410-
414 
20. Weber wIW, Mulholland EK, Greenwood BM, Respiratory syncytial virus infection in tropical 
and developing countries. Trap Med Int Health 1998;3:268-280 
21. Ruuskanen 0, Ogra PL. Respiratory syncytial virus. Curr Probl Pediatr 1993;23:50-79 
22. Holberg CJ, 'Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD and group health 
medical associates. Risk factors for respiratory syncytial virus associated lower respiratory 
illnesses in the first year of life. Am J EpidemioI1993;133:1135-1151 
23. De Silva LM, Hanlon MG. Respiratory syncytial virus: a report of a 5-year study at a Children's 
Hospial. J Med Virol 1986;19:299-305 
24. Deem M. Repeated infections with respiratory syncytial virus, J Inulluno11967;98:1115-1122 
25. Henderson FW, Collier AM, Clyde Jr "VA, et al. Respiratory syncytial virus infections, reinfections 
and inununity: a prospective, longitudinal study in young children. N Engl J Med 1979;300:530-
534 
26, Hall CH, Walsh EE, Long CE, KC S, Inummity to and frequency of reinfection with respiratory 
syncytial virus, J Infect Dis 1991;163:693-698 
27. Parrot RH, Kim HW, Arrobio JO, Hodes OS, Murphy Bl( Brandt CD, et a1. Epidemiology of 
respiratory syncytial virus infection in Washington DC. II: infection and disease with respect 
to age, inmmnologic status, race and sex. Am J Epidemiol 1973;98:289-300 
28. Kristensen K, Dahnl T, Frederiksen PS, Ibsen J, Iyore E, Jenen At\1, et a1. Epidemiology of 
respiratory syncytial virus infection requiring hospitalisation in East Denmark Pediatr Infect 
Dis J 1998;17:996-1000 
19 
Chapler 1 
29. Berglund B. Studies on respiratory syncytial virus infection. Acta Paediatr Scand 1967;176 
5uppl:9-40 
30. Simoes EAF, King SIr Lehr 1'IV, JR G. Preterm twins and triplets: a high risk group for severe 
respiratory syncytial virus infection. Am J Dis Child 1993;147:303-306 
31. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus 
infection for infants from low-income families in relationship to age, sex, ethnic group, and 
maternal antibody level. J Pediatr 1981;98:708-715 
32. Hortal M, Meny M, Russi Je, Chiparelli H. Meteorological variables and occurrence of 
respiratory syncytial virus in Urugay. Res Viral 1993;144:405-408 
33. Spencer N, Logan 5, Scholey 5, Gentle S. Deprivation and bronchiolitis. Arch Dis Child 
1996;74:50-52 
34. Pullan CR, Toms GL, Martin AJ, Gardner PS, Webb JKG, Appleton DR. Breast-feeding and 
respiratory syncytial virus infection. Br Med J 1980;281:1034-1036 
35. Carlsen KH, Larsen S, Bjerve 0, Leegaard J. Acute bronchiolitis: predisposing factors and 
characterisation of infants at risk. Pediatr Puhnonol 1987;3:153-160 
36. Downham MAPS, Scott R, Sims DG, Webb JKG, Gardner PS. Breast-feeding protects against 
respiratory syncytial virus infections. Br Med J 1976;2:274-276 
37. Golding J. Does breast feeding protect against nongastric infections? Early Human Develop 
1997:49:5105-5120 
38. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with 
bronchopulmonary dysplasia. Pediatrics 1988;82:199-203 
39. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, et al. Respiratory syncytial virus 
infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400 
40. Hall CD, Powell KR, MacDonald NE, Gala CL, Menegus, Suffin SC, et al. Respiratory syncytial 
virus infection in children with compromised immune function. N Engl J Med 1986;315:77-81 
41. Zegher F de, Boeck K de, Devlieger H, Voort Evan der, Elzenga NJ. Respiratory syncytial virus 
infection in infants with tmequal pulmonary perfusion. N Engl J Med 1991;324:1066-1067 
42. Fixler DE. Respiratory syncytial virus infection in children with congenital heart disease: a 
review. Pediatr Cardiol 1996;17:163-168 
43. Pohl C, Green M, Wald ER, Ledesma-Medina J. Respiratory syncytial virus infections in 
paediatric liver transplant recipients. J Infect Dis 1992;165:166-169 
44. Chandwani S, Borkowsky \\', Krasinksi K, Lawrence R, Welliver R. Respiratory syncytial virus 
infection in human imnuUlodeficiency virus-infected children. J Pediatr 1990;117:251-254 
45. Meert KL, Heidemann S, Abella fi, Sarnaik A. Does prematurity alter the course of respiratory 
syncytial virus infection? Crit Care Med 1990;18:1357-1359 
46. La Via ltVV, Marks MI, Stutman HR. Respiratory syncytial virus puzzle: clinical features, 
pathofysiology, treatment and prevention. J Pediatr 1992;121:503-510 
47. Welliver JR, Welliver RC. Bronchiolitis. Pediatr Rev 1993;14:134-139 
48. Hall CB, Hall WJ, Speers DM. Clinical and phYSiological manifestations of bronchiolitis and 
pneumonia. Am J Dis Child 1979;133:798-802 
49. Church f\.TR, Atlas NC, Hall CB, Brooks JC. Respiratory syncytial virus related apnoea in 
infants. Am J Dis Child 1984;138:247-250 
50. Anas N, Boettrich C, Hall CB, Brooks JG. TIle association of apnoea and respiratory syncytial 
virus infection in infants. J Pediatr 1982;101:65-68 
51. Brulm FW, Mokrohisky ST, McIntosh KM. Apnoea associated with respiratory syncytial virus 
infection in young infants. J Pediatr 1977;90:382-386 
52. Colditz PB, Henry RL, De Silva U ... L Apnoea and bronchiolitis due to respiratory syncytial 
virus. Aust Pediatr J 1982;18:53-54 
53. Stretton M, Ajizian SJ, .Mitchell I, Newth CJL. Intensive care course and outcome of patients 
infected with respiratory syncytial virus. Pediatr Pulmonol 1992;13:143-150 
54. Everard ML, Milner AD. TIle respiratory syncytial virus (RSV) and its role in acute bronchiolitis. 
Eur J Pediatr 1992;151:638-651 
55. Behrendt CE, Decker MD, Burch DJ, Watson PH for the international RSV study group. 
International variation in the management of infants hospitalised with respiratory syncytial 
virus. Eur J Pediatr 1998;157:215-220 
56. Steensel-Moll HA van, Voort E van der, Bas AP, Rothbarth PhH, Neijens HJ. Respiratory 
syncytial virus infections in children admitted to the intensive care unit. Pediatrie 1989;44:583-
588 
57. Frankel LR, Lewiston NT, Smith DW, Stevenson DK. Clinical observations on mechanical 
ventilation for respiratory failure in bronchiolitis. Pediatr Pulmonol 1986;2:307-311 
20 
General introductiol1 alld aims of fhe studies 
58. Tissing '''ryE, Steensel-Moll HA van, Offringa ~\'I. Risk factors for mechanical ventilation in 
respiratory syncytial virus infection. Eur J Pediatr 1992;152:125-127 
59. Forster J, Sclnunacher RF. TIle clinical pichue presented by premahuc neonates infected with 
respiratory syncytial virus. Eur J Pediatr 1995;154:901-905 
60. Wang EEL, Law BJ, Stephens D and other members of PICNIC. Pediatric Investigators 
Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors 
and outcomes in patients hospitalised with respiratory syncytial viral lower respiratory tract 
infection. J Pediatr 1995;125:212-219 
61. Hall CB, Douglas Jf RG, Geiman J~ ... f, l\'fessner MK. Nosocomial respiratory syncytial virus 
infections. N Engl J Med 1975;293(26):1343-1346. 
62. Eriksson M, Forsgren M, Sjoberg S, Sydow M von, Olontis S. Respiratory syncytial virus 
infection in young hospitalised children, Acta Paediatr Scand 1983;72:47-51 
63. Okuonghae HO, Nwankwo MU, Okol0 AA, SchuH KE. Nosocomial respiratory syncytial 
virus infection in a newborn nursery. Ann Trop Pediatr 1992;12:185-193 
64. Hornstrup MK, Trommer B, Siboni K, Nielsen B, Kamper J. Nosocomial respiratory syncytial 
virus infections in a pediatric department. J Hosp Infect 1994;26:173-179 
65. Langley Jl\tf, LeBlanc JC, Wang EEL, Law BJ, MacDonald NE, Mitchell I, et al. Nosocomial 
respiratory syncytial virus infection in Canadian pediatric hospitals: a pediatric investigators 
collaborative network on infections in Canada ShIdy. Pediatrics 1997;100(943-946) 
66. Agah R, Cherry JD, Garakian AJ, Chapin ~\'I. Respiratory syncytial virus (RSV) infection rate 
in personnel caring for children with RSV infections. Am J Dis Child 1987;141:695-697 
67. Friis B, Eiken ~t HomslethA, Jensen A Chest X-ray appearances in pnetullonia and bronchiolitis. 
Acta Paediatr Scand 1990;79:219-225 
68. Simpson W, Hacking PJ\·I, Court SDi\'I, Gardner PS. The radiological findings in respiratory 
syncytial virus infection in children. Part II: the correlation of radiological categories with 
clinical and virological findings. Pediatr Radiol 1974;2:155-160 
69. Hall CB. RSV: what we now know. Contemp Pediatr 1993:1-11 
70. Da"wson KP, Long A, KemlCdy J, Mogridge N. TIle chest radiograph in acute bronchiolitis. J 
Paediatr Child Health 1990;26:209-211 
71. Milner AD. The role of corticosteroids in bronchiolitis and croup. Thorax 1997;52:595-597 
72. Randolph AG, Wang EEL. Ribavirin for respiratory syncytial virus lower respiratory tract 
infection. Arch Paediatr Adolesc Med 1996;150:942-947 
73. Kellner JD, Ohlsson A, Gadomski AM, 'Wang EEL. Efficacy of bronchodilator therapy in 
bronchiolitis. A meta-analysis. Arch Paediatr Adolesc Med 1996;150:1166-1172 
74. Groothuis JR, Simoes EAF, Levin Ivlj, Hall CB, Long CE, Rodriguez Wj, et al. Prophylactic 
administration of respiratory syncytial virus imnume globulin to high-risk infants and yOlmg 
children. N Engl J ~\'led 1993;329:1524-1530 
75. llvIpact-RSV Study Group. Paliviztlllab, a humanised respiratory syncytial virus monoclonal 
antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. 
Pediatrics 1998;102:531-537 
76. Crowe Jr JE, nui PH, Siber GR, Elinks WR, Chanock RM, Murphy UR. Cold-passaged, 
temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly 
attenuated, immunogenic, and protecth'e in seronegative chimpanzees, even when RSV 
antibodies are infused shortly before immunisation. Vaccine 1995;13:847-855 
77, Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EAF. Safety and inummogenicity 
of a pmified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with 
bronchopulmonary dysplasia. J Infect Dis 1998;177:467-469 
78. Carlsen KH, Orstavik I. Bronchopulmonary obstruction in children with respiratoryvirus 
infections. Em J Respir Dis 1984;65:92-98 
79, Smith OW, Rector DM, Derish MT, Frankel LR, Ariagno RL. Pulmonary function testing in 
infants with respiratory syncytial virus brondtiolitis requiring mecllanical ventilation. Pediatr 
Infect Dis J 1990;9:S108-S111 
80. Hammer J, Numa A, Newth CJL. Acute respiratory distress syndrome caused by respiratory 
syncytial virus, rediatr PulmonoI1997;23:176-183 
81. Stokes GM, Milner AD, Hodges IGC, Groggins RC Ltmg ftmction abnormalities after acute 
bronchiolitis. J Pediatr 1981;98:871-874 
82. Dezateux C Hetcher ME, Dtmdas 1, Stocks j, Infant respiratory ftmction after RSV-proven 
bronchiolitis. Am J Respir Crit Care Med 1997;155:1349-1355 
83. Young 5, O'Keeffe PT, Arnott J, Landau LL Lung function, air"way responsiveness, and 
respiratory symptoms before and after bronchiolitis. Arch Dis Child 1995;72:16-24 
21 
Chapter 1 
84. McConnochie KM, Mark JD, McBride fT, Hall vVI, Brooks IG, Klein 5}, et al. Normal pulmonary 
hmction measurements and ainvay reactivity in childhood after mild bronchiolitis. J Pediatr 
1985;107:54-58 
85. Mallory Jr GB, Motoyama EK, Koumbourlis AC, Mutich RL, Nakayama DK, Bronchial 
reactivity in infants in acute respiratory failure with viral bronchiolitis. Pediatr Pulmonol 
1989;6:253-259 
86. Carlsen KH, Larsen 5, Orstavik 1. Acute bronchiolitis in infancy: the relationship to later 
recurrent obstructive airway disease. Eur J Respir I 1987;70:86-92 
87. Pullan CR. Hey EN. vVheezing, asthma, and pulmonary dysfunction 10 years after infection 
with respiratory syncytial virus in infancy. Br Med I 1982;284:1165-1169 
88. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman fi, Bjorksten B. Asthma and immunoglobulin 
E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with 
matched controls. Pediatrics 1995;95:500-505 
89. Long CE, McBride ]1', Hall Cn. 5equalae of respiratory syncytial virus infection. Am I Respir 
Cdt Care Med 1995;151:1678-1681 
90. Forster J, Tacke U, Krebs H, Streckert HI, Werchau H, Bergmann RL. Respiratory syncytial 
virus infection: its role in aeroallergen sensitization during the first two years of life. Pediatr 
Allergy Immunol 1996;7:55-60 
91. Webb MSC, Henry RL, 11ilner AD, Stokes GM, Swarbrick AS. Continuing respiratory problems 
three and half years after acute viral bronchiolitis. Arch Dis Child 1985;60:1064-1067 
92. Noble V, Murray M, Webb MSC, Alexander J, Swarbrick AS, Milner AD. Respiratory stahlS 
and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 1997;76:315-319 
93. Laing I, Reidel F, Yap PL, Simpson H. Atopy predisposing to acute bronchiolitis during an 
epidemic of respiratory syncytial virus. Br Med J 1982;284:1070-1072 
22 
CHAPTER 2 
PATHOPHYSIOLOGICAL AND CLINICAL ASPECTS OF 
RESPIRATORY SYNCYTIAL VIRUS INFECTIONS 
Chapter 2 
2.1 HISTORY 
Morris and co-workers isolated in 1956 a cytopathogenic agent from chimpanzees 
with coryza I" Because of the purulent rhinorrhea, the virus 'was called Chitnpanzee 
Coryza Agent (CCA). However, since animal handlers became ill and CCA was 
recovered fr01n tlu'oat swabs of infants ·with lower respiratory tract ilhless, luunan 
origin of the virus was highly suspected '. Because of its clinical manifestations and 
the characteristic cytopathologic findings in tissue culture where it forms syncytia of 
epithelial cells, the virus was named respiratory sYllcytial virlls (Figure 2.1). 
Epidemiological research carried out over the last fom decades demonstrated the 
h'emendolls inlpact of RSV on Imver respiratory tract infections in young children 3-7. 
ntis chapter discusses the current perspectives on the pathophysiology of infections 
by RSV. 
2.2 VIROLOGY 
2.2.1 RSV 
RSV is classified within the genus p"ellllloviridae which is a member of the family of 
parmllyxoviridae. TI,e virus is a pleomorphic (exhibiting both spherical and filamentous 
forms) enveloped cytoplasmic virus measlUing 80 to 500 nm (Figure 2.2). TIle spherical 
particles measure 100 - 350 lUn '. TI,e genome of RSV is a single-sh'anded negative 
sense RNA which contains 15.222 nucleotides (RSV A2 strain) from which tenmRNA's 
are transcribed 9,10, These encode for the viral proteins, The G and F proteins are 
envelope associated proteins. Both are the major antigenic detenninants of the virus 
inducing neutralising and protective antibodies 11 The G protein, a large glycoprotein, 
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Histopathological e:raJ/lple of post-
mortallllllg tisslle infected with RSV 
(200x). Note the characteristic 
syncytill forll/atioll highlighted ill the 
black lJox (400:r). (sollrce: www-
medlilJ.1Iled.lltali.edu, the internet 
pllfhology lalJorafory for medical 
edl/catiol/. COllrtesy by Prof Dr. E.e. 
Klatt, MD) 
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Figure 2.2 Electro1ll1licroscopy of respiratory syncytial virus (magnificatio1l 85.000 x, courtesy by Prof.Dr. 
A.D.M.E. Osterhaus) 
is responsible for attachment of the Vll'US to host cells, v .. rhereas the F protein - a 
disulphide bonded glycoprotein - is responsible for the characteristic syncytium 
fonnation. Heparin-like structures on the G protein seem to playa role in the attaclunent 
of RSV to the host cell surface 12. The L protein is believed to have polymerase activity. 
TIle ftmctions of the small hydrophic protein (SH) and of the non-structural proteins 
NSI and NS2 have not yet been elucidatcd. 
TIle use of specific monoclonal antibodies allows for the identification of two major 
groups of RSV, designated A and B 13. ". Differences between the two groups are mainly 
found in the G protein, which share only one of six epitopes and in the F protein, 
where differences in one epitope can be detected 13. TIle G protein may have only 53% 
amino acid homology between subtype A and B. This indicates that the F protein is 
rather conserved and demonstrates a degree of both genetic and antigenic homology 
between both subtypes 11. Genetic differences may be fOtmd among subtype A and B. 
Differences up to 20% have been described in the G protein sequences of subtype A 
and up to 9% for subtype B 15. 
2.2.2 TRANSMISSION OF THE VIRUS 
RSV infects through the eye and the nose. Transmission is conferred by direct 
llloculation with large droplets or self-inoculation after contact with contaminated 
surfaces 16,17, Direct llloclllation occurs only after close contact with an infected 
patient 17, Contmninated surfaces are an iInportant source of infection. HSV Ina), survive 
25 
Chapter 2 
for one hour on cloth and tissues '\vhereas surival on the skin luay persist for 30 
minutes. RSV can be recovered from cmmtertops for up to seven hours 16. Touching 
these counter tops without handwashing results in self-inoculation. 
The incubation period of RSV infection varies between two and eight days with a 
median of five days I'. Viral shedding may persist for up to three weeks in the individual 
patient. In the majority of patients viral shedding persists for ten days to two 
weeks 19-21. YOlmg infants were fOlUld to shed lnore virus than older infants 20. Viraenlia 
may occur as has been demonstrated by the presence of RSV-RNA in 
polylnorphonuclear cells, although no correlation between viraemia and severity of 
illness was found 22. 
2.2.3 VIROLOGICAL DIAGNOSIS OF INFECTIONS BY RSV 
Techniques for diagnosis of RSV infection include viral culture, (in)direct 
inummofluorescent antibody assay, enzyme linked immunosorbent assay (ELISA) 
and polymerase chain reaction (PCR) on respiratory secretions. The immuno-
fluorescent assay (lFA) can easily be carried out with results within one hour 23. TI,e 
sensitivity of the direct !FA is 95% to 97% with a specifity of 94% to 95% 24.27. However, 
the interpretation of inummofluorescence assays requires the availability of skilled 
laboratory persOImel. Other teclmiques include ELISA transformed into commercial 
kits such as the Abbott TestPack® with a sensitivity between 92% and 96% and a 
specifity of more than 95% 28-33. Reverse transcriptase (RT)-PCR is highly specific with 
a sensitivity of approximately 95% and a specificity of 97% >4,35. With RT-PCR, RSV 
can be detected at much lower 50% tissue culture infectious dose (TCIDso) pel' milliliter ". 
Serological diagnosis of RSV infection is by far inferior to viral cultme, D!F A and 
RT-PCR 37. For the nonculture teclmiques, IFA remains the most cost effective and most 
rapid technique currently available ". 
2,3 PATHOGENESIS OF INFECTIONS BY RSV 
2.3.1 PATHOLOGY 
RSV infects respiratOIY tract cells. Airways with a diameter of 75 to 300 pm are 
affected in children with bronchiolitis. After infection, necrosis of bronchiolar 
epithelium occurs followed by a peribronchiolar lymphocytic infiltration. The 
subnulCosa and adventitial tissues become oedenlatous and mucus secretion is 
enhanced resulting in the formation of thick plugs in tile airways leading to obstruction 
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of air flow. This obstruction results in air trapping or consolidation of pulmonary 
areas. Elastic and muscular tissues remain tmaffected ". RSV antigen can be detected 
in epithelial cells throughout the respiratory h'act, with paranuclear eosinophilic 
inclusions in a great I1tllnber of RSV positive cells 40. 
RSV pneumonia is characterised by a interstitial in£ilh'ation of mononuclear cells 
with interalveolar wall thickening. The degree of pathological changes varies from 
relatively mild to severe epithelial necrosis and eosinophilic sloughing of the lwnen 39. 
The virus load is relatively high in bronchiolitis compared to pnelll110nia, 39,41. 
Reduced levels of sudactant protein (SP) A, Band D are found in ventilated infants 
with RSV infection as measured by bronchoalveolar lavage. This may be due to an 
invasion of the type II pneumocytes by RSV. Howevel~ no clear relationship between 
SP level and arterial alveolar oxygen ratio was observed ". Adequate levels of SP-A 
seem to be important in RSV -infection. A recent study in mice demonsh'ated that SP-A 
played an important role in the host defense against RSV infection with hmg 
inflanunation and viral titers increased in SP-A negative lnice 43. Low levels of SP-A 
may contribute to the obstruction of smaller airways because of possible collapse of 
slnall airways by higher surface tension 4-1. 
Bronchiolar obstruction may further be enhanced through the release of potent 
bronchoconstrictors such as IL-ll, histamine and LTC, by mast cells and macrophages 
with subsequent bronchoconstriction 45-47. Neural mechanis111S governing 
broncholllotor tone and various neuropeptides further contribute to 
bronchoconsh'iction 48, 
2.3.2 CELLULAR IMMUNE RESPONSE 
A graphic model of the pathogenesis of RSV infection is presented in Figure 2.3. 
The inflalmnatory proces caused by RSV takes place in puhnonary tissue. Immune 
cells leave the blood and redistribute to the lungs with the use of vascular cell adhesion 
molecule (VCAM)-l 49,SO,51, 
2.3,2, 1 INITIAL RESPONSE TO RSV INFECTION 
RSV activates both the classical and alternative pathways of complement ". 
Neutrophils, the predomh1ant cell type h1 RSV lower respiratory tract disease, adhere 
to infected epithelial cells with subsequent release of oxygen radicals induced by RSV 
antigen-antibody complexes 53.,., This results in complement-dependent neuh'ophil-
mediated cytotoxicity and subsequent lysis of RSV huected cells 57, 
RSV particles are then phagyocytosed by neuh'Ophils with subsequent production 
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Figure 2,3 Hypotllethiml graphic model of fhe pathophysiology of illfectiolls by RSV 
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of cytokines such as IL-6, IL-8 and IL-lO 53, IL-6 has two functions: it may act as an anti-
inflanunatory agent by promoting humoral and cellular defence mechanisms, but it 
Inay also act as a pro-inflammatory cytokine 59, Neonatal blood cells have a dirninished 
capacity to produce IL-6 60, IL-8 acts as a chemoath'actant and activator for neuh'ophils, 
T-cells, basophils and primed eosinophils with functional IL-8 receptors 61, IL-IO 
functions as a regulatory cytokine controlling IFN-y expression during RSV-
infection 62. 
RespiratOlY epithelial cells express MHC class I molecules and are ftuther destroyed 
by the cytolytic action of multiplying and budding virus, Natural killer cells are 
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activated and produce interferon (IFN)-y. Subsequently, CD8+ cytotoxic T lymphocytes 
appear and destroy RSV infected cells which express MHC class I 63."-
Macrophages release cytokines such as TNF-o:, IL-I, IL-6, IL-8, IL-IO, platelet 
activating factor (PAF) and prostaglandin E, 6%7. The production of IL-6 and TNF-o: 
further enhances the inunune response 63, IL-IO acts as an nnti-inflanlInatOlY cytokine 
\",hich Inay interfere with the establislU11ent of an effective llluluule response 69, 
Monocytes stimulate the synthesis of interferon regulatory factor (IRF) - 1 and 
interieukin-lB converting enzyme (ICE) 70. 
2.2.3.2 ACTIVATION OF T-CELLS 
Viral particles are presented by the macrophage in association with MHC class II 
to CD4+ T lymphocytes which respond by proliferation and cytokine production. 
Within the T-helper cells, two subsets can be identified: Tit I-cells which produce IL-
2 to promote further T-cell proliferation and lFN-y. TH-l cells are involved in cellular 
llnnuule responses, TH-2 ceUs are involved in the production of inununoglobulins and 
the induction of eosinophilia. T H-2 cells produce IL-4 and IL-S. IL-4, when expressed 
in abundance, decreases viral clearance and dinunishes induction of CTL's 71, Anti IL-
4 h'eahnent after inununisation with inactivated RSV can shift the lll1l1UUle response to 
a TII-l like response with augmented CTL activity". IL-12 reduces the level of 
eosinophilia follow RSV challenge, which llldicates that it directs towards a TH-llike 
response 62, 
Both CD4+ and CD8+ T lymphocytes are involved in the termination of RSV 
replication after infection. The number of CD8+ T cells increases during the course of 
RSV infection so. They dowl1l'egulate T H -2 cytokine secretion and decrease pulmonary 
eosinophilia 73. This may be done t1u'ough lFN-y". The appearance ofCD8+ cytotoxic 
T lymphocytes (CTL) is related to the clearance of the virus six to nine days after 
infection 75,76, However, the clearance of virus by CDS + lytnphocytes also appears to 
Inediate illness 77,78, 
Live RSV has been f01Uld to induce a Tft I like reponse /9,80, However, others reported 
evidence of a TII-2like response 81. Hussel and co-workers showed both Tit 1 and T H2-
responses III Inice 82, TIle character of the RSV antigen initially presented to the inUll1me 
system is important in inducing different T H subsets. The F-protein elicits in vitro a T H-
I response \vhereas the G protein elicits a TH-2 response with extensive puhnonary 
eoslll0philia &3,8-1, Further evidence for this observation can be found III the presence of 
abundant IL-4 and Il-S secretions despite high concentrations of lFN-yindicating the 
activation of both T-helper subsets, thus suggesting that the initial exposure to either 
For G antigen dictates the cytokine response 81. Recently, Spender and co-workers 
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obsen'ed in mice eosinophilia despite an abundant IFN-y production ". TIms, the 
pitellotype of effector cells rather than the cytokine pattern alone is also important in 
determining disease 85, 
Conflicting results have been reported on the production of IFN-y in RSV infection. 
Hall and colleagues found that infants with RSV produced significantly less interferon 
,,,,hen cOlllpared to infants with influenza and para-influenza virus infection 86, 
Nakayama and co-workers did find IFN-a in nasopharyngeal secretions. The decline 
in mean titer was parallel to the quantity ofRSV antigen 87. 
2.3.2.3 A TTRACTION OF INFLAMMATORY CELLS 
Eosinophils are attracted towards puhnonaty tissue as a result ofT H-2 cell activation 
and release of IL-4. Superoxide atld LTC, are released ". Activated eosinophils also 
release eosinophilic cationic protein (ECP) 89.90. Viral induced eosinopenia may occm 
during RSV infection 91. Infected epithelial cells express RANTES (Regulated on 
Activation, Normal T cell Expressed atld presumably Secreted) atld MIP-1 (macrophage 
inflammatory protein 1), atld IL-8 is produced with resulting further attraction of 
neutrophils, basophils, monocytes, T-cells and primed eosinophils 54. Production of 
monocyte chemotactic protein (MCP)-l and MIP-1 occurs in epithelial cells of small 
airways and lungs. RANTES atld MIP-1 enhance IgE atld IgG4 production and induce 
degratutlation of NK cells and CTL's. The production of RANTES is stinntlated by 
IFN- y, and eosinophils also Catl secrete RANTES ". 
The pro-inflammatory cells adhere to the respiratory epithelium through 
intercelhtlar adhesion molecule-1 (ICAM-1) using C018 receptors 93-95. Noninfected 
cells may also express ICAM as a result of pro-inflanunatOlY cytokine expression by 
neighbouring cells 96. TIle expression of ICAM-1 is primarily mediated by IL-1a 97. 
2.3.2.4 ANTIBODY-DEPENDENT CELL MEDIATED CYTOTOXICITY 
As a result ofTH-2 cell stinutlation, plasma cells produce immunoglobulins such 
as IgG atld IgE. Antibody-dependent-cell mediated-cytotoxicity (AOCC) associated 
with RSV -IgG antibody, reaches a maximum between one and two weeks after the 
onset of illness 93,99. In contrast, atltibody-dependent enhancement of infection may 
also occur and form an explanation for the sh'iking observation that yOlmg infatlts 
develop severe disease despite the presence of maternal antibodies 100. 
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2.3.3 ANTIBODY MEDIATED IMMUNITY 
TIle humoral response of infants with RSV infection is influenced by their age, by 
the presence of maternal antibodies and by the viral antigen. Young age influences the 
response to both the G and F protein of RSV. The G protein is heavily glycosylated and 
may thus be less inummogenic in young infants. Also, the decreased response to the G 
protein is influenced by the presence of maternal antibodies 101. Low levels of maternal 
antibodies are not related to a severe disease course 102. 
Primary infection of infants with RSV results in production of senml antibodies 
that are subgroup specific and cross-reactive 103.1",. Especially antibodies against the F 
protein are cross-reactive given the conserved region in the F protein. Yamazaki et nl 
reported that patients infected with subtype B did not develop an antibody response to 
the G protein of the A2 sh·ain but did develop antibodies to the F protein of the A2 
sh·ain I"'. The presence of antibodies against both glycoproteins leads to some degree 
of resistance to reinfection 105. Others observed that prior group A infection primed for 
a more extensive cross-reacting antibody response at the tinle of the second RSV 
infection than infections by group B 1(16. 
RSV infection induces IgM, IgG, IgA and IgE antibodies. IgM senmllevels can be 
detected after approximately tlu-ee days of illness and may persist for two to ten weeks 
107.10'. TIle quantity of IgG antibodies measured in the infant is influenced by the height 
of senillllevels of maternal antibodies. Large quantities of maternal antibody may 
protect against severe disease 109. In infants younger than three months of age greater 
geomeh·ic mean titers of IgG were observed than in infants aged 3 to 6 and 6 to 12 
months of age. Within 10 to to 14 days after the onset of iliness, an increase in geometric 
mean titer may be observed with a peak titer three to four weeks later followed by a 
decrease 107. Convalescent phase titers were twofold greater in infants older than 6 
months of age. Subclass specific antibodies are mainly in the IgG 1 and 3 subclass "". 
111. Secondary infections lead to a greater, more persistent IgG response than pl"imary 
infections 107. 
RSV infected cells may be coated with immtmoglobulins with IgA being the 
predominant inummoglobulin 112. IgA coated RSV infected cells are detected in the 
first available nasal sample taken at day 1 or 2 of hospitalisation with an average of 3.5 
days. Subsequently cell-free anti-RSV IgA appears with a gradual increase after 10 to 
14 days after the onset of ilhless 108. TIle appearance of IgA coincided with the 
termination of viral shedding, so that these cell-bound inu-ntUloglobulins neuh·alise 
vims after budding from the cell surface lOS. Cell-free IgA may conh·ibute to recovery 
from primary infection since its increase in titers is stronger than IgG 113. 
Cell-bound IgE may be detected within hvo days after the onset of illness '14. IgEhas 
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also been found in nasopharyngeal secretions, indicating that RSV-IgE production 
takes place in the mucosa 115. 111is IgE response Inay be observed as early as six to eight 
days after the onset of ilhless 116. Peak concentrations do not occur until some rune after 
the acute illness 117. The developlnent of IgE correlated 'with increasing concentrations 
of histamine as a possible result of latent sensitisation to RSV 117,118, It has been suggested 
that the titers of RSV-IgE in nasopharyngeal specimens may be predictive for recurrent 
'\vheezing 119. However, others '\vere unable to demonstrate specific RSV-IgE in 
nasopharyngeal specirnens 120. 
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ABSTRACT 
We investigated whether a relationship between clinical severity of RSV infection 
and dish'ibution of subtype A or B could be demonstrated. The data of 232 children, 
who were admitted to or diagnosed with RSV infection in the outpatient deparhnent of 
the Sophia Children's Hospital, Rotterdam between 1992 and 1995, were studied. The 
diagnosis of RSV was confinned by a direct imtllUnofluorescence assay. Subtyping 
'vas perfonned by an indirect immunofluorescence assay using specific 1110noclonal 
antibodies. Gender, age at diagnosis, gestational age and birthweight, the presence of 
lU)derlying diseasesf unpaired feeding, the presence of ,vheezing and retractions, 
respiratory rate, tetllperature, c1inical diagnosis at prcsentationf Sa02, pC02 and pH, 
characteristics of hospitalisation and the need for mechanical ventilation were 
observed. Analysis \vas perfonned on data front all patients diagnosed with RSV 
infection in the period between 1992 and 1995 spalUling three RSV seasons, alld 
seperately on the RSV season 1993 -1994. The outcome of the tluee year analysis (150 
(64.7%) subtype A vs 82 (35.3%) subtype B) was compared with the outcome of the 
season 1993 - 1994, a mixed epidemic with 37 (60.7%) subtype A alld 24 (39.3%) 
subtype B isolates. None of the variables observed in the season 1993 - 1994 differed 
significalltly between RSV -subtype A and B. Similar results were obtained from the 
analysis in the period 1992 until 1995, with the exception of pCO, (a more high pCO, 
was found in subtype A, p < 0.001) and retractions (illore retractions were noted in 
patients with subtype A, p ~ 0.03). After correcting for possible confotmders using 
regression analysis, these differences were not significant anYll10re. 
Our data indicate that there is no relationship between clinical severity of RSV 
infection and subtype. 
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3.1 INTRODUCTION 
RespiratOly syncytial virus (RSV) is the most conunon cause of respiratory h'act 
infections in infants and yOllllg children. The clinical presentation can vary from a 
mild upper respiratory tract infection to severe bronchiolitis. 111e incidence of RSV 
bronchiolitis reaches a InaxinlUlll at the age of two Inonths and declines ,,,,ithin the 
first year of life I. The majority of infections have a mild clinical course. A minority 
of infants, 0.5 to 2%, has to be admitted to the hospital. Between 7% and 21% of these 
patients 'will need lllcchanical ventilation 2,.1, 
Severe infections may occur in premature infants or patients suffering from an 
tmderlying disease, such as congenital heart disease (CHD), bronchopulmonary 
dysplasia (BPD) or T-cell-inummodeficiency '. 111e mortality of infants hospitalised 
with RSV is approximately 0.5% to 1.5%. In infants with an tmderlying disease higher 
lnortality rates are f01Uld 5,6, 
Two major antigenic groups of RSV, subtype A and subtype B, can be identified 
by specific lnonoclonal antibodies 7. TIle antigenic diversity bet'ween these two 
subtypes is detennined lnainly by G-proteins, lNhich are responsible for attaclunent 
of the virus and to a lesser extent by the fusion proteins, the F-proteins. The two 
subtypes can circulate independently from each other, but they may also codrculate 
during one epidemic 8. The identification of the two subtypes has led to the speculation 
that therc might be a relationship between clinical severity of infection and RSV 
subtype. A limited number of shldies wcre carried out to establish such a relation-
ship 9.12. 111ese shldies provide conflicting results. 
The objective of our shtdy was to investigate whether a relationship between 
clinical severity of RSV infection and subtype could be demonsh'ated in children 
YOlmger than 12 months. 
3.2 PATIENTS AND METHODS 
Patients younger than 12 months who either were admitted to the Sophia 
Children's Hospital or visited the outpatient deparhnent due to RSV infection in the 
period between 1992 and 1995, were included in this shldy. The Sophia Children's 
Hospital is a cOlnbined secondary-tertiaty care university hospital. 
RSV infection was confirmed by a positive direct immunofluorescent assay (IFA) 
using FlTC labeled monoclonal antibodies against RSV (DAKO, Ely, UK) performed 
on cells of nasopharyngeal washing atld/or a positive viral culture on HEp2 cells13, 
In 97.4% (n = 226) both DIFA and viral culhlre were positive, in 1.3% (n = 3) only the 
DIFA was positive and in 1.3% (n = 3) only the viral culture was positive. RSV 
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sub typing was performed using RSV subtype specific monoclonal antibodies (MAB) 
in an immunofluorescence assay on cells of nasopharyngeal washings as described 
by Taylor ef al u. MAB's used were 92-11C for subtype A and 102-lOB for subtype B 
(Chemicon, Temecula USA) '. Briefly, cells of nasopharyngeal washings were fixed 
on glass slides in acetone. RSV subtype specific MAB's were incubated for 30 minutes 
at 37° C. After washing tlu'ee times in PBS the slides were incubated with the conjugate 
anti-mouse FITC (Dako, Ely,UK). When the IFA was negative and viral culture was 
positive, the subtype specific inummofluorescence was performed on RSV infected 
HEp2 cells. 
Epidemiological and clinical data were retrospectively obtained from the medical 
charts. Patient characteristics include gender, age at diagnosis, birthweight, gestational 
age and the presence of underlying disease (congenital heart disease with 
hemodynamic consequences i.e. left/right slumt, bronchopulmonary disease and T-
cell immunodeficiency). Clinical observations at presentation include impaired 
feeding (defined as normal feeding, slow feeding with normal volume, decreased 
voltnne and no oral feeding), the presence of ,vheezing and retractions, and 
telnperature. TIle use of lllechanlcal ventilation ,vas registered dtuing admission. 
TIle decision for ICU admission and mechanical ventilation was made before subtype 
was known. Other clinical parmneters include characteristics of hospitalisation: 
nmnber of admissions and length of stay in hospital and ntunber of intensive care 
unit (ICU) admissions and length of stay in ICU. 
LaboratOly parameters measured at presentation included oxygen saturation (SaO,), 
pCO, and pH. SaO, was measured transcutaneously with the use of a pulse oximeter, 
pCO, was measured on capillary blood samples. All parameters were measured 
irrespective of severity of disease. 
Tlu'ee diagnostic categories were defined: bronchiolitis/pneumonia (lower 
respiratory tract infection, LRTI), upper respiratory tract infection (URTI) and apnoea. 
TIle diagnosis bronchiolitis was based on clinical features and hypertranslucency, 
atelectasis or bronchial thickening on chest radiograph. URTI was defined as coughing 
and! or rhinitis, v,"ith no abnormalities on chest radiograph. Apnoea at presentation 
was defined as a cessation of respiration for a period over 20 seconds and! 01' 
bradycardia with accOlnpanying cyanosis. The diagnosis pneumonia was based on 
clinical features and the presence of an infiltrate on chest radiograph. 
Statistical analysis was performed using the X' test, the students t-test and the 
Mann Whihley-U test. P-value ,; 0.05 was considered significant. In order to examine 
the independent effect of virus subtype on the severity of disease we adjusted for 
gender, age in months, prematurity (gestational age,; 37 weeks), the presence of 
underlying disease and year of diagnosis with logistic and linear regression analysis. 
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Linear regression ",Tas used to investigate if there were differences between the hvo 
virus subtypes in SaO, or pCO,. Logistic regression was performed with dichotomous 
outcome variables such as hnpaired feeding, the presence of wheezing and reh'actions, 
the clinical diagnosis (bronchiolitis/ pnetunonia or upper respiratory tract infection), 
need of mechanical ventilation and ICU admission. 
3.3 RESULTS 
In the period between 1992 and 1995 covering three RSV seasons, 232 children 
with RSV infection visited OUr hospital. hl1992 - 1993 a predominance of subtype B 
was found. Ten out of 68 children. were infected with subtype A (14.7 %) versus 58 
children with subtype B (85.3 %). TIle season 1993 -1994 showed a mixed epidemic: 37 
chilch'en were infected with subtype A (60.7%) and 24 chilch'en were infected with 
subtype B (39.3%). TIle season 1994 - 1995 showed an epidemic in which all 103 
children were infected wilh subtype A. 
Based upon the subtype dish'ibution, two analysis were perfomed: one on the entire 
period from 1992 lmti11995, covering three RSV seasons and one on the mixed A/B 
season 1993 -1994. The results of the outcome of the analysis of the period 1992 -1995 
were compared with the outcome of the analysis of the season 1993 -1994. 
Table 3.1 PatinJl characteristics 
Boys 
Girls 
Mean age (months) 
Patients < 3 months 
3-6 months 
> 6 months 
Mean gestational age (weeks) 
Gestational age ::;; 34 weeks 
35-37weeks 
> 37 weeks 
Mean birthweight (gr) 
Underlying disease state 
Prematurity and BPD (n) 
CHD (n) 
BPD(n) 
Subtype A 
(n-150) 
63.3 
36.7 
3.5 ± 3.0 
48.0 
26.7 
25.3 
37.3± 3.8 
18.4 
10.3 
71.3 
2936 ± 875 
16.3 
10 
14 
o 
No significallt differecens betweCll RSV subtype A alld B were observed. 
BPD: brollc1lOplllmollary dysplasia, CHD: cOllgellifal heart dist'flse 
NI/mbers expressed as % ll1JleSS stateii of/lerwise 
Subtype B 
(n - 82) 
67.1 
32.9 
3.6 ± 2.9 
47.6 
26.8 
25.6 
37.8± 3.3 
12.7 
12.7 
74.6 
3023 ± 804 
11.0 
4 
3 
2 
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Table 3.2 ClilliCIII parameters lit presCIltafioll 
Impaired feeding 
Wheezing 
Retractions 
Mean respiratory rate (/min) 
Mean temperature (0C) 
Mean 8a02 (%) 
Mean pea, (kPa) 
Mean pH 
Subtype A 
(n - 150) 
71.6 
36.0 
58.0 
52 ± 15 
37.8 ± 1.0 
90.3 ± 11.3 
6.8 ± 2.2 
7.35 +0.1 
Subtype B 
(n - 82) 
64.6 
34.1 
41.8 
51 ± 13 
38.0 ±0.8 
9004 ± 9.2 
5.8 ± 1.0 
7.37+0.1 
No sigllijiCfJllf differences betCll('t'1l RSV subtype A a1ld B were ollst'Yut'd, except for flIt' presellce of retractio1ls 
(p ~ 0.03) <llId pCO, (p < 0.001). 
NJ/mllers expressed as % IIlIless stated otherwise. 
3.3.1 ANALYSIS OF THE DATA FROM THE PERIOD 1992 UNTIL 1995 
This period included 232 children: 150 (64.7%) were infected with subtype A, 82 
(35.3%) with subtype B. The male/female ratio was 1.8 (150/82). Table 3.1 (page 43) 
shO'\vs the population characteristics. 
Clinical parameters are shown in Table 3.2. No significant differences ,vere fOlmd 
regarding unpaired feeding, the presence of 'wheezing, respiratory rate, te1nperahue, 
SaO, and pH. Significant differences were fOlmd regarding pCO, and the presence of 
retractions. The average pCO, for subtype A is 6.8 kPa against 5.8 kPa for subtype B (p 
< 0.001). Reh·actions were noted in 84 children infected with subtype A and in 28 
children infected with subtype B (p ~ 0.03). No significant differences were fmmd 
regarding underlying disease. Table 3.3 shows the clinical diagnosis at presentation. 
In Table 3.4 (page 46) the characteristics of hospitalisation are shown. 
The pCO, was measmed in 213 children: 136 (90.1%) samples were collected in 
patients with subtype A and 77 (94.0%) for subtype B. We noted in the season 1994-
1995 more children with a high pCO, (above 10.0 kPa) than in the other two seasons. 
We also found in the season 1994 - 1995 a significant difference in the number of 
children < 2 months of age (in the first two seasons 19.4% against 34.0% of the children 
in the season 1994 -1995, P ~ 0.01). Furthennorewe found a significantly higher pCO, 
in children < 2 months of age (7.5 kPa vs. 6.0 kPa for children ;0, 2 months of age, 
p < 0.001). 11,is also applies to all three seasons separately. 
Twenty-eight (12.1%) children required mechanical ventilation. Twenty-one of these 
were infected with subtype A, 7 with subtype B (p ~ 0.22). Two children died. One of 
them was infected with subtype A, the other child was infected with subtype B. 
Adjusttnent for confounders ,vith regression analysis did not reveil a significant 
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Table 3,3 Clinical diagnosis nt preselltatioll 
Apnoea ± URTI 
URTI 
Bronchiolitis/pneumonia 
WithURTI 
With apnoea and URTI 
Subtype A 
(n-150) 
5.3 
24.7 
3.3 
52.0 
14.7 
No sigllijiCllnf differeIJces lIetwt't'Il RSV sulltype A and B were ol)sl'rved 
URT1: upper respiratory fmct infixtioll 
Numbers expressed as % unless stated otherwise 
Subtype B 
(n - 82) 
3.7 
28.0 
2.4 
56.1 
9.8 
difference between subtype A and B for any of the disease outcOlne parruneters such as 
impaired feeding, presence of wheezing, presence of reh'actions, 5a02 and pC02, Imvel' 
respiratory tract infection, lCU-admission and tnechruucal ventilation, 
3.3.2 ANALYSIS OF THE SEASON 1993 - 1994 AND COMPARISON OF BOTH ANALYSES 
This period included 61 patients. The male/female ratio was 1.3 (35/26). We did 
not find a significant difference in the study population characteristics between subtype 
A and subtype B. No significant differences were found between subtype A and subtype 
B for all the observed variables. 
The outcome of the analysis of the data from the season 1993 -1994 was equal to the 
outcome of the analysis of the data from the period 1992 -1995, covering three separate 
RSV seasons, except for pCO, and the presence of retractions. 
3.4 DISCUSSION 
We investigated whether a relationship between clinical severity of RSV infection 
and subtype A or B could be demonsh·ated. The results of our study indicate that such 
a relationship does not exist. 
T'iYO ru1alyses were perfonned: one on data from the whole period between 1992 
and 1995, covering tlu'ee RSV seasons, and one on data of the season 1993 -1994. By 
comparing the ontcOlne of one season 1Nith the outcOlne of tlu'ee seasons, the possible 
effect of confolU1ding variables frOln a particular season was ruled out, 
As strong indicators for severity of infection in this study were used oxygen 
saturation (SaO,), pCO" clinical diagnosis (upper respiratory h'act infection versus 
lower respiratory tract infection), lCU adtnission and the need for lnechanical 
ventilation, These indicators are strongly related to puhnonary dysnu1ction 10,15, 
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Table 3.4 Clwmcteristics of hospitalisation 
Number of admissions 
Mean length of stay (days) 
Number of leu admissions 
Mean length of stay in leu (days) 
Mechanical venlilation 
Subtype A 
(n = 150) 
76.7 
lOA ± 6.2 
34.0 
6.2 ± 8.3 
14.0 
No sig1lificant differe1Jces betwet'll RSV subtype A and B were observed. 
leu: illtensive care ullit. 
Numbers expressed as % Illlless stated ot1tenoise. 
Subtype B 
(n = 82) 
85.4 
9.3 ± 4.8 
23.2 
5.9 ± 5.0 
8.5 
None of the variables observed in the season 1993 - 1994 were significantly different 
between patients infected with subtype A and subtype B. This was also found in the 
analysis of the period 1992 - 1995, except for the presence of retractions and pCO,. 
More retractions were noted in patients with subtype A than in patients with subtype 
B. However, the association did not hold after correcting for confotmders using logistic 
regression analysis. 
The other variable that showed a significant difference is pCO,. This is due to a 
relationship between yotmg age and high pCO" as has been demonstrated by 
Mulhollandel a[16. In the season 1994 -1995 (a season with only subtype A infections) 
significantly more children younger than two months of age were acbnitted with RSV 
than in the two preceding epidemics. The mean pCO, of these children is significantly 
higher than the mean pCO, of children;" 2 months. Tlus influences the mean pCO, for 
subtype A In the whole period covering tile three seperate RSV -seasons. After correcting 
for age, the association between high pCO, and subtype A did not hold. 
Several studies investigated the possible relationship between clinical severity of 
RSV infection and subtype. MCCOlUloclue el al conclude that subtype A is related to a 
more severe disease '. TIley analysed data from 157 patients with known subtype, 
using arbitrary cut-off values at 'which a variable ,vas to be considered severe. Significant 
differences were observed In pCO, > 45 nun Hg, SaO, < 87% and respiratory rate> 72 
min-I. A significant difference was also observed between subtype A and subtype B 
regarding mechanical ventilation. Straliotto el al concluded that subtype B was related 
to a more severe disease, but their population was rather small: 29 patients ll. The 
results of both these studies are conflicting with those from our study. David el at 
concluded that there is no difference in severity between subtype A and subtype B. 
They analysed their data using a severity index consisting of three groups: severe, 
moderate and mild ['. 
In conclusion, the outcome of the analysis of the data obtained in our study indicate 
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that there is no relationship between clinical severity of RSV infection and subtype A 
or B. Hence it is not necessary to determine subtype at presentation, because there are 
no consequences for clinical lllanagenlent. TIle outCOlne of our study also hnplies that 
the developlllent of a vaccine has to use a strategy which uses antigenic epitopes, 
which are shared by subtype A as well as by subtype B. 
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ABSTRACT 
Respiratory syncytial virus (RSV) infections are characterized by upper or lower 
respiratOlY tract diseases induding bronchiolitis and pneumonia. Apnoea may be the 
first sign of disease in children with RSV infection. The aims of this study were the 
identification of independent risk factors for RSV associated apnoea and the prediction 
of the risk for mechanical ventilation in children with RSV associated apnoea. Medical 
records of children YOlmger than 12 months of age admitted with RSV infection between 
1992 and 1995 to the Sophia Children's Hospital, were reviewed. Demographic 
parameters, clinical features and laboratory parameters (SaO" pCO, and pH) were 
obtained upon admission and during hospitalisation. Children with and without 
apnoea were compared using muvariate and Inlutivariate logistic and linear regression 
analysis. One hundred and eighty-five patients with RSV infection were admitted. 
TI1irthy-eight (21 %) presented with apnoea. Patients with apnoea were significantly 
YOlUlger, had a significantly lower temperature, higher pCO, and lower pH and had 
on chest radiographs also more signs of atelectasis. TI,e number of patients admitted 
to the lCU because of mechanical ventilation and oxygen administration was 
significantly higher in children with RSV associated apnoea. Apnoea at admission 
was a strong predictor for recurrent apnoea. TIle relative risk for Inechanical ventilation 
increased with the number of episodes of apnoea: 2.4 (95% CI 0.8 - 6.6) in children with 
one episode of apnoea (at admission) versus 6.5 (95% CI 3.3 - 12.9) in children with 
recurrent episodes of apnoea. 
Conclusions Age below 2 months is the strongest independent risk factor for RSV 
associated apnoea. Apnoea at admission increases the risk for recurrent apnoea. The 
risk for mechanical ventilation significantly increases in children who suffer frolll 
recurrent apnoea. 
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4.1 INTRODUCTION 
RespiratOlY syncytial virus (RSV) has been identified as the most important cause 
of respiratory tract infections in infants and Y01U1g children since its first isolation 
from an infant with lower respiratory tract infection in 1956 3,6, RSV, a member of the 
genus pneunloviddae fronl the family of paranlyxoviridae, causes ·worldwide aIulual 
epidemics, Most infections have a mild course, However, a small number of infected 
children (05% to 2%) develop severe disease necessitating hospitalisation 5, 
The major presenting symptoms in RSV infection are those of upper respiratory 
tract infection (URTI) and lower respiratory tract infection (LRTI), including 
bronchiolitis and pneumonia in infants younger than six months of age 9,11, Apnoea 
may be the first sign of disease, The incidence of RSV associated apnoea in Y01U1g 
infants is estimated at 16% to 20%, Suggested risk factors for apnoea include young 
age and prelnaturity 1,2.4, The aetiology of apnoea however renlains unknown. 
Ftuthernlore, there is limited information about the need for Inechanical ventilation 
after an initial episode of apnoea 12. 
The objective of this study was (iJ to look for independent risk factors for the 
development of RSV associated apnoea and (ii) to study the risk for mechanical 
ventilation in infaIlts with RSV associated apnoea. 
4.2 PATIENTS AND METHODS 
4,2,1 PATIENTS 
Patients younger than 12 months of age who were admitted to the Sophia Children's 
Hospital Rotterdam due to RSV infection in the period between 1992 and 1995 were 
included in the study, The Sophia Children's Hospital is a lmiversity hospital with 
secondary and tertiary care function, 
RSV infection "vas virologically confinned by a positive direct inununofluorescent 
assay (DIFA) and/ or a positive viral culhu'e on HEp-2 cells performed on specimen 
obtained from nasopharyngeal washing, 
4,2,2 VARIABLES 
Medical records were reviewed to collect demographic and clinical data, 
Demographic parameters included gender, age at diagnosis, gestational age, 
birthweight and the presence of any of the three following lU1derlying diseases: 
congenital heart disease, bronchopulmonaty dysplasia and T-cell immlU1odeficiency, 
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Clinical data obtained at presentation included information on impaired feecting, the 
presence of wheezing, the presence of reh'actions, respiratmy rate and body temperature. 
Laboratmy parameters obtained on admission included SaO" pCO, and pH. TI,e arterial 
oxygen saturation (SaO,) was measured h'anscuteanously by a pulse oximeter (Nellcor 
100/200). pCO, and pH were measured on capillary blood samples. 
4.2.3 DIAGNOSTIC DEFINITIONS 
Apnoea at admission was defined as the following: (i) apnoeic spells (a history of 
respiratOlY arrest with cyanosis) leading to hospitalisation, or (ii) an observation in 
the paediatric emergency room of respiratory arrest for a period longer than 20 seconds 
and/ or bradycardia with accompanying cyanosis or oxygen desahlration below 90%. 
Recurrent apnoea was defined as apnoea during hospitalisation - observation (v,"ith 
a Nellcor 100/200, alarm set at oxygen saturation below 95% and/or heart rate below 
100/min) of respiratory arrest for a period longer than 20 seconds and/or bradycarctia 
with accompanying cyanosis - following a prior episode of RSV associated apnoea 
whicilled to hospitalisation. Upper respiratory tract infection was defined by coughing 
and/or rhinitis ,vith no abnonnalities on chest radiograph. Lower respiratory tract 
30 
25 
10 
0- <, 2 4 6 
Age <3\ oomisslon (mooths) 
mApnoea al admlss!on 
ONo apooe.a al admisskal 
10 11 
Figure 4.1 Tile relatioll lietweell age allli RSV associated apnoea at admissioll in a total group oj 185 patients 
l/Ospifalised with RSV injectio1l (1992 - 1995). 
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infection was defined by clinical featmes (signs of URTI with tachypnoea, diffuse 
rhonchi, fine rales and wheezing) and the presence of atelectasis, hyperinflation, 
bronchial thickening and/or an infilh·ate on chest radiograph. Chest radiographs 
,vere assessed by two radiologists. The following characteristics of hospitalisation 
were also documented: the dmation of (ICU) admission, oxygen administration and 
Inechanical ventilation. Indications for Inechanical ventilation ,vere to control apnoea, 
clinical deterioration or acidosis with severe hypercarbia (pCO, > 8.0 kPa). 
4.2.4 STATISTICAL ANALYSIS 
Subjects were divided into two groups: group I (apnoea at admission) and group II 
(no apnoea). Tabular analysis was performed using the X'-test or the Fisher Exact Test 
when the value of any cell was belmv five. Mean values 'were cOlnpared using either 
the Student's I-test or the Maml Whitney-U test when data were not normally 
dish·ibuted. To identify risk factors for apnoea, the relative risk (RR) and 95% confidence 
interval were calculated from 2 x 2 tabels. A RR with the 95% CI including 1 indicates 
no significant association betvveen a risk factor and apnoea. As the various factors 
,vere interrelated, all findings were corrected for gender, age at adnlission and 
gestational age using llndtivariate linear and logistic regression analysis to examine if 
the association between apnoea and a certain variable relnained. 
Patient characteristics - based upon the literatme - which might playa role in the 
developlllent of RSV associated apnoea ,vere subsequently entered in a ll1ultivariate 
logistic regression model in order to assess their independent contribution to the 
probability of such an apnoea. A forward inclusion selection of variables ,vas pedonned 
to identify the l1l0st ilnportant predictors for apnoea. Variables were entered until no 
remaining candidate variable met a significance level of 0.05 or below. TI,e vill·iable(s) 
in the final model were considered to be the strongest predictor(s) for RSV associated 
apnoea. 
Statistical anal),sis was performed using the software program SPSS 6.1"" for 
vVindmvsThf. P - values::; 0.05 ,vere accepted as significant. 
4.3 RESULTS 
4.3.1 VALIDITY OF THE STUDY 
In 179 children (97%) both DIFA and viral culhu·es were positive. In three patients 
only the DIF A was positive illld in illlOther tluee children only viral cultmes were 
positive. Data on gender illld poshlatal age could be obtained in all patients. Data on 
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Table 4.1 Characteristics of 185 patiel/ts hospitalised with RSV illfectioll between 1992 and 1995 
Group I 
(apnoea a 
admission) 
(n - 38) 
Patient demographics 
Boys/Girls (~ RC) 20/18 
Underlying disease 6 
Gestational age (wks) 36.6 ± 3.8 
< 32 weeks 4 
Birthweight (gr) 2813 ± 7 
Age (months 2.3 ± 2.5* 
.s: 60 days 19 
~ 42 days 14 
.s: 28 days 7 
Weight at admission(gr) 4769 ± 1888 
Findings on admission 
Impaired feeding 30 
Presence of wheezing 15 
Presence of retractions 21 
Temperature (0C) 37.3 ± 1.2*" 
Respiratory rate (/min) 54 ± 21 
Blood gas analysis 
SaO, (%) 85 ± 16' 
pCO, (kPa) 7.4 ± 2.4* 
pH 7.31 ± 0.13' 
Features on chest radiograph 
Atelectasis 18' 
Hypertranslucency 20 
Infiltrate 3 
Bronchial thickening 16 
Type of disease 
LRTI 28 
URTI 9 
Characteristics of hospitalisation and disease cours 
Duration of hospitalisation (days) 10.7 ± 6.2 
Number of leU·admissions 31 * 
Duration of ICU stay (days) 7.2 ± 10.5 
Oxygen administration 29* 
Duration of 0, adm. (days) 6.1 ± 5.9 
Mechanical ventilation 14** 
Duration of mech. vent (days) 6.2 ± 5.1 
Apnoea during hospitalisation 18"* 
*p < 0.05, ** P < 0.005 
Numbers expressed as absolute figures or menn ± stm1dard deviatioH 
NA: not applicable, RC: referel1ce category 
Group II 
(no apnoea at 
admission) 
(n -147) 
99/48 
22 
37.6 ± 3.6 
10 
2998 ± 1885 
3.3 ± 2.8 
47 
28 
11 
5855 ± 4290 
103 
47 
80 
38.0 ± 0.9 
51 ± 15 
90 ±9 
6.5 ± 1.8 
7.36 ± O. 
37 
73 
9 
45 
109 
38 
9.7 ± 5.5 
46 
5.3 ± 4.2 
80 
5.3 ± 10.4 
14 
5.6 ± 3.6 
6 
RR (95%CI) 
0.6 (0.4 -1.1) 
1.1 (0.4-2.8) 
n.a. 
1.6 (0.5 - 4.7) 
n.a. 
n.a. 
1.6(1.1-2.3) 
1.9 (1.2 -3.2) 
2.7 (1.2 - 6.3) 
n.a. 
1.1 (0.9-1.4) 
1.4 (0.7 - 2.9) 
0.9 (0.4 - 2.0) 
n.a. 
n.a. 
n.a. 
n.a. 
n.a. 
1.4 (1.0 -1.9) 
1.1(0.9-1.4) 
1.5 (0.5 - 4.5) 
1.2 (0.9 - 1.7) 
1.0 (0.8 - 1.3) 
RC 
n.a. 
9.7 (4.0 - 23.7) 
n.B. 
2.7 (1.2 -6.1) 
n.a. 
5.5(2.3-13.1) 
n.a. 
gestational age, birthweight and weight at admission could be acquired in 90%, 85% 
and 94%. Data on chest radiographs were obtained in all but one patient. Findings on 
admission were complete for more than 94% of the study population. SaO, was 
measlU'ed in 85%. Data on blood gas analysis were obtained in 88% of the study 
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population. 
4.3.2 APNOEA AT ADMISSION 
Between 1992 and 1995, 185 children with RSV infection were admitted to the 
Sophia Children's Hospital. The clinical characteristics of these patients are 
slllunarized in Table 4.1. TIlirty-eight children (21 %) presented with apnoea. Eighteen 
of the 38 patients with apnoea at admission (47%) developed recurrent apnoea (RR 
11.6, 95% CI 4.9 - 27.2). A history of apnoea of premahlrity was docllllentated in only 
two (5%) children who presented with RSV associated apnoea. 
Significant differences were found in nlean age, lnean peoz' nlean pH, Inean 
tempera hIre and presence of atelectasis on chest radiograph. The age distribution is 
depicted in Figure 4.1. Characteristics on disease course and of hospitalisation are 
sununarized in Table 4.1. More children ,vith apnoea than without apnoea were 
admitted to the intensive care ,mit (RR 9.7, 95% CI 4.0 - 23.7), received oxygen 
adminish'ation (RR 2.7, 95% CI 1.2 - 6.1) and required mechanical ventilation (RR5.5, 
95% CI 2.3 -13.1). 
In further analysis, all findings were corrected for gender, age at admission and 
gestational age using multivariate lineal' and logistic regression analysis. TIus analysis 
delllonstrated that the assocation behveen apnoea and respectively lmver telnperatw'e, 
high pCO" low pH, the presence of atelectasis, ICU adnussions and mechanical 
ventilation relnained. 
Table 4.2 shows the conh'ibution of gender, age at adnussion, premahlre birth, 
weight at admission and type of disease to the risk for developing RSV associated 
apnoea. After a forwru'd inclusion, age at adlnission renlained the only significant 
variable contributing to the risk for apnoea. TI,e probability of RSV associated apnoea 
Table 4.2 The c01ltribution of gender, age at admission (months), premature birth, weight and type of disease 
to the risk for apl/oea at admission (jJ coefficiellt's estimate, SE stalldard error of the coefficiellt's t'stimafe) 
B SE p- value 
I Full model 
INTERCEPT ·0.89 0.64 
Gender 0.70 0.39 0.08 
Age at admission (monlhs) ·0.16 0.10 0.13 
Premature birth 0.29 0.47 0.53 
Weight on admission (gr) -6.5x10-5 0.00 0.56 
LRTI ·0.05 0.44 0.90 
/I After fOlWard inclusion of variables: 
INTERCEPT -0.87 0.27 
Age at admission (monlhs) ·0.17 0.08 0.04 
Reslllts are from a forward c01lditi01l stepwise logistic regressio1l analysis procedllre 
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Figure 4.2 The prollallility of delleloping RSV associated apnoell at admissioll as a flll/etioll of age at 
admissioll (the contillued fille represellts the probability, wllt're the daslIed linl's represellt tlte Ilpper lIud lower 
limits of fhe 95% confide1lce interval) 
at admission, as a ftmction of the child's age at admission, is depicted in Figure 4.2. 
Twenty-fom children developed an episode with RSV associated apnoea in hospital. 
Apnoea during hospitalisation occurred in 54% 'i'ithin the first day after admission 
and in 88% '''ithin two days after admission, 
4.3.3 APNOEA AND MECHANICAL VENTILATION 
TIle lllunber of episodes with apnoea influenced the risk for nlechanical ventilation. 
The relative risk for mechanical ventilation increased from 2.4 (95% CI 0.8 - 6.6) in 
patients with only (a history of ) apnoea at admission to 6.5 (95% CI 3.3 - 12.9) in 
patients ,,,ith reCUlTent apnoea. 
Two patients died. One death, a term born 1 month old child, was conh'ibutable to 
apnoea at home. The other death, a term born 3 month old, suffered from gangliosidosis 
type I. 
4.4 DISCUSSION 
Of all children admitted with RSV infection to the Sophia Children's Hospital 
56 
Risk factors for RSV associated apllOea 
between 1992 and 1995, 21 % presented with apnoea. 111is is in agreement with other 
studies, reporting that the incidence of R5V associated apnoea varies between 16% 
and 20% 1>.'. 
Y mUlg age was related to the development of R5V associated apnoea as has been 
demonstrated previously I.'. Age remained the only independent risk factor for R5V 
associated apnoea after logistic regression analysis. Especially children younger than 
two 1110nths of age 'were at an increased risk for the developl11ent of RSVassociated 
apnoea. 
Children admitted with RSV associated apnoea - either at home or observed in the 
pediatric elnergency r00111 - were at increased risk for the developlnent of reClUTent 
apnoea. Patients with recurrent apnoea often required Inechanical ventilation. This 
finding has iInplications for clinical lnanagelnent; infants 'with increased risk for 
recurrent apnoea should be closely 111onitored. The risk for RSV associated apnoea 
was highest in the first 48 hours after admission and diminished thereafter. 
Prematurity ,vas not related to RSV associated apnoea. 111is finding is in contrast 
'with previous studies 1,2,4. In these studies, it was also reported that a history of apnoea 
of prematurity was more frequently fmUld in infants with R5V associated apnoea. 
This could not be confirmed in our study. 
The aetiology of RSV associated apnoea remains lmknmvn, although several 
theories have been proposed. Church et al suggested that severe clinical illness may 
predispose to R5V associated apnoea'. 111is may be due to a more severe degree of 
hypoxenua, secondary to severe Imver respiratory h'act disease. Another group of 
investigators reported that in patients with apnoea lllore signs of pulmonary 
parenchYlnal involvenlent, iIlCluding an increased nurnber of infiltrates, were found 
lOW' data indicate that there was no difference in5aO, and also no difference regarding 
type of disease between patients with and without (a history of) apnoea at admission 
after correcting ,vith l11ultivariate logistic regression analysis. However, we did find 
l110re atelectasis and a higher pC02 and an iIlcreased need for oxygen treatment in 
patients with apnoea. 111is 111a1' indicate a l110re severe disease state. The higher pC02 
values and increased tendency to atelectasis could also be considered as a result of 
apnoea, and not as a causative factor. 
Another explanation for apnoea is that respiratory syncytial virus alters the 
sensitivity of laryngeal chcl11oreceptors, thus causing a prolonged or even fatal apnoea 
when these receptors are stiInulated 8,10. Furthermore, the OCClUTence of apnoea is not 
related to R5V subtype, as was previously reported by our group '. 
A factor that most likely plays an important role in RSV associated apnoea is a 
inmlaturity of the respiratory conh'ol cenh'e in the brain stem. In our study, only ymUlg 
age was independently related to apnoea, indicating that the degree of matlll'ation of 
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the respiratory control center in yOlUlg infants plays a role in RSV infection. This 
implies that RSV associated apnoea is of cenh'al origin. 
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ABSTRACT 
Respiratory syncytial virus (RSV) accmmts for the majority of lower respiratory 
tract infections (LRTI) in infants and ymmg children. A chest radiograph is frequently 
performed in infants with RSV LRTI. TI,e aim of this study was to develop and validate 
a prediction model to estimate the probability for a normal chest radiograph by using 
easily obtainable diagnostic parameters in children with RSV infection. TItis prediction 
model may be applied to decide which patients do not have an indication for a chest 
radiograph. 
TI,e data of 287 children admitted with RSV infection 01' diagnosed as such in the 
outpatient department of the Sophia Children's Hospital between 1992 and 1996, 
were studied. The derivation set comprised 232 patients (1992 -1995), the validation 
set contained 55 patients (1995 -1996). A chest radiograph was designated as normal 
when atelectasis, hyperinflation and pulmonary infiltrates were absent. In order to 
develop a prediction lHodel, patient history, clinical and laboratory variables were 
consecutively entered into a logistic regression model according to the diagnostic 
work-up in practice. Variables with p - values,,; 0.10 were retained in the model. The 
predictive accuracy of the 111ultivariable 1110dels 'was exmnined using the area under 
receiver operating curve (ROC-area). 
In 202 (87%) patients from the derivation set a chest radiograph was performed. A 
normal chest radiograph could be predicted by increasing age, increasing birthweight, 
presence of rhinitis, absence of reh'actions and increasing Sa02, The ROC-area was 
0,80 in the derivation and validation set. This prediction lnodel was tnulsfonned into 
a score chart. 
COllclusiolls A normal chest radiograph can easily be predicted using a model 
including easy obtainable patient characteristics, clittical and laboratory variables. It 
may be a useful tool in the decisiomnakingwhether or not to perfonn a chest radiograph 
in patients with RSV-ituections. 
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5.1 INTRODUCTION 
Respiratory syncytial virus (RSV) accounts for the majority of lower respiratory 
h·act infections in infants and yOtUlg children '. The diagnosis of RSV infection is 
based upon clinical findings and virological confirmation. The chest radiograph is 
not diagnostic. Also, the spectrum of roentgenographic findings in RSV infection -
atelectasis, hyperinflation or pulmonary infiltrate - does not necessarily correlate ·with 
severity of illness 2,.3, However, a chest radiograph is still performed in approximately 
70% of all hospitalised infants visiting the pediatric outpatient department with signs 
and symptOlns of RSV lower respiratory hact infection 4, Hence, it ,vould be interesting 
to identify a subgroup of RSV patients in which a normal chest radiograph can be 
predicted. Identification of these patients reduces the number of Ulmecessary chest 
radiographs. 
The aim of tlus study was to develop and validate a prediction model to estimate 
the probability for a normal chest radiograph inRSV patients using easily obtainable 
diagnostic parameters documented fr0111 the patient's historYI physical exanlination 
and laboratory results. 
5.2 PATIENTS AND METHODS 
5.2.1 PAT/EIfTS 
The shldy population consisted of children younger than 12 months of age, who 
either visited the outpatient deparhnent or were adntitted to the Sopltia Children's 
Hospital with virologically confirmed RSV infection in two periods: 1992 - 1995 
(derivation set) and 1995 -1996 (validation set). Data from the first period were used 
to derive a prediction model (derivation set) and from the second period to evaluate the 
performance of the prediction model in an independent population (validation set). 
Virological confinnation was defined by a positive direct imnllUlOfluorescent assay 
(DIFA) and/ or a positive viral cuItme on HEp-2 cells performed on specimens obtained 
froln nasopharyngeal washings, Children with nosocontial RSV infections were 
excluded, Demographicall clinical and laboratory data obtained at arunission ,,,ere 
acquired by a review of the patient's medical chart as previously described '. In brief, 
these included gender, postnatal age, gestational age, birthweight, the presence of an 
underlying disease state, presence of impaired feeding, presence of wheezing and 
reh'actionsl respiratory ratel body teInperaturel transcuteanously registered oxygen 
sahlration measmed by a Nellcor 100/200 and pCO, measmed on capillary blood 
smnples, 
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5.2.2 CHEST RADIOGRAPHY 
Chest radiographs were assessed by one of two paediatric radiologists of our 
hospital. The outcome was classified as normal, atelectasis, hyperinflation or 
pulmonary in£iltrate. Atelectasis was defined as a collapse of bronchioli without air 
bronchogram 6. Hyperinflation was defined as a depression of the diaphragm below 
the 6th intercostal space of the anterior rib. A pulmonary infilh'ate was defined as 
lobar, segmental or subsegmental opacities with discrete or irregular margins. A chest 
radiograph was designated as normal when atelectasis, hyperinflation and pulmonaq 
infiltrates were absent. 
5.2.3 STATISTICAL ANALYSIS 
The aiIn of the analysis "Vas to discriminate between patients ·with a nonnal chest 
radiograph and patients without a normal chest radiograph. In the derivation set the 
probability of a normal chest radiograph was related to each potential predictor to 
identify candidate predictors using univariable logistic regression analyses (SPSS 8.0, 
Chicago, Illinois, USA, 1998). Variables with p-value,; 0.15 were consecutively entered 
in the multivariable models starting with the demographic, history and physical 
examination variables and subsequently extending with laboratory variables 7.8. 
Variables with p-values,; 0.10 in the multivariable models were retained in the model. 
Missing values ,vere inlputated using the expectation and lnaxilnization lnethod 
avaible in the standard SPSS software to increase statistical efficiency 9.10. Such 
hnputation is based on the correlation between each variable with missing values 
from all other variables. These correlations are estimated from the subjects from which 
all data were available. 
Predictive accuracy of the multivariable models was distinguished in reliability 
and discrimination '. Reliability (goodness of fit) was assessed using the Hosmer & 
Lemeshmv nlethod 11,12. TIle discrinlination of each lnodel was assessed using Receiver 
Operating characteristic (ROC) Ctffi'es. TI,e area under the curve (ROC area) is a suitable 
paratneter to sununarize the overall discriminative or diagnostic value of a nl0del 8,12. 
The ROC area can range from 0.5 (useless model, like a coin flip) to 1.0 (perfect 
discrimination). A value of 0.80 or greater can be interpreted as good 13. TI1e difference 
in ROC area (with 95% confidence interval) between models was used to estimate the 
added value of an extended model over a reduced model I'. In these comparisons, 
correlation between mode1s Was taken into account as they were based on the saIne 
cases 15. 
The final prediction lnodel was rransfonned into a score chart. Scores for each 
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Table 5.1 COlllparisoll of delllographiClll characteristics of pafiel/ts ill tlte derivatioll a11d i11 tile validatioll sef 
Age (months) 
Birthweight (kg) 
Gestational age (weeks) 
Weight (kg) 
Underlying disease state 
Normal chest radiographs 
Derivation set 
(n - 202) 
3.3 ± 2.9 
2.9 ± 0.9 
37.4 ± 3.6 
5.5 ± 2,0 
15.8% 
37% 
Validation set 
(n - 51) 
4.7 ± 3.7 
3.2 ± 0.8 
37.7 ± 3.0 
6.3 ± 2.4 
7.8% 
45% 
predictor were derived from the logistic regression coefficients, multiplied by 10 and 
rounded to ·whole nl.unbers. 
5.3 RESULTS 
5.3.1 STUDY POPUlATION 
Between 1992 and 1995, 232 children were diagnosed with RSV infection. In all but 
six children both DIFA and viral culture were positive. In 202 children (87%) a chest 
radiograph was performed. Data of these children were used for the derivation set. 
Gestational age, birthweight and weight at presentation were obtained in 89%, 85% 
and 86% respectively. Clinical findings at presentation were present for at least 92% of 
the study population, The arterial oxygen saturation ·was nleaSlll'ed in 82%, blood gas 
analysis was performed in 95%. The results of the analyses based on the complete 
subjects (n ~ 138) and on subjects after imputation, yielded no differences so that the 
imputated approach is presented. The same method was applied to the validation set. 
Out of 202 children in whom a chest radiograph was performed, 75 (37%) had no 
abnormalities. 127 (63%) children had either atelectasis, hyperinflation and/or 
pulmonary infilh'ate found on chest radiographs. 
In 1995 - 1996, 55 children were diagnosed with a virologically confirmed RSV 
infection of which 93% had a chest radiograph. Table 5.1 summarizes the demographic 
characteristics of the derivation and the validation set, which yielded the same 
distribution except for age which was significantly higher in the validation set 
(p ~ 0.04). 
5.3.2 DERIVATION OF THE PREDICTION MODEL 
Table 5. 2 sllnmlarizes the results of the tmivariable analysis. Variables significantly 
associated with a normal chest radiograph were increasing postnatal age, increasing 
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Table 5.2 Results from the IIl1ivariable analysis all predictors for a lIorlllal cltest radiograplt (Ilbsel/ce of 
atelectasis, llyperillfiafioll and/or pllimollary jllfiltrate) ill the derivatioll set, Figures are depicted as eitller 
lIIefl1lS ± stalldard deviatiolls or absolute lIumbers 
Normal chest 
radiograph 
(n = 75) 
DemograpMc characterisUcs and paUenl history 
Male gender 
Postnatal age (months) 
Gestional age (weeks) 
Birthweight (gr) 
Underlying disease state 
Cough 
Rhinitis 
Impaired feeding 
Apnoea at admission 
Physical examination 
Pulse rate (Imin) 
Respiratory rate (lmin) 
Weight (kg) 
Temperature (0G) 
Retractions 
Wheezing 
Laboratory investigation 
8a02 (%) 
pCO, (kPa) 
51 
4.2 ± 3.4 
37.7 ± 3.3 
8 
67 
71 
46 
11 
145 ± 24 
52 ±20 
6.1 ± 2.3 
38.0 ± 0.8 
28 
22 
94,1 ±5,8 
5.7+1.0 
Abnormal chest 
radiograph 
(n = 127) 
79 
2.7 ± 2.4 
37.2 ± 3.8 
24 
116 
105 
96 
26 
154 ± 27 
52 ± 15 
5.2 ± 1.8 
37.8 ± 1.0 
79 
52 
87.9 ± 12.3 
7.0± 2.1 
P- value 
0.41 
0.001 
0.35 
0.10 
0.12 
0.64 
0.02 
0.03 
0.44 
0.03 
0.97 
0.01 
0.07 
0.001 
0.10 
< 0.001 
< 0.001 
birtlnveight, the presence of rhinitis, increased pulse rate, increasing body 'weight, 
decreasing body telnperatul'e, the absence of retractions, the absence of wheezing, 
increasing h·anscutaneously measured oxygen saturation and decreasing pCO,. These 
variables lvere consecutively entered into a 11lltltivariable logistic regression analysis. 
Table 5.3 presents the reslllts of the multivariable logistic regression aUlalysis. The 
initial model contained the significant variables poshlatal age in months, birthweight 
in kg, the presence of rhinitis and the absence of retractions. The area under the ROC-
curve for this model was 0.74 (SE 0.04) (Figure 5.1). After adding SaO, and pCO, to the 
model, only SaO, conh-ibuted significantly to the outcome of the chest radiograph. TIle 
ROC-area increased to 0.80 (SE 0.03). All models showed good reliability; the Hosmer 
& Lonleshe,v test ,vas far frOtn significant (data not shown). 
5.3.2 PERFORMANCE OF mE MODEL 
The logistic regression coefficients (the OR) of the final model from table 5.3 were 
h·ansfonned to a score chart (Table 5.5). Table 5.4 summarizes the performance of the 
prediction model in both the derivation and validation set. TIle original score ranged 
from -56 to 27, a correction factor of +56 was added to the prediction role to make the 
score range from 0 to 83 points. The value -64 represents the intercept from the logistic 
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Table 5.3 Results from fI/{' llIultillarillte logistic resressiollllllillysis 0/1 predictors for 1l1lormal cllest radiograph 
Model Modell 
Demographical characteristics 
and patient history 
Variables 08 (95% Cit 
Demographic characteristics, patient history and physical examination 
Age (months) 1.2 (1.1 - 1.4) 
Birthweight (kg) 1.3 (1.0 - 1.6) 
Presence of rhinitis 3.4 (1.0 - 10.9) 
Absence of retractions 2.6 (1.4 - 4.8) 
Laboratory examination 
Sa02 
ROC area (95% CI) 0.74 (0.66 - 0.82) 
Model 2 
Model 1 + laboratory 
examination 
OR (95% Cit 
1.2 (1.1-1.3) 
1.2 (1.0 - 1.6) 
3.2(1.0-11.1) 
2.2 (1.2 - 4.3) 
1.8 (1.3 - 2.6) 
0.80 (0.74 - 0.86) 
* Tire log OR is equal to the logistic regressioll coefficiCllt, wlliell is lIsed to make the scorillSs /'/lie 
OR: Odds ratio, C[: collfidence interval 
Table 5.4 Distributioll of patiellts witll find without a normal cltest radiograph according to the calClllated 
score llsing tilt' diagnostic model from Table 5.3 ill the derillatioll alld r'fllidation set. Values I'epft'sellf ailsolllte 
IIIll1liJcrs (%). 
Score Total Normal chest Abnormal chest 
radiograph radiograph 
Derivation set 
:$;20 6 (3) 1 (1) 5 (5) 
21 - 30 18 (9) 1 (1) 17(13) 
31- 40 33 (16) 2 (3) 31 (24) 
41 -50 47 (23) 15 (20) 32 (25) 
51 -60 60 (30) 28 (37) 32 (25) 
61-70 34 (17) 24 (33) 10 (8) 
;::.: 71 4 (2) 4 (5) 0(0) 
All 202 (100) 75 (100) 127 (100) 
Validation set 
:$;20 0(0) 0(0) 0(0) 
21- 30 3 (6) 0(0) 3 (11) 
31 -40 7 (14) 3 (13) 4 (15) 
41 -50 11 (22) 3 (13) 8 (30) 
51 - 60 12 (24) 8 (35) 4 (15) 
61 -70 15 (30) 8 (35) 7 (26) 
;::.: 71 2 (4) 1 (4) 1 (3) 
All 50 (100) 23 (46) 27 (54) 
regression model. From Figure 5.1, one can identify the best probability threshold 
(associated with the highest sensitivity and the lowest most acceptable false positive 
rate (FPR). For instance, a total SUln score of 52 or greater ,"vas associated with a 
sensitivity of 70.7% and a FPR of 25.2. From Table 5.4, the corresponding sensitivities 
and FPRs are sUlllfllarised for various probability categories. For exrunple, in the 
derivation set the model placed 98 patients (49%) with a sum score of> 50 of which 56 
indeed had a normal chest radiograph (correctly identifying 75%) and 42 had not 
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Table 5.5 Score clllll't for calculating the probability for II norlllal cliest radiograph in RSF illjectioll 
Age (in months) 
0 1 2 3 
0 2 3 5 
Birthweighl (kg) 
:-:;: 1.99 2.0 - 2.49 
2 4 
Rhinitis 
Present 
12 
Retractions 
Present 
0 
8a02(%) 
:-:;: 74 75-79 
6 12 
4 5 6 7 8 9 10 11 
7 9 11 13 14 16 18 20 
2.5 - 2.99 3.0 - 3.49 3.5 -3.99 4.0 - 4.49 ~ 4.5 
6 8 10 12 14 
Absent 
0 
Absent 
8 
80 84 85 - 89 90-94 ~95 
18 25 31 37 
Sum score (add) 
Score 
-64 
Correction factor (add to sum score) 56 
Total score 
(incorrectly identifying (FPR) 32%). 
5.3.3 VALIDATION OF THE PREDICTION MODEL AND USE OF THE SCORE CHART 
The area under the ROC cmve of the validation set was 0.81 (SE 0.07), suggesting 
identical performance compared to the derivation set. 
For individual patients, the scores corresponding to the values of the predictors 
can be filled in on the score chart. For example, a one month old infant with a 
birthweight of 2750 grams, presence of rhinitis, presence of retractions and 
h"anscutaneously Ineasw"ed oxygen saturation of 94%, has a total stun score of 43. The 
selected score tlueshold will detern1ine ,vhether or not this total stun score is associated 
with a normal chest radiograph (sensitivity 90%, FPR 55%, figme 5.1). 
5.4 DISCUSSION 
In clinical practice, a chest radiograph is performed in a large number of patients 
visiting the outpatient clinic with LRTI by RSV '. This study provides evidence for a 
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reduction in the number of chest radiographs by identifying patients with a probability 
for a normal chest radiograph, Independent predictors for a normal chest radiograph 
in this study ,vere increasing poshlatal age in 111onths, increasing birthweight in kg., 
presence of rhinitis, absence of feeding difficulties, absence of reh'actions and increasing 
h'anscutaneously measured oxygen saturation. TIley can predict the outcOlne of the 
chest radiograph with good accuracy, 
Age and bil'thweight were independent predictors for a normal chest radiograph, 
Young age, especially below 6 months of age, is a risk factor for severe RSV-disease 
,vhich often includes pulnlonary involvement as represented in an abnol'1nal chest 
radiograph 16, Low birthweight is associated ·with slnalliower airways. TIlliS with 
increasing age and increasing birthweight, the probability for a normal chest radiograph 
increases. 
Physical exanunation of infants with RSV bronchiolitis often reveals retractions 3. 
111 this shldy, it suggests lower respiratory h'act involvement yielding a decreased 
probability for a nonnal chest radiograph. Arterial oxygen saturation nleasured 
transcuteanously is a strong measure of severity of lmver RSV infection 2,16-20. Absence 
of hypoxia may thus indicate a Honnal chest radiograph. 
The prediction lllodel Hllist serve as an additional tool in the diagnostic procedure 
fr01n which a physician can detennine which tlu'eshold one favours balancing the 
benefits ofperfonning a chest radiograph and the non-benefits of missing abnormalities 
100,0 -
" " 
36 34 32 30 28 26 24 
90,0 -
W,O 
70,0 
60,0 -
i 56 50,0 56 
40,0 
60 
30,0 
0,0 10,0 20,0 30,0 40,0 50,0 00,0 70,0 80,0 90,0 100,0 
false posl11ve rale (FPRj 
Figure 5.1 ROC-Cllr(lt' rieriued frol1l tile multivariate logistic regression analysis all data from tile derivatioll 
set for predictors for a 1I0rl1lal chest radiograph. 
67 
Chapter 5 
on chest radiograph. A total sum score of > 52 (Figure 5.1) is in our view associated 
with the best performance of the prediction model (the most balanced positive and 
negative predictive value, Figure 5.1). However, in approximately 25% of the patients 
an abnormal chest radiograph shall then be falsely predicted as normal. Tlus must be 
judged in the light of clinical practice. A poor correlation between the clllucal diagnosis 
of broncluolitis and the presence of hyperinflation has been described 21. Atelectasis is 
usually transient and resolvement starts within a few days. Within three months after 
initial diagnosis of respiratory tract infection, atelectasis has resolved cOlnpletely 22, 
However, atelectasis also Inay reinain present and becOIne a focus for bacterial 
superinfection, One group found atelectasis to be Blore COB1Blon in combined bacterial 
and RSV infection than in infections with RSV alone. The authors suggested that chest 
radiographs are llnportant III the asseSSInent of 'which patients 'with bronchiolitis 
need to be treated with antibiotics ". Howevel~ other iovestigators reported that bacterial 
superlluection seldomly occtrrs 2-1,25, 
We suggest to perform chest radiographs in children with RSV-LRTI if they have a 
low probability for a normal chest radiograph as can be calculated by OUI' 111odel, and 
if there is an lU1expected deterioration III the patient's condition 26, 
A limitation of our study is that not in all children a chest radiograph was performed. 
Ho,\vever, the reason for the Olnission of a chest radiograph will be the presence of a 
(very) nllld disease. No differences in demographical and clinical characteristics 
between patients 'with a normal chest radiograph and patients with a llussing chest 
radiograph were fOlUld. Therefore, tlus selection bias has not influenced our results. 
11,e chest radiographs were assessed by one of two paediah'ic radiologists. No 
lluonnation on lllterobserver reliability between the two radiologists 'was available. 
111is may have influenced especially the number of pulmonary infiltrates. One study 
reported a Inoderate lllterobserver coefficient for perihilear linear opacities or 
infiltrates 27, 
Although the prediction model was validated, tlus model requires a prospective 
validation, 
In conclusion, this study demonstrates that an increased probability for a normal 
chest radiograph III RSV infection is associated with lllcreasing age, increaslllg 
birthweight, the presence of rhlllitis, the absence of retractions, and lllcreaslllg 
transcutaneously measured oxygen saturation. vVith the prediction lllodel, the 
probability for a normal chest radiograph in the individual patient can be estimated. 
111is model may be a useful tool in the decisionmaking whether or not to perform a 
chest radiograph. TIlis will reduce exposure to radiation and costs associated 'with 
chest radiography. 
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ApPENDIX 
TIle exact formula to calculate the SLUn score is: 
Sum score (normal chest radiograph): -6.43 + 0.18 * (age in months) + 0.21 
(birthweight) + 1.18 * (rhinitis) + 0.80 (reh'actions) + 0.61 (h'anscuteanously measlU'ed 
oyxgen satmation). 
For birthweight the following strata have been applied where 1 ~ S 1.99, 2 ~ 2.00-
2.49, 3 ~ 2.50 - 2.99, 4 ~ 3.00 - 3.49, 5 ~ 3.50 - 3.99, 6 ~ 4.00 - 4.49 and 7 ~ ~ 4.50. The 
variable rhinitis is 1 'when present and 0 'when absent, the variable retractions is 0 
when present and 1 ,vhen absent. For transcuteanously Ineasured oxygen saturation 
the following strata have been applied where 1 ~ S 74, 2 ~ 75 -79, 3 ~ 80 - 84, 4 ~ 85-
90, 5 ~ 90 - 94 and 6 ~ ~ 95. The corresponding probability is calculated by (1 / (1 + 
exp(-(sumscore / 10)))) * 100. 
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ABSTRACT 
Objective To investigate the occurrence and clinical features of nosocomial RSV 
infections in comparison with COlIulUUlity acquired (CA-RSV) RSV infections in the 
Sophia Children's Hospital in the period between 1992 and 1995 and to propose a 
guideline for the prevention of nosocomial RSV infections. 
Desigll Retrospective. 
Methods Children YOlmger than 12 months of age withRSV infection were included. 
The diagnosis RSV infection 'vas con finned by a positive direct imnnmofluorescent 
assay (DIFA) and / or a positive viral culture on materials obtained from 
nasopharyngeal washes. A nosocOlnial RSV infection was defined by an infection 
,vhich occurred 1110re than five days after hospital adlnission for any lUlderlying 
disease. Denlographical and clinical data were studied and c0111pared between 
children with nosocomial RSV infections and those with conunlillity acquiTed RSV 
infections. 
Results 1260 children younger than 12 months of age were admitted during tluee 
RSV seasons. Thirty-four (2.7%) of these children developed a nosocomial RSV 
infection. The number of nosocomial RSV infections decreased during the study 
period. 232 children with a community acquired RSV infection were included. 
Significant differences between NA-RSV and CA-RSV were only fOlmd regarding 
birthweight (2.5 kg ± 0.9 versus 3.0 ± 0.9 for community acquired RSV -infection, 
p = 0.004), cough (64.7% versus 91.8%, p < 0.001) and impaired feeding (100% versus 
68.9%, p < 0.001). All children with BPD and NA-RSV required mechanical ventilation. 
COllcillsioll The lllunber of nosocomial RSV infections decreased during the period 
1992 -1995. Nosocomial RSV infections are comparable to community acquired RSV 
infections in severity of disease. Based upon the literahu·e, handwashing renlains 
the best preventive approach. 
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6.1 INTRODUCTION 
Respiratory syncytial virus (RSV) relnains the 1110St important canse of virallo,ver 
respiratory h'act infections in infancy and has great health care impact on the elderly 
and inunllll0colllprOlnised patients 1. This virus conunonly causes nosocOlnial 
infections, which are infections acquired during hospitalisation and Inay result in a 
severe disease course with increased 1110rtality rates in a general hospital popula-
tion 2.-1, 
The percentage of nosocomial infections by RSV varied in American and Europerul 
studies behveen 3.5% and 7% -l-B, Very fe,Y data are available about the situation in 
TI,e Netherlands. 
The objectives of this study were (i) to estitnate the percentage of nosocomial 
infections by RSV, (ii) to compare characteristics of nosocomial infections by RSV 
(NA-RSV) with COllUlUUlity acquired RSV infections (CA-RSV), and (iii) to develop 
clinical guidelines for the prevention of nosocomial RSV infections. 
6.2 PATIENTS AND METHODS 
h1 this study, infants younger than 12 months of age eliagnosed with a RSV infection 
between 1992 and 1995 - spamung t1U"ee separate RSV seasons - at the Soplua 
Children's Hospital were included. The RSV-season starts October 1st and ends March 
31st the following year. Demographical and clinical data were retrieved frOl11 the 
patient's medical chart'. The eliagllOsis RSV infection was virologically confirmed by 
a positive direct inununofluorescent assay (DIF A) ruldj or a positive viral culture on 
HEp-2 cells of materials obtained from nasopharyngeal washings. The total number 
of children ),OlUlger than 12 months of age admitted to the h,tensive Care Ulut (ICU) 
and Meelilun Care Unit (MCU) of our hospital dming the RSV season was determined. 
TIle incubation period of RSV is approximately five days 10. Hence, a nosocomial 
infection by RSV was defined as a RSV infection occurring more than five days after 
hospital admission for any other cause. For children with NA-RSV the titne span was 
determined between date of adnussion for the underlying elisease and virological 
confirmation of the RSV infection. 
Patients were divided into two groups. Group I comprised all NA-RSV, whereas 
gl'oup II comprised all CA-RSV. Statistical analysis for elichotomous variables was 
performed using the X' test (for 2 by 2 tables or 2 by II tables to estimate the siglillicance 
of a trend) or the Fisher Exact test. The MaIm Wlutney-U test was applied for continous 
variables. All statistical aI1a1ysis were carried out using SPSS 8.0 (Chicago, Illinois 
USA 1998). A P - value <; 0.05 was accepted as statistically significant. 
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6.3 RESULTS 
Between 1992 and 1995, 266 children were diagnosed with an infection by RSV. 
111irthy-four of these children had a nosocomial infection by RSV. In the same period 
1849 children YOlUlger than 12 months of age were admitted either at the ICU or the. 
MCU of the Sophia Children's Hospital. From these infants 1260 were admitted during 
the RSV seasons. The percentage of NA-RSV was estimated at 2.7%. This percentage 
was 2.9% (12 out of 409 admissions) in the ICU and 2.6% (22 out of 851 admissions) 
in the MCU. 
The percentage of children with NA-RSV decreased dming the study period as is 
depicted in Figure 6.1. This decrease was highly significant (p < 0.001). Table 6.1 
smmnarizes the characteristics of NA-RSV compared with CA-RSV. Patients with 
NA-RSV had a significantly lower bi.rthweight (2.5 ± 0.9 kg) in comparison with 
patients with CA-RSV (3.0 ± 0.9 kg, P ~ 0.004). Approximately 35% of the children 
with NA-RSV occurred in children with congenital heart disease (CHD) or 
bronchopulmonary dysplasia (BPD). Other lUlderlying diseases comprised gash'o-
intestinal diseases (21%) and neurologic diseases (18%). 
Table 6.1 also summarizes the clinical features of patients with NA-RSV and CA-
RSV. With the exception of significant differences between the two groups regarding 
Table 6.1 Comparis01l of c1Jildrt'1I with 1I0socomial infectiolls by RSV al/d (Olll1llllllity acquired infectio1ls by RSV 
ill illfilllls alld yO/illS c!Jildrt'1l 
Nosocomial RSV 
infection 
(n = 34) 
Demographic parameters 
Boys/girls 20114 
Age (months) 3.7 ± 3.5 
Gestational age (weeks) 36.2 ± 4.0 
Prematurity «37 weeks) 12 
Bi,lhweight (kg) 2.5 ± 0.9 
BPD andCHD 12 
Weight (kg) 4.9 ± 2.3 
Clinical parameters 
Apnoea 2 
Cough 22 
Rhinitis 29 
Impaired feeding 34 
Retraclions 13 
Wheezing 8 
Respiratory rate (/min) 52 ± 15 
Pulse rate (/min) 139 ± 39 
Temperature (0 C) 36.7 ± 6.B 
Laboratory parameters 
8a02(%) 89.4 ± 7.9 
pCQ, (kPa) 6.7 ± 2.1 
74 
Community 
acquired RSV 
infection 
(n - 232) 
150182 
3.5 ± 2.9 
37.5 ± 3.6 
58 
3.0 ±0.9 
33 
5.B ±3.B 
38 
213 
204 
160 
11 
82 
52 ± 17 
146 ± 36 
37.9±1.0 
90.3 ± 10.6 
6.5 ± 2.0 
P - Value 
NS 
NS 
NS 
NS 
0.004 
0.002 
NS 
NS 
< 0.001 
NS 
< 0.001 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
600 -
300 
'00 
Ol.'umW ofctl'd(ffi < 12 months adm'tled 
ot.'urr,wofin"e<:l;oos by RSV 
ONwllWofcn'd(en < 12mooths adm'tledl\'th RSV 
rnt.'umw ofnosocDm:al in'8cUons h" RSV 
1992 - 1993 
Nosocomial i1lfectio1ls lIy RSV 
'" 
1993.1994 1994-1995 
Season 
Figure 6.1 CO/lrse hI time of tile 1Il11ll1ler ojlJosocomial il/fecti01ls by RSV compared fa the fota/1Jlllllber oj iIJfectiolls 
by RSV alld the tofallllll/lber oj cllildreu youllger 1111111 12 1I10llfl1s of age admitted to the Sophia Childrell's Hostlital 
the presence of cough (64.7% versus 91.8%, p < 0.001) and impaired feeding (100% 
versus 68.9%, p < 0.001), no other differences were observed. The lllunber of patients 
which required mechanical ventilation (NA-RSV 21% versus CA-RSV 13%) or oxygen 
supplementation (NA-RSV 50% versus CA-RSV 51%) was equally dish'ibuted among 
NA-RSV and CA-RSV. The number of deaths was significantly increased in the NA-
RSV group. 
All fot1l' children with BPD and NA-RSV required mechanical ventilation 
compared with two out of 16 children with BPD and CA-RSV (p = 0.0005). One out of 
eight children with CHD and NA-RSV required mechanical ventilation compared 
with two outof 17 children with CHD and CA-RSV (p = NS). 
6.4 DISCUSSION 
The incidence of nosocolnial RSV infections in infancy in the study 'was 
approximately 3% and decreased during the study period 1992 -1995. Patients with 
a nosocOlnial infection by RSV did not experience an enhanced disease course 
compared with those with conummity acquired infections by RSV. Only children with 
BPD and NA-RSV required more often mechanical ventilation compared with children 
with BPD and CA-RSV. Hence, hospitalised children with BPD should be considered 
for prophylaxis against infections by RSV. 
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Infants with NA-RSV had a significantly lower birthweight and more impaired 
feeding than infants with CA-RSV. These differences may be a reflection of the 
underlying disease and the characteristics of the population of the Sophia Children's 
Hospital. We could not draw any conclusion about the prolonged hospital stay in 
patients with NA-RSV. It is difficult to determine precisely the lUunber of extra hospital 
days attributable to NA-RSV since it is tmclear which endpoints need to be applied 
(clinicalimprovement? Negative RSV test?). 
Approximately 25% ofNA-RSV suffered from CHD. However, children with CHD 
and NA-RSV did not suffer frOl11 a nlore severe disease course cOl11pared "with childTen 
with CHD and CA-RSV. 11,e recollunendations from American studies to avoid hospital 
admission for patients with CHD during the RSV season are therefore not directly 
applicable for the Dutch situation '. 
The clinical presentation of children with NA-RSV was equal to that of children 
with CA-RSV. Therefore, clinical features that give evidence of a nosocOI11ial infection 
, 
by RSV are comparable to those of CA-RSV and include cough, rhinitis, dyspnoea 
and/ or apnoea. The clinical disease course was also cOl11parable behveen children 
with NA-RSV and CA-RSV. Selection bias as a result of an increased awareness of the 
occurrence of an infection by RSV dtu'ing the season may influence these observations, 
although this could not be confirmed in this study. 
Infection with RSV occurs through contact of the virus via the nose and eyes as a 
result of a large droplet aerosol or tlu'Ollgh self-inoculation after touching contamined 
surfaces on vvhich RSV inay survive for up to six hours 11. Sh'ict handwashing before 
and after any patient contact or after touching contaminated surfaces in the vicinity of 
a patient reduces the survival of RSV and thus reinains the 11l0St ilnportant preventive 
approach 1,7. 
Table 6.2 Recommellded approaches to prevcllt 1losocomial i1ljcctiolls by RSV 
Isolation of patients with infections by RSV 
rapid viral diagnosis is essential 
cohort nursing (RSV-ward or admission to a single·persons room) 
II Handwashing before and after contact with a patient 
gloves are of no use, handwashing after removing gloves remains necessary 
hands must be washed after touching contaminated surfaces such as furniture 
or toys present in the patient s room 
Use of gowns in patients with infections by RSV 
Per patient toys that may not be used by other patients 
11/ Hospital staff needs to follow appropiate guidelines when experiencing signs and symptoms 
of a cold; they need to use a mask, apply strict handwashing and may not take care of high-
risk patients 
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The use of gloves lnay have a supplementary effect when compliance vdth 
hand washing is low 2,10. Hmvever, survival of RSV on gloves is increased c01npared 
,vith bare skin. I-Iencer handwashing after relnoval of the gloves relnainsnecessary. It 
is also advisable not to share toys behveen patients ". 
The use of gowns and lnasks relnains conh'oversial despite being intensively 
investigated. Two independent groups reported a beneficial effect associated with 
the use of gowns and lnasks 2,10. Contrasting, one study included 162 children aged 
between two ·weeks and tlu'ee years during two RSV-seasons. In the first season, 
gowns and masks where used whereas in the second season they were not. No 
significant differences in the number of NA-RSV was observed between the two 
years 12. This observation ,vas confirmed by other groups 1..1. A possible explanation 
for this observation may be that RSV also infects tlu'ough the eyes U Masks do not 
cover the eyes, hence droplet-aerosols may reach the eyes lmhampered. The use of 
combined eye-nose goggles may prevent this route of infection 13. Isolation of patients 
with RSV on a special RSV-ward is a useful tool in decreasing the number of NA-
RSV 10.14.15. Rapid diagnosis of the infection should be applied before a patient is 
adtnitted to this RSV -ward or isolated in a single-persons romn. Table 6.2 sUllunarizes 
the general llleans of preventing nosoc01nial RSV infections. 
Hospital staff tOl'ln an ilnportmlt vector in transmitting RSV and may thus provide 
an important source of NA-RSV 3.16. Consequently, they ought to respect all 
reconunendations ill order to prevent NA-RSV from occurring in a certain patient 
especially when they experience signs of a cold. 
The Sophia Children's Hospital pursues guidelines which comprises isolation of 
patients ·with a virologically proven or a suspicion of an infection by RSV, 
hand,vashing before and after contact with a patient and the use of gowns in patients 
with RSV. As a result of these guidelines the number of NA-RSV in our hospital 
proved low and had decreased during the study period. Hmveverr no conclusion 
could be drawn about cOlnpliance vdth hand washing or the use of gowns as a result 
of the study design. A more strict appliance of the reconunendations may result in a 
fmther decrease in N A -RSV. 
111 COJ1clusiol1, the nlUnber of nosocOlnial infections by RSV in the period between 
1992 and 1995 was approximately 3%. Infants with BPD and NA-RSV experienced 
enhanced disease course. For other infants, the disease course ofNA-RSV was fotmd 
comparable with that of CA-RSV. 
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ABSTRACT 
Identification of one or more independent variables predictive for the duration of 
RSV associated hospitalisation Inay be useful for preventive and therapeutic 
approaches. A recent published prediction model ("Michigan model") for the duration 
of hospitalisation in RSV infection demonstrated good discrimination between children 
with and without an increased likelihood of a prolonged hospital stay:;, 7 days, but 
required exanunation of it's generalizability to other centers. TIle Michigan lllodel 
cOlnprised the variables log 'weight, congenital heart disease, failure to thrive, prelnature 
birth, bronchopuhnonary dysplasia, other pulmonary disease, Iniscellaneous 
conditions, early mechanical ventilation and early ribavirin treatment.The objective of 
this sh1dy was (i) to validate the Michigan model and (ii) to derive a prediction model 
for prolonged hospital stay:;, 9 days using the Rotterdam database since duration of 
hospitalisation in The Netherlands is doubled when compared to the USA. 
Methods Data of 177 children younger than 12 months of age admitted with 
virologically confirmed RSV infection to the Sophia Children's Hospital Rotterdam 
between 1992 and 1995, were used. 
Results Mean duration of hospitalisation for the Rotterdam database was 10.3 
(± 6.3) days with a median of 9 days. 138 (75%) patients had a hospital stay:;' 7 days. 
The Michigan-model performed poorly in the Rotterdam database. The area under the 
ROC ClU've was 0.65 (SE 0.04). TIle Rotterdam prediction model (hospital stay:;' 9 days) 
cOlnprised v'leight and need for oxygen supplelnentation. TIle area lUlder the Receiver 
Operating Characteristic cmve of 0.65 (SE 0.04). 
COIlc/usiolls Both the Michigan and the Rotterdam model could not predict the 
duration of hospitalisation as assessed by the conlbination of a high sensitivity 'with 
a low false positive rate. Prediction of the duration of RSV associated hospitalisation 
'vas not possible in this study as based upon denlographical and clinical variables. 
Duration of RSV associated hospitalisation therefore is not a good outconle variable 
in llutlticenter h'ials which evaluate the results of therapeutic trials. 
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7.1 INTRODUCTION 
For more than four decades, the respiratOlY syncytial virus (RSV) is known to be 
responsible for the great ll1ajority of lmver respiratory tract infections in infants and 
yotmg children. Despite its great impact, hospitalisation for RSV infection occurs in 
only a small minority of approximately 0.5% to 2% of these children 1. 
The duration of hospitalisation may be related to severity of disease. The 
identification of one or 1110re independent variables predictive for the duration of 
hospitalisation in RSV infection could be useful in preventive and therapeutic 
approaches. However, it seems not possible to predict the duration of RSV associated 
hospitalisation '. Very recently, Moler and Olunit developed a model to predict a 
hospital stay ;0: 7 days. The parameters used in this model include patient weight, 
underlying disease state and early therapeutic interventions such as lnechanical 
ventilation and ribavirin (Michigan-model) 3. The model demonstrated good 
discrimination as assessed by the area lmder the Receiver Operating Characteristic 
(ROC) curve of 0.89. The authors proposed to examine the generalizability of their 
model to other centers. Since duration of hospitalisation for RSV infection differs 
significantly between Europe and North Alnerica , this validation is of interest in 
Europe'. 
TIus study was tmdertaken (i) to validate the Michigan-model for RSV hospitalised 
patients in a large tuuversity hospital in TI,e Netherlands and (ii) to develop and 
validate our o\"n model predicting the likelihood of a prolonged hospital stay greater 
than the median lUunber of days admitted to our hospital. 
7.2 PATIENTS AND METHODS 
7.2.1 PATlEMTS 
TI1is study was performed as part of a cwucal epidemiological study of RSV 
infections in young cluldren. The design of the study has been described earlier'. In 
brief, clilldren with a postnatal age below 12 months of age admitted with RSV infections 
to the Sophia Children's Hospital, Rotterdam between 1992 and 1996 were included. 
The study period spalmed tiuee RSV seasons from October 1" to Aprill" the following 
year. The diagnosis RSV infection was virologically confirmed by a positive direct 
inununofluorescent assay (DIFA) al1d/or a positive viral culture on Hep-2 cells 
perforn1ed on spechnen obtained from nasopharyngeal ,vashings. 
Den10graphical and clinical parall1eters ,vere retrospectively obtained frotn the 
patient's medical chart 5. Defuutions applied by Moler and Olmut were adapted 3. 
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Patients were diagnosed with failure to thrive when after correction for gestational age 
their weight plotted on standard Dutch growth charts was below the third percentile. 
7.2.2 VALIDATION OF THE MICHIGAN-MODEL 
TI,e Michigan-model was validated on the data of 1992 - 1995. This prediction 
model ("munber one") comprised the variables: logarithm of the weight, congenital 
heart disease, failure to thrive, premature birth, bronchopulmonary dysplasia, other 
pulmonary diseases, miscellaneous conditions, early lllechanical ventilation and early 
ribavirin (see the appendix for the exact rule). 
Using this rule, for each patient the probability of prolonged hospital stay" 7 days 
was calculated. TI,e area tmder (AUC) the Receiver Operating Characteristics ctuve 
(ROC) was calculated. Also, the sensitivity, specificity, positive (PPV) and negative 
predictive value (NPV) were calculated for different cut-off points on the range of the 
prolonged hospital stay" 7 days. 
7.2.3 DERIVATION AND VALIDATION OF THE ROTTERDAM-MODEL 
For the Rotterdam-model, the outcome was defined as a hospital stay greater than 
the median number of days (9 days). In the tmivariate analysis predictors for a hospital 
stay" 9 days were identified by estimating the association (odds ratio (OR) and it's 
95% confidence interval (CIl) between each potential predictor and the duration of 
hospitalisation. 
Subsequently, all potential predictors with a p - value s 0.10 were entered into a 
multivariable logistic regression model to evaluate which variables independently 
predicted a prolonged hospital stay" 9 days. Variables with a probability s 0.10 were 
retained in the lluutivaTiate Inodel. 
Reliability of the model was estimated (goodness of fit) using the Hosmer & 
Lelneshow 111ethod, and discrimination of the model ,vas assessed using the area 
tmder the Receiver Operating Characteristic (ROC) Clllve. An ROC-area under the 
TabJe 7.1 Comparison of characteristics of IlOspitalisation between the MiclJigml and the Rotterdam database 
Number of patients 
Study period 
Mean duration of hospitalisation (days) 
Median 
Mode 
Upper quartile 
Mean age 
82 
Rotterdam database 
177 
1992 -1995 
10.3 ± 6.3 
9 days 
7 days 
12 days 
3.1 ± 2.7 months 
Michigan database 
802 
1983 - 1992 
5.S±7.2 
4 days 
Not mentioned 
7 days 
5.9 ± 5.5 months 
Duration of hospitalisation ill RSV illfections 
curve (AUC) of 0.80 or greater indicates good discrimination of the model between 
patients with and without a hospital stay" 9 days '. All statistical analyses were 
performed using SPSS 8.0= (Chicago, minois, USA, 1998). 
Data on gestational age, birthweight and weight at presentation were present in 
90%,86% and 94%, respectively of all patients. Clinical characteristics including details 
from physical examination were present for at least 93% of the patients. The arterial 
oxygen saturation was transcutaneously measured in 85% and blood gas analysis 
performed in 98% of the children. 
IInputation of rnissing values using the expectation and nlaximization rnethod 
available in standard SPSS software was applied in order to increase the statistical 
efficiency'. 
7.3 RESULTS 
7.3.1 PATIENT CHARACTERISTICS 
185 infants were admitted to our hospital. Data on the duration of hospitalisation 
could be acquired in 177 infants. The mean duration of hospitalisation was 10.3 days 
(standard deviation 6.3 days) with a range of 1 to 38 days. The median was 9 days. A 
hospital stay" 9 days was observed in 96 patients. Table 7.1 compares characteristics 
of hospitalisation from the Michigan database with the Rotterdam database. Duration 
of hospitalisation for the tiu-ee seasons separately was comparable (data not shown). 
7.3.2 VALIDATION OF THE MICHIGAN-MODEL 
In our database, 138 of the 185 patients had a hospital stay" 7 days. TI,e area 
under the ROC curve was 0.65 (95% CI 0.57 - 0.73). TIle validation of the Michigan-
model for different thresholds or cut-off points of the hospital stay" 7 days can be 
seen in Figure 7.1. For example, when a tiu-eshold for a hospital stay" 7 days at 0.50 
is used, then 44% of all patients with a hospital stay" 7 days would be correctly 
identified (Le. the sensitivity at this tiu-eshold). However, the false positive rate (FPR) 
would then be 33%. An increase in sensitivity was accOInpanied by an increase in 
FPR. 
7.3.3 DERIVATION OF THE ROTTERDAM-MODEL 
Table 7.2 slUmnarizes the results of the univariable analysis on all investigated 
predictors for a prolonged hospital stay" 9 days. Variables significantly associated 
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Table 7.2 Results from tile IIllivariate analysis 011 predictors for duration of hospitalisation ~ 9 days 
(* p ::; 0.15). OR: odds ratio, CI: cOllfidence illterval 
Hospital stay (days) 
;;:.: 9 days < 9 days OR 
(n = 96) (n = 81) (95% CI) 
Patient demographics 
Boys vs girls 29/67 34/47 0.6 (0.3-1.2)· 
Age (months) 2.9 ± 2.7 3.2 ± 2.7 0.9 (0.7 -1.3) 
Gestational age (weeks) 37.6 ± 3.5 37.5 ± 3.7 1.0 (0.9 -1.1) 
Prematurity 24 24 0.8 (0.4-1.6) 
Birthweight (kg) 2.9 ± 0.9 2.9 ± 0.8 0.9 (0.7 -1.3) 
BPD without prematurity 2 0 
CHD 9 3 2.7 (0.6 -13.6f 
Prematurity + BPa 7 5 1.2 (0.3 - 4.6) 
Weight (kg) 5.1 ± 1.9 6.3 ± 5.3 0.8 (0.7- 1.0f 
Clinical findings at admission 
Apnoea's 23 14 1.5 (0.7 - 3.4) 
Cough 85 74 0.7 (0.2 - 2.2) 
Rhinitis 81 72 0.7 (0.3 -1.7) 
Impaired feeding 70 60 0.9 (0.5 - 1.9) 
Wheezing 33 27 1.0 (0.5 - 2.0) 
Retractions 53 43 1.1 (0.6-2.1) 
Temperature (0G) 37.8 ± 1.0 37.7 ± 1.0 1.1 (0.8 - 1.5) 
Pulse rate (/min) 151 ± 42 142 ± 33 1.0 (1.0-1.0)· 
Respiratory rate (1m in) 53 ±20 50 ± 13 1.0 (1.0-1.0) 
8a02 (%) 88.4 ± 11.3 90.1 ± 10.9 1.0 (1.0-1.0) 
pCO, 7.0 ± 2.2 6.3 ± 1.4 1.3 (1.0-1.5)· 
Findings on chest radiograph 
Atelectasis 32 22 1.3 (0.7 - 2.) 
Hyperinflation 58 41 1.5 (0.8 - 2.8) 
Infiltrate 7 5 1.2 (0.3 - 4.6) 
Characteristics of hospitalisation 
2.3 (0.6 - 6.0)· Mechanical ventilation 19 8 
Oxygen administration 65 42 2.0 (1.0 - 3.8)· 
with prolonged hospital stay;o, 9 days included gender, CHD, weight, pulse rate, 
Sa02, tnechanical ventilation and oxygen supplelnentation. These variables were 
consecutively entered into multi variable regression analysis. The independent 
predictors for prolonged hospital stay ;0, 9 days were weight and oxygen 
supplementation (Table 7.3). The Hosmer & Lemeshew test was far from significant 
(chi square 4.77, p = 0.7814), indicating good reliability of the model. However, the 
area under the ROC-curve was only 0.65 (95% CI 0.57 - 0.73). The performance of the 
model can be seen in Figure 7.1 For example, when a threshold at 0.20 is used, the 
sensitivity would be 40%. The false positive rate would then be approximately 15%. 
7.3.4 VALIDATION OF mE ROTTERDAM-MODEL 
Forty-two patients with infections by RSV were admitted in the period 1995 -1996. 
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Table 7.3 Results of tlte lJIultivariate mlfllysis 011 predictors jor proloJJged hospital stay;? 9 days 
Variable 
Weighl (kg) 
Oxygen supplementation 
Roe area (95% el) 
OR (95% el) 
0.9 (0.7-1.0) 
1.7 (0.9-3.3) 
0.65 (0.57 - 0.73) 
Unfortunately, the false positive rate never decreased below 35% (Figme 7.1). 
7.4 DISCUSSION 
This study validated a prediction model developed by Moler and Olunit for the 
duration of hospitalisation in RSV infection 3. In their population, severe infections 
were represented by a prolonged hospital stay for seven or more days (the upper 
quartile of dmation of hospitalisation). The model had a good discriminative value 
with the area under the ROC-Clilve of nearly 0.90. When evaluated on the Rotterdam 
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database, the Michigan model demonsh'ated acceptable sensitivity (dependent upon 
the cut-off probability used), but the FPR did not decrease below an acceptable value. 
TI1is might be explained by the longer duration of hospitalisation in TI,e Netherlands 
compared to the United States. The upper quartile in the Michigan database is 12 
days. 11UIS, in Otu' institution, a cut-off at seven days does not necessarely correctly 
discrhninate behveen NIess severe" and Nsevere" infections. Secondly, the patients in 
our population were almost twice as young compared with the Michigan population. 
This difference in age may have influenced the severity of disease in the study 
population 8. Severity of illness between the lVlichigan and the Rotterdam model was 
comparable for the number patients requiring mechanical ventilation (9.1% for the 
Michigan database versus 15.% for the Rotterdam database), but was not comparable 
for the number of ICU admissions (15.1% for the Michigan database versus 41.6% for 
the Rotterdam database). All of these differences may account for the inapplicability of 
the Michigan-model to our hospitaL TI1erefore, we describe independent predictors 
for a hospitalisation <': 9 days (the median) in RSV infections for the Rotterdam database. 
Independent predictors for a hospital stay <': 9 days were weight and need for oyxgen 
supplementation. These variables are also associated with the severity of infections 
by RSV 9.10. 
Unforltmately, when validated on data from a single RSV-season our model also 
failed to accurately predict the duration of hospitalisation and identify patients at risk 
for prolonged hospital stay with a low false positive rate. A reliable prediction of 
duration of hospitalisation in RSV infection seems not feasable. Differences in RSV 
subtype are not responsible for the observation that the duration of hospitalisation in 
children with RSV infections is tmpredictable 11. Parental-related factors or doctor-
related factors not included in the model may influence the duration of hospitalisation. 
For instance, there Inay be an interobserver variability in the decision 'whether a patient 
has to remain hospitalised. The PICNIC study demonstrated that RSV associated 
duration of hospitalisation can be a useful outcome in clinical trials in case of a high 
interobserver reliability 12, 
One could argue that the duration of hospitalisation in RSV infection may not be 
an adequate criteritun for severity of RSV associated disease. However, Inany 
multicenter trials investigating the efficacy of preventive h'eahnent such as RSV-IVIG 
(including 54 centers in the United States) and Palivizumab (including 139 hospitals 
from the United States, Canada and the United Kingdom) included duration of 
hospitalisation as an endpoint in the assmnption that duration of hospitalisation 
reflects the severity of disease 13,14, 
III collclusioll a reliable prediction of the duration of RSV associated hospitalisation 
based upon demo graphical and clinical variables was not possible. Therefore, the 
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dmation of hospitalisation in RSV infections may not be an adequate criterimn for the 
severity of disease and outcome of clinical h·ials. 
ApPENDIX 
The exact rule of the Michigan model is: 
Probability for prolonged hospital stay;o, 7 days = 1 / (1 + exp (- [score] )), where the 
score is calculated by: 0.Q905 + (-1.678 * log weight) + (1,456 * CHD) + (1.850 * FIT) + 
(0.922 * premature birth) + (1.633 * BPD) + (1.671 * other pulmonmy disease) + (0.812 
* miscellaneous conditions) + (3.213 * early mechanical ventilation) + (0.659 * early 
ribavirin). 
The exact rule of the Rotterdam model is: 
Probability for prolonged hospital stay;o, 9 days = 1 / (1 + exp (- [score] )), where the 
score is calculated by: 0.5954 + (-0.1367 * weight in kg) + (0.5502 * need for oxygen 
supplementation). 
For dichotonl0Us variables 1 should be filled in when variable is present 'where 0 
should be filled in if variable is absent. 
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ABSTRACT 
111is review discusses the current knowledge on treahnent and prevention ofRSV 
infections in children. Unfortunately, effective therapy is not yet available for children 
with RSV infections. TIle efficacy of corticosteroids and bronchodilators has not yet 
been adequately documented. The use of ribavirin in patients with RSV infection is 
only indicated in a highly selected group of high risk patients with T-cell 
illummodeficiency. TIle results of studies on the efficacy of vitamin A, interferon and 
antibiotics showed disappointing results. Vaccination research has produced 
candidate vaccines such as the recOlnbinant vaccine BBG2Na, a subunit vaccine PFP-
2 and coldpassaged-tempemture sensitive vaccines. However, phase III efficacy h'ials in 
infants, young children and the elderly are still lacking. Hence, it will take many years 
before effective vaccines will becOlne available for routine use, Passive protection against 
infections by RSV can be conferred by the use of RSV hyperinumme globulin (RSV-
IVIG) or by the administration of palivizlUnab, a monoclonal antibody. TIle efficacy of 
these two cOlnpolulds has been demonsh'ated. The easy route of adnunistration and 
the nunor side effects of palivizlunab Inake this drug a promising drug. Hmvever, 
large costs are involved. In addition, 11lajor differences have been reported in the 
prevalence of RSV lmver respiratory tract infections in different cOlulh'ies, regions and 
even withing well-known high-risk populations. We therefore suggest that the 
development of local and regional guidelines, based on hospitalisation rates in high-
risk infants and cost-benefit analysis studies is necessary. 
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8.1 ImRoDucnoN 
Respiratory syncytial virus (RSY) is a member of the genus Pllellllloviridae of the 
family Pamlllyxoviridae, lts genome consists of linear, single stranded RNA and encodes 
ten proteins of which two of the transmembrane surface proteins (G and F proteins) 
are of Inost interest, since they are involved in viral pathology and infectivity -t6, The G 
protein is responsible for attachment of the virus to the host cell, the F protein is 
responsible for fusion of the virus with the host. Both F and G proteins induce 
neuh'alising antibodies ll6, Two major antigenic groups of RSY - subtypes A and B-
may be identified by the use of monoclonal antibodies 127, 
RSV is the worlds leading cause of viral respiratory tract infection in infants and 
young children 70, The clinical spech'um extends from a mild upper respiratOlY tract 
infection to severe lower respiratory h'act disease including bronchiolitis 79, In the 
United States, RSV infection ailliually leads to approximately 100,000 hospital 
admissions with an estimated number of 4500 deaths 57, 
RSV associated lower respiratory h'act disease especially occurs in yotmg children 
with a peak incidence betvveen two and six nlonths of age 12, In some of these young 
infants a severe disease course Inay be observed, Children with underlying chronic 
diseases such as bronchopulmonary dysplasia, congenital heart disease and T-cell 
ilnnuulodeficiency or prenlaturely bonl infants have a higher risk for severe RSV 
infections 41,51,82, 
RSV associated broncluolitis results from an inu11lmopathological process in whicll 
T-cells playa major role 13,"", Neuh'Oplills andeosinophils are also involved in the RSV 
related disease process 33,72, Eosinophils becOIne activated and subsequently release 
mediators which are thought to be responsible for wheezing dming acute infection ", 
Currently, the treatment of RSV infections is mainly supportive, TIle therapeutic 
effects of corticosteroids, bronchodilators, ribavirin, and RSV imnume globulin and 
the prevention of RSV infections by hyperinu11lme globulin and monoclonal antibodies 
have been investigated in many studies, TIle interpretation of the results of these shtdies 
and the itnplenlentation in clinical practice Inay vmy considerably as was illush'ated 
by a poll among members of the European Society for Paediatric Infectious Diseases ", 
Recent studies "'lith new candidate vaccines have yielded prOInising results 37,66,71, 
This review seeks to provide the reader with a comprehensive overview of the 
current knowledge on the treahnent and prevention of RSY infections in infants and 
yotmg chilchen, 
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8.2 TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION 
8.2. 1 CORTICOSTEROID THERAPY 
A large body of experimental data lmderscores the important role of the host inumme 
response in RSV induced bronchiolitis. 1ltis has led to the hypothesis that a modulation 
of the imnllme response by the use of corticosteroids may have a beneficial effect on the 
outcome of children with RSV infections"'. Data from studies carried out in the 1960's 
were conflicting and difficult to interpret 17,81.W>, 129. Tal and co-,vorkers described clinical 
iInprovement after the use of a combination of dexamethasone and salbutanlOl in a 
group of 32 infants with RSV infections LIt. Howevel~ the index group in this study was 
not only restricted to infants with acute bronchiolitis. 
TIle inh'avenous use of hydrocortisone 1 mg/kg/ day and subsequently prednisone 
2 mg/kg/ day orally in combination with albuterol inhalations was investigated in50 
infants YOlmger than one year with a first episode of bronchiolitis 126, hl this study no 
clinical benefit was deillonstrated. The efficacy of intranulscular dexamethasone (1 
mg/kg) administered in 65 infants was compared with that of placebo given to 53 
infants \vithan intial episode of wheezing tH, The dtu'ation of oxygen therapy or time 
to resolution of symptoms did not decrease. TIlis lack of benefit was also observed 
when the efficacy of oral dexmnethasone ,vas investigated 73. Van \I\'oensel ef aT studied 
the effect of oral prednisolone 1 mg/kg/ day for seven days in 27 RSV positive infants 
131i. They observed a significant reduction iIl sylnptOIll score in the first three days of the 
h'eahnent,vith a non-significant tendency to treahnent benefit in children \",ho suffered 
fr01n severe bronchiolitis. TIle dtu'ation of mechanical ventilation was not reduced in 
the treahnent group as cOlnpared to the control group, ,\~hereas the duration of 
hospitalisation was significantly reduced in the treahnent group 1.'.(', 
hlvestigators have also studied whether corticosteroids prevent post-bronchiolitic 
wheezing. The use of either oral prednisone with J52-agonists or nebulized budesonide 
did not reduce the prevalence of wheezing, respiratory sympt0111 scores or the 
proportion of children requiring bronchodilators or steroids one year after the acute 
illness 1I);J, 
Corticosteroids are not effective and therefore not indicated in children with 
bronchiolitis or as part of a prophylactic t!lerapy to prevent post-bronchiolitic wheezing. 
The Infectious Diseases Society of An1erlca accordingly advised against the. use of 
corticosteroids 85, 
8.2.2 BRONCHODILATOR THERAPY 
Bronchodilators are frequently used in children with RSV infections because of the 
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similar disease presentation in infants with asthlna and 'withRSV bronchiolitis. Airway 
obstruction in RSV induced bronchiolitis is characterised by necrosis and lysis of 
respjratory tract cells lvithedema of the sublnucosa, excessive 111UCUS secretion with or 
without bronchial hyperreactivity and slu'factant abnormalities associated "with airway 
collapse J, 15-agonists do not only generate bronchodilatation, but also contribute to 
IllUCUS clearance, production and release of surfactant 27, Four studies have 
demonsh'ated beneficial effects of fl-agonists on the course of !,SV induced bronchiolitis 
in infancy ·tJ,!J,!, 13-t. A short term improvClllent in clinical scores was seen in children 
treated with 15-agonists &<;, The use of salbutamollllay lead to a short-tel'ln reduction in 
the respiratory distress assessment instrument (RDA!) lasting approximately 30 
minutes 7'!,Recently, a French group reported a significantly greater improvement in 
respiratory rate, accesory llluscle an lNheezing score in infants treated with 0,15 mll 
kg/dose nebulised salbutamol ". Schuch et al demonstrated in a non-controlled study 
of 50 infants with RSV bronchiolitis a significant hnprovent in all,\vay conductance as 
a result of h'eatment with a bronchodilator 125, However, the study group was not 
restricted to first tiIlle wheezers. Also, the bronchodilator-response group ,vas 
characterised by a sh'onger family history of atopy and clu'onic bronchitis, 111is may 
indicate that infants prone for atopic astluna were included in the study popUlation, 
Other investigators have failed to demonsh'ate a beneficial effect ofbronchodilators 
or an improvenlent in RSV associated respiratory failure 16,:\<;,39,52,62, A randomised 
controlled trial in 62 patients between 2 and 241110nths of age comprising fmu' h'eannent 
groups (salbutamol 0,15 mg/kg/dos plus ipratropimn bromide 125 ~lg or 250 ~lg in 
infants aged 61nonths or more, salbutmnol alone, ipratropilllll bromide alone or saline) 
delllonstrated no significant change in oxygen saturation, change in clinical score or 
dtu'ation of hospitalisation w, Two l'andOlnised trials including 88 and 83 children 
respectively failed to delllonstrate a significant irnprovement on oxygen saturation by 
the lise of salbutamol 7-t. 15-agonists were also reported to induce bronchospaSIllS 62, 
Racemic adrenaline provides a significant improvelllent in the clinical score and 
transcutaneously IlleaSlll'ed carbon dioxide tension in children treated with adrenaline 
as compared "with the control group, although a significant difference in Sa02 was 
only found inunediately after nebulisation 7"', Ipratroprilllll brOlllide has no benefit as 
adjuvant therapy for bronchiolitis 60, 11Y, 120, 
Flores et al 36 therefore justifiable concluded on the basis of an extensive Ineta-
analysis that there is insufficient evidence to support the efficacy of 152 -agonist therapy, 
However, bronchodilators may produce a lllodest short-tenn iInprovelnent in clinical 
scores as suggested in a study using the Cochrane database fi9, Currently, 
bronchodilators are frequently used as supportive treatment despite the lack of 
evidence-based support for this practice 73,83, 
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8.2.3 ANTIVIRAL THERAPY 
Ribavirin (Virazole ®) is the only drug registered for the treahnent of children with 
RSV induced bronchiolitis. Ribavirin has been licensed by the American Food and 
Drug Association (FDA) since 1985. Ribavirin (1-11-D-ribafuranosyl-1,2,4-h'iazole-3-
carboxamide) is a virostatic synthetic nucleoside analogue 47, In vih'o it is active against 
a wide variety of DNA and RNA viruses such as herpes, cytOlnegalovirus and influenza 
A and B viruses 35. After administration, the drug is phosphorylated into ribavirin 
triphosphate, which is the highly active metabolite. Ribavirin is sttbsequently 
catabolised to triazole carboxanlide, This inactive nletabolite is excreted in the urine 18, 
Ribavirin is administered by a nebuliser. Administration of a large dosage of 
aerosolised ribavirin aerosols in a short period (6 mg per 100 ml water for a period of 
2 hours tlu'ee times a day) leads to an equal effect as the gift of a low dosage during a 
longer period (6 gram per 300 ml water for 18 hours a day) without an increased 
ribavirin concentration in the patient or an increased ribavirin concenh'ations in the 
enviromnent 32, 
Teratogenic, carcinogenic and Inutagenic side-effects of ribavirin have previously 
been described in aninlalln~dels 56, Carcinogenic effects occurred after rats ""lere 
c1u'onically fed with hlgh doses of ribavirin, whereas teratogenicity Was only seen 
,,,hen ribavirin ·was administered during the first h'unester of pregnancy 35, Orally 
administered ribavirin Inay also inhibit red cell production 35, However, very little 
side-effects were reported in hmnan clinical studies. The drug was not detected in 
either plasma or red blood celI samples of health care workers ". 
8.2.3.1 RIBAVIRIN IN NON-VENTILATED CHILDREN 
Hall and co-workers observed that the drug significantly improved the overall 
clinical score, decreased the nllllber of lO""ler respiratory hact associated symptonls 
and inlproved the arterial oxygen saturation in 33 infants of ·which seventeen ,,,,ere 
treated with ribavirin 50. Taber et al and Rodriguez et al confirmed the observation of 
il11prOVeInent in the clinical score and increased rate of iInprovenlent of oxygen 
saturation by the use of ribavirin 112.130 • Barty et al fOWld a significant decrease in 
cough and crepitations in children h'eated with ribavirin 6. Beneficial effects of ribavirin 
were also observed in children with congenital heart disease or bronchopuhnonmy 
dysplasia <S.49. Conrad et al compared 33 infants treated with ribavirin with a 
retrospectively obtained control group 21. The demographics of tile h'eahnent and conh-ol 
group ,,,,ere not fully cOlnparable, since infants h'eated with ribavirin ,,,,ere Significantly 
YOlmger than the control group. Ribavirin significantly reduced the duration of 
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hospitalisation, Inechanical ventilation and 111ean therapeutic intervention scores, The 
use of ribavirin did not lead to a sigrtificantly lo,ver airway resistance 01' increased 
c0I11pliance 6-1, Inconh'ast to these observations, two recent studies failed to deInonsrrate 
a beneficial effect of ribavirin 80,93, 
8,2,3.2 RIBAVIRIN IN VENTILATED CHILDREN 
Three studies evaluated the efficacy of ribavirin in ventilated patients 87,90, J2.t, SInith 
and cO-V\Torkers observed an unproved arterial oxygen saturation, a significant 
reduction in duration of mechanical ventilation, duration of oxygen suppletion and 
duration of hospitalisation in ventilated infants with RSV infections, who were treated 
with ribavu'ul 124, In two recent studies in 41 and 439 patients these observations could 
not be cOnfU'I11ed 87,90, Ho·wever, in these studies sterile ,vater was used as placebo, 
Wheeler et al retrospectively compared two hospitals: Ul one hospital ribavirul \vas 
routinely used whereas in the other hospital only supportive therapy for RSV 
bronchiolitis was given 145, No significant differences in Inortality, duration of 
hospitalisation and duration of mechanical ventilation ,vere obsenTed, 
The early studies demonstrated beneficial effects of ribavirin. However, these 
ulvestigations ,vere critisized on theil' Inethodo}ogy and use of subjective endpoints 
such as clinical score rather than major endpoints such as mortality, oxygen saturation 
and lllechanical ventilation, Fm'thermore, several groups used aerosolized water which 
may induce bronchospasms as part of the placebo treatment ". Additional problems of 
ribavirin include high costs of the drug, difficulties with adminish'ation and the 
potential teratogenic and carcinogenic effects. TI,e American Academy of Pediatrics 
have altered their recoI1llnendations froIll ushould be used" to umay be considered" in 
1996. These guidelines indicate treatment with ribavirin in high risk children (CHD, 
BPD, premahlrity and age < 6 weeks), inununodeficient children and severely ill 
children with or without Inechanical ventilation 2, However, in our opinion there is 
not enough evidence that ribavirin has a beneficial effect in high risk children with 
CHD, BPD, premann'ity or even in severely ill children requiring mechanical ventilation. 
A meta-analysis addressed the question whether ribavirin is useful in the h'eatment of 
RSV -infections 107. These authors concluded that the relative risk for mortality was 
0.42 (95% CI 0,13 -1.44, P ~ NS). The risk for respiratory deterioration was 0.42 (95% 
CI 0.16 -1.34, P ~ NS). They concluded that the use of ribavirin was not associated 
with a significant benefit. However, the individual h'ials Inay lack sufficient power to 
provide reliable estimates of the effects 10'. We therefore suggest to resh'ict administration 
of ribavil'in to inlIllunodeficient children, in ,vhich ribavirin Inay reduce the duration 
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of viral shedding of RSV St"'. 
The prevention of long term sequelae of RSV bronchiolitis after the use of ribavirin 
has also been investigated. Infants treated with ribavirin demonstrated significantly 
lower RSV-specific IgE responses (which may be responsible for the wheezing) with 
lmver geometric lnean titers than controls 115, TIle use of ribavirin did not result in 
differences in lung function or in decreased respiratory syInptoms after RSV 
bronchiolitis in treated verslis non-treated infants five to six years after the initial 
ilh1ess ". Recently, Edell el al retrospectively demonstrated in a group of 22 infants 
younger than 6 1110nths of age h'eated ,vith ribavirin a significant reduction in the 
prevalence of reactive airway disease one year after bronchiolitis 30, TIlis effect was 
only detected in the group with urnildrl reactive airway disease, However, the study 
subjects were not randomized for h'eatment and loss to follow-up was high (36 out of 
77 hospitalised infants). 
8.2.4 RSV-IMMUNOGLOBUUN 
Adminish·ation of aerosolised RSV-inummoglobulin in the cotton rat results in a 
sh'ong reduction of viral titers in pulnl0nary tissue and cleaTance of detectable virus in 
lnost of the anirnals 97, FtU'thennore, a 11UICh lower dose is needed to achieve similar 
effects ,vhen RSV -IVIG is adlnirustered topically instead of inh'avenously IW. These 
observations in annual studies raised the possibility to use RSV-irrunluloglobulin in 
the h'eahnent of RSV -bronchiolitis. 
Rodriguez el al performed two clinical trials to investigate the efficacy of RSV-
specific inununoglobulin (RSV -MG) in the treahnent oflower respiratOlY tract infection 
by RSV ll1.ll3. In the first study, RSV-IVIG was used in yOlmg children with BPD, 
clU'onic lung disease, congenital heart disease or prematurity < 32 ,"veeks of gestation. 
There were no significant differences in dmation of RSV-hospitalisation, ICU stay and 
lnechanical ventilation between the treatment and the control group 113. 
The second study emolled previously healthy infants who were hospitalis~d with 
RSV infection 111. Again, efficacy of RSV -IVIC could not be confirmed. 111erefore, RSV 
inununoglobulin is not used as therapy for infections by RSV. 
8.2.3 OTHER THERAPIES 
8.2.3.1 V,TAM,N A 
Senun vitamin A levels were significantly decreased in chilli'en Witl1 RSV infections, 
thus possible contributing to a more severe course of infection. 11,ese data suggested 
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that vitamin A might be a useful adjtmctive therapy 91,106, Ho\vever, in a subsequent 
study oral adnunistration of vitamin A did not decrease respiratory Inorbidity in 
children with acute RSV bronchiolitis 100 
8.2.3.2 ANTIMICROBIAL THERAPY 
The risk of a secondary bacterial infection in patients with RSV bronchiolitis is 
very low 52. Hence, the routine use of antibiotics in the h'eahnent ofRSVbronchiolitis is 
not warranted. The decision whether or not to start antibiotics generally depends on 
the clinical impression of the patient, increased white blood cell cmmt (WBC) and 
elevated C-reactive protein. White blood cell COlmts greater than 15 x 10' II have been 
associated with bacteremia 133. Although white blood cell counts may increase up to 20 
X 10'/1, serum CRP-Ievels in RSV-infection are usually low 118. We suggest to resh'ict 
the use of antibiotics to those children in whom an unexpected clinical deterioration is 
seen accOlnpanied by an increase in inflanunatory paratneters such as C-reactive 
protein. 
8.2.3.3/NTERFERON 
Interferon (IFN) is released by leukocytes in response to viral infections and may 
induce a state of resistance to replication in host cells 101 The interferon response to 
RSV infection in children was fmmd to be minimal when compared to that by other 
respiratory viruses such as influenza 43. 
Higgins et al conducted a double-blind, placebo-conh'olled sh.dy to investigate the 
clinical and prophylactic efficacy of IFN-2a ". Although a prophylactic effect was 
observed, the severity of signs and sYlnptons nor the duration of ilhless was influenced 
by IFN-2a. Therefore, IFN-2a has little value in the h'eatment of infections by RSV ". 
8.3 PREVENTION OF RSV INFECTIONS 
8.3.1 VACCINATION 
A fonnalin inactivated alumllulln precipitated RSV vaccine was developed and 
tested in infants and children in the 1960's. Unforhmately, not only did this vaccine 
fail to protect against naturally acquired RSV infection, but on rechallenge with RSV it 
induced an inUlltllle-nlediated response resulting in increased hospitalisation rates 
for lower respiratory tract pathology and increased mortality 37.66.71. The 
pathophysiology of this processs was explored in animal models. In the cotton rat 
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formalin did not ablate all of the epitopes on the F and G glycoproteins, resulting in 
high levels of antibodies against the F and G protein 103. TIus led to an aberrant inunune 
response resulting in lnore severe puhnonmy histopathology 98, Subsequent studies 
showed that CD4+ T cells playa role in the enhanced pulmonary histopathology and 
that formalin inactived RSV vaccine induced low levels of major lustocompatibility 
complex class I resh'icted cytotoxic T-cell activity as opposed to nahu'al acquired RSV 
infection 20, FOflnalin inadived RSV vaccine pruned for a Thdper2 cell response, which 
is interleukin (IL) -4 and IL-I0 dependent. Such a response has been associated with 
disease progression in nuce 19, Also, formalin inadived RSV-vaccine induced antibodies 
to the F protein, that were deficient in their fusion inlubiting activity 91. 
TIle development of an effective vaccine against RSV still experiences several 
obstacles. A new vaccine has to protect against RSV subtypes A and B ". Also, RSV 
affects especially infants ymmger than six months of age with increased morbidity 
thus necessitating lnaternal or neonatal inl1llunisation 140, I-Iowever, the presence of 
maternal antibodies may diminish the antibody response of infants on exposure with 
a RSV vaccine 31. In addition, the ability to respond to viral sl11'face glycoproteins 
appears to be low dl11'ing the first six to nine months of life ". A vaccine has to protect 
for at least the first years of life. Finally, there may remain concern for an enhanced 
puhnonary disease COlli'se as ,vas previously induced by the formalin inadived vaccine, 
8.3.1.1 RECOMBINANT VACCINES 
A newly developed recombinant fusion protein BBG2Na - RSV G protein fragment 
aa 130-230 with a conserved subgroup A specific protective epitope, lined up with the 
alblllnin-binding region (BB) of streptococcal protein G and a stretch of amino acids 
residues cOlnpletely conserved in all known luunan A and B RSV isolates- was shown 
to be protective in Illice and cotton rats \02, Maternal itnnumisation resulted in a passive 
transfer of high levels of RSV-A antibodies to offspring, protecting them from RSV 
challenge for up to 14 weeks. Also, maternal antibodies did not suppress the effect of 
neonatal vaccination. A phase I trial with BBG2Na on healthy vohmteers has been 
performed in mu' institution. The vaccine was lughly inulUmogeruc, well tolerated 
and resulted in few side effects (Power UF et ai, Safety and inununogerucity of a 
recOlnbinant subunit vaccine against RSVi absh'act book "RSV after 43 years", Stuart, 
Florida 1999). 
Other recombinant vaccines include those with a vedor such as the recOlnbinant 
adenovirus type 4,5 and 7 expressing either the F and G or both proteins, a recombinant 
bacteriophage displaying a chimeric coat protein fused to a protective epitope from the 
glycoprotein G or an optinlized plasmid DNA-vector expressing the RSV fusion protein 
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(DNA-F) '. TI,e bacteriophage induced a high level of RSV-specific antibodies in BALB/ 
c nuce. TIlese candidate vaccines are still evaluated in animallllodeis. 
8,3,1,2 SUBUNIT VACCINES 
Animal studies demonstr'ated that purified F and/or G protein protect inummised 
mice against subsequent challenge by RSV 116, In humans, the use of Purified Fusion 
Protein-l (PFP-l) did not prevent infection, although severe respiratory tract disease 
did not OCClU' 9. Importantly, when PFP-l was administered intranulscularly, none of 
the recipients developed enhanced disease after vaccination or-subsequent infec-
tion 135. 
PFP-l contains approximately 90% - 95% F -protein, whereas PFP-2 contains 
approxhnately 98% F-protein and to a lesser extent other virus proteins 143. 
Acbninistration of PFP-2 resulted in a good inumme response and a significantly 
reduced nlunbel' of Imver respirator tract ilhlesses in childen -with cystic fibrosis or 
bronchopulmonalY dysplasia ", Other subunit vaccines include the RSV fusion protein 
with cholera toxin (CT) as an adjuvant or a subluut vaccine of pmified fraction 21 of 
Qllillaja sapollarin with the fusion protein 137,133, 
8,3,1,3 LiVE VACCINES 
Since killed RSV vaccines produced paradoxical effects, attention has focussed on 
live attenuated RSV vaccines. A live RSV vaccine ,vas shown to be ineffective 10. Over 
the past decades, attenuated vaccines such as host range 111utants, cold-passaged 
mutants (cp) and temperature sensitive (Is) mutallts (RSV replicates at 37° but not in 
lugher temperatrlres) were created ", A group of British investigators developed Is 
mutants of RSV str'ain A chemically mutagenized by growth in the presence of 5-
fluorouracil (IslA al1d Is19A) or mutagelused by growth in ICR 340 or ICR 372 (IslE 
alld 1819B) 86, Inh'allasal acbninistration of tlus candidate vaccine was evaluated in 20 
healthy voitulteel's. The vaccine ,vas able to produce a secondary iInmune response 
almost equal to wild type RSV, but with a reduction in morbidity, However, the authors 
concluded that "the residual pathogelucity of even the most modified mutalltwould 
not be acceptable in WalltS", 
RSV strain A2 mutagenized twice with 5-FU in Vera cell monolayer cultrITes yielded 
a series of calldidate vaccines designated cpls-248, cpls248/404 and cpls530/1009 23,67, 
All tlu'ee cat1didate vaccines protected (seronegative) chimpanzees against challenge 
-with wild type RSV 23, 26,67. However, when evaluated in young children, itnportant 
side-effects - especially in infallts YOlUlger than two months of age - were seen including 
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Table 8.1 SllIIlIIwry of tile rt'S/llts frolll the three studit's all tilt' /lse of RSV-/V/C 
Study RSV-IVIG Control group % reduction 
(750 mg/kg) 
Groothuis et al IN Engl J Med 1993;329:1524-1530) 
Inclusion: children < 4 years with BPO, CHO or premature birth 
Sample size (n) 81 89 
All RSV-LRTI (n) 7 20 62 
Moderate-to severe RSV-LRTI (n) 3 12 72 
Number of hospitaHsaUons (n) 6 18 63 
Hospital days 43 128 63 
ICU admissions (n) 1 6 82 
Groofhuis et al (Pediatrics 1995;95:463-467) 
Inclusion: premature infants with of without BPO 
Sample size (n) 58 
All RSV-LRTI (n) 4 
Moderate-to severe RSV-LRTI (n) 1 
Number of hospitalisalions (n) 4 
Hospital days 31 
Prevent Study Group (Pediatrics 1997;99:93-99) 
Inclusion: premature infants with of without BPa 
Sample size (n) 250 
Number of .hospilalisalions (n) 20 
Hospital days 60 
Hospital days on oxygen 34 
Hospital days cfassified as severe 49 
ICU admissions (n) 8 
58 
14 
10 
13 
83 
260 
35 
129 
85 
106 
12 
71 
90 
69 
63 
41 
52 
60 
54 
31 
P - value 
0.01 
0.03 
0.02 
0.02 
0.12 
0.01 
0.006 
0.02 
0.06 
0.046 
0.045 
0.007 
0.049 
0.41 
upper respiratory tract symptoms such as nasal congestion (Kan-on RA et ai, Evaluation 
of live recombinant RSV A2 vaccines in children over 6 tnonths of age; abstract book 
"RSV after 43 years", Stuart, Florida, 1999). An important characteristic of this vaccine 
was the stability of the tell/peratllre sellsitivity phenotype. In order to simulate the 
condition of htunan infants with lllaternally derived antibodies against RSV, sOine 
chitnpanzees 'were intravenously pretreated '\vith RSV illunlUle globulin. Viral 
replication was highly restricted in both upper and lower respiratory tract after 
challenge with wild type RSV, although protective efficacy was not altered 23. At tlus 
Illolllent, it seenlS that it,vill take several years before one of these vaccines "dll becOine 
available for infants. 
8.3.2 PASSIVE IMMUNISATION 
8.3.2. 1 INTRAVENOUS IMMUNOGLOBULINS 
Studies in the cotton rat demonstrated that adeql1ate neutralising antibody titers 
provided protection from RSV infection and did not result in RSV associated disease 
"'. Topicaladminish·ation oflower dosages had equal effects 59. In htunans, nel1h-alising 
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antibody titers between 1:200 and 1:400 correlate with less severe pulmonmy infection 
42, Huwever, standard inunllllogiobulins Inay not contain sufficient RSV neutralising 
m1tibody to mneliorate or prevent RSV -LRT disease ". 111is problem eM be resolved by 
the use of RSV specific immunoglobulin 121. m. 
The first study which investigated the effect of RSV -Ig was performed in 1993 and 
included 249 infants and children younger than four years of age with BPD, CHD or 
prematurity +1. RSV-Ig was given up to a total of five monthly infusions during the 
RSV-season in either high dose (750 mg/kg) or low dose (150 mg/kg). Recipients of 
the high dose had a 62% reduction in incidence of RSV -infections and 72% reduction 
in moderate to severe infections (Table 8.1). The high dose group differed significm1t1y 
f1'0111 the control group in the ntunber of hospitalisations and the duration of 
hospitalisation. 111e greatest benefit of RSV-Ig was fOtmd among pretenn infants and 
infants ,""ith BPO, Adverse events occulTed only in three percent and cOlnprised a mild 
fluid overload, tHild decreases in oxygen saturation and fever, Six deaths occurred 
which 'vere non ath'ibutable to infusion of RSV-Ig. Five out of the six deaths were 
patients with CHD. These deaths were not dil'ect attributable to RSV related disease. 
l1wee deaths were related to cOlnplications of cardiac surgery. 
A subanalysis from this study included premahu'ely born infants with or without 
BPD ". The efficacy of high dose RSV -Ig (n = 58) was compared to that of placebo (n = 
58). Again, RSV -Ig significm1t1y reduced the number of moderate-to-severe RSV-LRTI's 
m1d the lUunber of RSV-hospitalisations. Duration of hospitalisation nearly reached 
significant difference (p = 0.06). Adverse events were seen in 5% of the shldy population. 
The second shldy investigating the use of RSV-IVIG in premature infants and infants 
with BPD was carried out by the PREVENT group in 1997 103. High dose RSV-IVIG 750 
mg/kg (n = 250) was compared to placebo (n = 260). RSV -IVIG prophylaxis was 
associated with 41% reduction in RSV-hospitalisation and 53% reduction in total 
days of RSV hospitalisation (Table 8.1). Children with RSV-IVIG had a significantly 
reduced nmnbel' of days on supplemental oxygen. The munber of patients requiring 
mechanical ventilation did not differ behveen the hvo groups. Adverse events were 
infrequent m1d mild. 
The outcomes of the two studies resulted inRSV-IVIG (RespiGam®) being licensed 
by the Food and Drug Adminish'ation (FDA) in January 1996 for use in the prevention 
of RSV infection in infants and children younger than 2 years of age with BPD 01' a 
history of premature birth (..; 35 weeks). The recommendations were supported by the 
Atnerican Acadelny of Pediah'ics with a nunor lllodification of the histOlY of prelnaturity 
(~32 ,yeeks).1t ,vas advised to defer n1easles-nllunps-l'ubella-val'icella vaccinees until 
9 months after the last dose '. 
111e beneficial effect of RSV -IVIG was demonstrated in a systematic review of all 
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published studies on RSV-IVIG 142. It was found that RSV-IVIG effectively prevents 
hospitalisations and ICU-admissions by RSV, but does not result in a reduction of 
Inechanical ventilation. 
Currently, RSV -IVIG is not indicated in children with CHD. In a recent study, 202 
children younger than foUl' years of age with congenital heart disease or 
cardiomyopathy received 750 mg/kg RSV-IVIG, whereas the 214 controls received 
albumin 123. Neither the number of RSV -associated RTI's, nor the lUunber of hospital 
days for RSV-LRI differed between the two groups. No significant differences regarding 
ICU-admission and mechanical ventilation were observed between the hvo groups. hl 
eight children, the infusion of RSV-IVIG resulted in unanticipated cyanosis 
necessitating inunediate cardiac intenTention. 
Several drawbacks are associated with the use of RSV-IVIG. TI,e drug has to be 
administered inh'avenously, with occasional problenls to obtain inh'avenous access. 
Also, several hours of hospital adlnission are required. The volume ·which has to be 
administered can be considerable using the recommended dosage of 15 ml/kg. RSV-
IVIG interferes with routine vaccinations. One of the Inajar dravvbacks is the costs 
associated with the use of RSV-IVIG. Costs per patient per season range from 
approximately $2000 to $ 6700 dependent upon the patients weight. The costs for 
immunisation will exceed the costs of hospitalisation avoided as a result of prophylaxis 
for Illast infants 95. In other ·words, the use of RSV-IVIG may not result in net savings in 
medical resources 55. The net cost of prophylaxis with the use of RSV -IVIG seems to be 
the lowest for preterm infants with BPD and age < 3 months". 
Robbins ef at calculated the Number Needed to Treat (NNT) based upon data h'Om 
the above mentioned studies 110. These authors concluded that RSV-IVIG should not be 
routinely adnlinistered in premature infants younger than 6 months of age without 
BPD since 62.5 infants need to be treated withRSV -IVIG in order to prevent one hospital 
admission 110. Twelve Infants with BPD need to be treated in order to prevent one 
hospital admission. 
8.3.2.2 MONOCLONAL ANTIBODIES 
Monoclonal antibodies are used to distinguish between the two known subtypes 
of respiratory syncytial virus, designated A and B. In animal studies monoclonal 
antibodies directed at the F-protein were responsible for fusion of the virus to its host 
and protection against infection in the absence of exacerbation of disease 132, 139. 
Inh'anasal administration of these monoclonal antibodies resulted in clearance of the 
virus fronl the lungs 25. 
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B.3.2.2.1/GG MONOCLONAL ANTIBODIES 
Johnson and coworkers developed a humanised 19G monoclonal antibody against 
RSV, designated MEDI-493 ". MEDI-493 was initially administered intravenously in 
prematUl'ely (<; 35 weeks gestation) born infants ymmger than 6 months of age and 
infants ,vith BPD YOtlllger than 24 months of age in various dosages and cOlnpared to 
0.9% saline as a placebo 128. Few adverse events were observed. hl a consecutive study, 
intramuscularly administered MEDl-493 yielded similar results 117. Monthly 
intraluuscular injections of 15 mg/kg resulted in luean serum concentrations above 
40 pg which in annnal 1110dels is associated with a 99% reduction in puhnoI1my virus 
titer. 
TI,e clinical efficacy of MEDl-493 (also known as palivizumab or Synagis®) was 
investigated by the lmpact-RSV Study Group 63. A randomized double blind, placebo 
controlled trial was performed in 139 centers in the United States, Canada and United 
Kingdom which included 1502 children with a history of premature birth <; 35 weeks 
and younger than 6 months of age, and infants with BPD ymmger than 24 months of 
age. They received either 15 mg/kg palivizmnab or placebo evelY 30 days. The results 
showed a 55% reduction in RSV hospitalisations for all infants. No deaths were 
ath'ibutable to the use of palivizmnab. TI,e reduction in RSV hospitalisations was 
highly sig1lificant in the group of pretenn infants (RSV hospitalisation rate of 1.9% for 
the palivizlmlab group versus 8.1% for the placebo group indicating a 78% reduction, 
p < 0.001) but borderline siglillicant in the BPD group (RSV hospitalisation rate of 
7.9% for the palivizumab group versus 12.8% for the placebo group indicating a 39% 
reduction, p = 0.038). The lUunber of RSV hospitalisation days per 100 cllildren (36.4 
days in the palivizumab group and 62.6 days in the placebo group, p < 0.001) and 
days with increased supplemental oxygen pel' 100 children (30.3 days in the 
Palivizumab group and 50.6 in the placebo group, p < 0.001) were sig1lificantly 
decreased in the palivizumab group. The number of lCU admissions was not 
sig11ificantly different between the treahnent and the conh'ol group (1.3% in the 
palivizumab group and 1.3% in the placebo group, p = 0.23). The lUunber of infants 
requiring mechanical ventilation was also not altered by palivizumab. Few adverse 
events ,vere reported: Inainly fever and injection site reaction ",vere observed. The ll1ean 
serunl concenh'ations of palivizlunab 'ivere above 40 pg/ml. 
TI,e American Academy of Pediatrics recently reconunended the use of palivizmnab 
according to the following indications J: 
cllildren with chronic llmg disease (CLD) YOlmger than 2 years who have 
required medical therapy for their CLD within 6 months before tl,e RSV -season 
children YOlmger than 12 months of age at the start of the RSV season born after 
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a gestational age of 28 weeks or less 
children YOlUlger than 6 months of age at the start of the RSV season born after 
a gestational age behveen 28 and 32 weeks 
children YOlUlger than 6 months of age at the start of the RSV season born after 
a gestational age between 32 and 35 ,veeks vdth risk factors such as a 
predisposition for respiratolY cOlnplications, day care attendance, surgery for a 
non-cyanotic congenital heart defect, exposure to tobacco stnoke and living a 
long distance from the hospital. 
Palivizlunab has several advantages over RSV-IVIG. It can easily be administered 
and does not interfere ·with nonnal vaccinations. However, one tnajor disadvantage is 
the high costs. Annual costs are approximately $4500 per patient pcr season 89 The 
lllunber-need-to-treat (NNT) 'with palivizlunab in order to prevent one RSV 
hospitalisation was calculated at 17 regardless the underlying disease state. TIus 
results in a total cost of more than $77.000,- to prevent one hospital admission. In 
addition, the observation that palivizmnab appears to be less effective in the lughest 
risk group is of concern. The NNT for patients with BPD and for patients born before 
32 weeks of gestation can be calculated from the IMpact study and is 20 and 21 
respectively. The costs in order to prevent one hospital admission would then be 
approximately $90.000 and $95.000. This indicates that palivizumab is more effective 
in infants born with a gestational age of 32 - 35 weeks (NNT 12) so. 
Local guidelines for palivizLUnab have to be developed since the efficicacy of 
palivizumab will depend on the number of prematmely born infants, rehospitalisation 
rates and duration of hospitalisation 53. ,For instance, rehospitalisation rates in several 
studies for pretenn born infants vary between 3% and 25% 53, 111ese aspects have to be 
taken into account when the econOlnical effects of palivizumab are investigated in 
order to balance the efficacy of prophylaxis in the local high risk population and the 
costs, 
Other IgG-monoclonaI antibodies are cmrently lU1der study and/or tested in healthy 
volunteers and may be future candidates for phase III studies in high-risk infants ,vith 
infections by RSV 24,". 
8.3.2.2.2 IGA MONOCLONAL ANTIBODIES 
HNK20 is an IgA-monoclonal antibody directed against two submuts of the F 
glycoprotein. HNK20 significantly reduces the virus titer in both upper and lower 
respiratory tract of mice and Rhesus tllonkeys 144., Thus far, results of hUlllan studies 
HNK20 have not been published. 
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8.4 CONCLUSIONS 
8.4.1 TREATMENTOFRSVINFECTION 
Currently no effective therapy is available for children with infections by RSV. 
Treahnent of RSV infection therefore relnains l11ainly symptomatic. Because of their 
lack of efficacy corticosteroidsf vitamin A, interferon and antibiotics are not indicated 
in patients with infections by RSV. Although the routine use of bronchodilators is not 
yet supported by evidence-based data, one Inay consider its use in the individual 
patient. Routine use of ribavirin as a therapy in high risk children with infections by 
RSV is not indicated any 111m'e, Adnlinistration of this drug lnay only be considered in 
the patient ,"vith a T-cell inununodeficiency. 
8.4.2 PREVENTION OF RSV INFECTION 
Research on the prevention of RSV infections has focused on active and passive 
inununisation. Interesting candidate vaccines include the recolnbinant vaccine 
BB2GNa, the sublmit vaccine PFP-2 and cold passaged temperature sensitive (cpls) 
candidate vaccines such as cpls-248, cpls248/404 and cpls530/1009. TI,e recombinant 
vaccine BB2GNa and the sublmit vaccine PFP-2 seem to be effective against both RSV-
A and RSV-B leading to adequate levels of neutralising antibody titers in both animal 
and lllunan studies, FlU'ther studies are necessary to investigate whether or not these 
candidate vaccines are truly effective and can be safely appHed in infants. 
Passive imnllmisation may be achieved by the administration of RSV immune 
globulin (Respigam®) and monoclonal antibodies (palivizlUnab /Synagis®) in infants 
born prematmely (,032 weeks) and chilcbnl with BPO. RSV-IVIG should be used with 
great caution given the high costs and difficulties with the intravenous route of 
administration. RSV-IVIG is contra-indicated in patients with (cyanotic) CHO. 
Paliviztunab is the 11lost recent novel C0111pound licensed for prevention of infections 
by RSV. However, large costs are involved when palivizmnab is routinely used in 
high-risk infants, Hence, cost-effectiveness analyses which need to take into accolU1t 
local and regional differences in RSV hospitalisation rates in the high risk population 
are necessary in order to detennine the appropriate indications for the use of 
palivizumab. Ftu·thermore, a EtU'opean trial on the efficacy of palivizlunab lnay be 
considered since the severity of infections by RSV may differ between the USA and 
Europe 8. Using data frOln the USA in European cost-effediveness analysis Inay be 
nusleading. 
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ABSTRACT 
One of the major questions regarding long-term side effects of bronchiolitis by 
respiratory syncytial virus (RSV) is whether or not it induces astluna in later life. In 
this quantitative review the data of 10 conh'olled studies are analysed. 
Methods Follow-up studies of RSV bronchiolitis published between January 1978 
and December 1998 were identified through a MEDLINE search. Studies were selected 
if (i) poshmtal age at the time of the inital illness was below 12 months, (ii) all children 
were hospitalised for RSV bronchiolitis, (iii) the diagnosis RSV was virologically 
confinned in all casesl and (iu) a control group was used. 
ReslIlts Six studies met all selection criteria. Up to five years of follow-up after RSV 
bronchiolitis in infancy, 40% of children reported wheezing as compared to only 11 % 
in the conh'ol group (p < 0.001). Between five and ten years of follow-up 22% of the 
bronchiolitis group reported wheezing against 10% of the control group (p = 0.19) TI,e 
incidence of recurrent wheezing as defined by tlu'ee or more wheezing episodes also 
decreased 'with increasing years of follow-up: at five or Illore years of follmv-up the 
difference between the RSV group and the control group was no longer significant. 
Fmthennore, the presence of either a personal andl or a family history of either atopy 
and I or astluna did not differ between ti,e two groups. COIlc/lIsiollS Wheezing is common 
after RSV bronchiolitis in infancy. It may persist for for more than 5 years of follow-up. 
Howevel~ no significant difference between the RSV-bronchiolitis and the conh'ol group 
was observed regarding recurrel1t \vheezing by five years of follow-up. No significant 
difference between the RSV bronchiolitis and the conh'ol group were fOtmd regarding 
a personal history of atopy, a family history of atopy and lor asthma. Therefore it 
seems unlikely that RSV bronchiolitis is a cause of atopic astluna in later life. 
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9.1 INTRODUCTION 
In the late 50's, Wittig e/ al described an association between viral bronchiolitis in 
infancy and asthma in later life. Over the past decades} IllUllerous reports 'vere 
published investigating a possible relationship. 11,ese studies suggested that acute 
viral bronchiolitis may lead to wheezing during childhood [~. Respiratory syncytial 
virus (RSV) is the most important pathogen in respiratOlY tract infection in infants and 
young children and the major causative agent in bronchiolitis. By the age of two years, 
approximately 80% to 90% of all children has experienced at least one episode of 
infection by RSV. Most of these infections are characterised by a mild disease course. 
However, 0.5% to 2% of children develop severe Inwer respiratory tract infection 
requiring hospitalisation 7-9. 
Wheezing in early childhood is a heterogenous condition 10. A distinction can be 
made between \vheezing as a result of atopic asthnla (when there is a personal history 
of atopy and often a family histOlY of astim1a and/or atopy) and non-atopic h"tnsient 
wheezing 10. The tenn astluna represents a condition characterised by chronic airway 
inflanunation leading to repeated wheezing episodes, shorh1ess of breath and cough 
whkh is (partially) reversible I,ll, 
Shldies investigating the possible relationship between RSV bronchiolitis in infancy 
and wheezing and asthma in later life cannot be easily compared because of 
methodological differences, However, the existence of a relationship between RSV 
bronchiolitis in infancy and recurrent wheezing or astluna in later life may have great 
implications for patient management and for further research, We therefore performed 
a quantitative review to determine (i) the course of wheezing, (ii) the incidence of atopy 
in children with RSV bronchiolitis and (iii) the association between a preceding RSV 
bronchiolitis and the development of recurrent wheezing in children hospitalised for 
RSV bronchiolitis in infancy, 
9.2 MATERIALS AND METHODS 
9.2.1 STUDY PROTOCOL 
Shldies were selected if they met the following criteria: (i) the age of all patients was 
below 12 months at the time of the initial illness, (ii) children were hospitalised for 
RSV bronchiolitis, (iii) the diagnosis RSV infection was virologically confirmed, and 
(iv) a control group was used. The inclusion criteria were defined prior to the screening 
of the literature, 
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9.2.2 DEFINITIONS 
The definition of wheezing was adapted from the authors of included shtdies. It 
was doclUnentated by history taking using a questiOtUlaire ("a whistling sound coming 
from the chest"). Recurrent wheezing was defined by at least three episodes of wheezing 
verified by a physician, or the use ofbronchoclilators in the year preceeding the follow-
up study. 
Atopy was defined by the presence of allergic rhinitis and/or urticaria and/or 
rashes in response to food, inhalation antigens, or drugs and/or an elevated IgE level. 
A positive skin prick test (SPT) was defined as positive when the diameter of the wheal 
"vas 3 111m or greater. OutcOlnes of interest were wheezing, recluTentwheezing, personal 
history of atopy, positive SPT's and a family history of astluna and/or atopy. 
9.2.3 DATA SOURCES 
Controlled follow-up shtdies of bronchiolitis due to respiratory syncytial virus 
through a MEDLINE search of articles published from January 1978 to December 1998 
using PubMed (http://www.ncbLnhn.nhi.gov) were identified. Both prospective and 
retrospective case control studies and longitudinal cohort studies "\vere included. 
Combinations of the keyword RSV and following keywords were used: bronchiolitis, 
wheezing, reClU'rent "\vheezing, asthma, atopy, bronchial hyperreactivity, follow-up 
and long term effects. These keywords were combined with viral bronchiolitis in a 
second search. Additional studies were identified f1'0111 review articles and references 
of the retrieved articles. 
9.2.4 ANALYSIS 
Summary data were collected from tabular and written presentation in the 
publications after a thorough review. When a study was designed as a longitudinal 
follow-up shtdy, only the last year of follow-up year was included for analysis. TIus 
applied to Pullan '82 (last two years of follow-up) 13, Sigttrs '95 (third year of follow-
up) 15, Osundwa '93 (second year of follow-up) 16, and for Sly '89 (fifth year of follow-
up) 18. 
For each individual shtdy, Odds Ratios (OR) and their 95% confidence intervals 
(95% CI) and p - values using the X' test were calculated. It was attempted to combine 
the results of the individual shtdies. With the Mantel-Haenzel method a pooled OR 
and it's 95% CI was calculated. If a p -value was'; 0.05, it was accepted as statistically 
significant. The odds ratio and its 95% confidence interval were logaritlUllically 
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Table 9.1 Descriptive data on study population and study design 
Sims Mok Pullan Murray 
(12) (16) (13) (17) 
Year of publicati 1978 1982 1982 1992 
Total number of RSV 35 100 130 73 
patients 
Study type P, CC P, CC P, CC P,CC 
Control group (N) 35' 200' 111' 73' 
Duration of fol!ow~up 8 7 10 5.5 
(year) 
Bronchiolitis as first Unknown Unknown Unknown Yes 
wheezing episode 
Data on: 
wheezing + + + + 
asthma + + + 
atopy +' + + +' 
famil history of asthma + + + 
and/or atopy 
P prospective; R retrospective; CC case control; LC longitudinal cohort; C case only 
I Included the use of a retrospective control group 
2 Prospectively followed control group 
J Skin prick test perfonned 
First author (reference) 
Sigurs Osundwa 
(14) (15) 
1995 1993 
47 70 
P, LC R,CC 
93' 70' 
1,2and3 2 
Unknown Unknown 
+ 
+ + 
+ 
+ 
,[ Results on a personal history of atopy, family histonj of atopy and/or asthma and number of positive skin prick 
tests were reported in a later study which was used for analysis (Sims et aI, Br Med J 1981, pages 2086 ~ 20SS) 
Welliver Sly Welliver 
(18) (19) (20) 
1993 1989 1986 
43 48 38 
P, C P,C P,C 
7-8 1,2,3,4 4 
and 5 
+ + 
+ + 
+' 
+ 
Sigurs 
(21) 
1994 
34 
P,C 
2 
+ 
+ 
+' 
~ 
C;; 
~ 
~ ,. 
a. 
~ 
'" 
v, 
" ~ ~ 
~. 
~ 
'2 
;; 
"-~ 
~. 
~. 
~ 
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Figure 9.1 Relationship betweell RSV brollchiolitis in illfallcy alld wheezillg dllring (early) c1lild}/Ood. The 
thick vertical line represellts the odds ratio, the small vertical lilies represellt t}1e 95% cOIifidellce iI/terval of the 
odds ratio. For the pooled OR, 110 heterogeneity was oilserved. YFU: years of follow-IlJ1. 
First 
author 
Pullan 13 
Sims1:? 
Murray 17 
Sigurs 14 
< 5 years 
;::: 5 years 
Years of 
follow-up 
8 - 10 
6-8 
5.5 
3 
I 
c--I-, 
Favours no association OR =: 1 Favours association 
transformed for graphic presentation. 
RSV Conlrol OR (95 % CI) 
29/13014/11 2.0 (1.0 - 4.0) 
8/35 1/35 10.1 (1.2-85.6) 
17142 11173 3.8 (1.6 - 9.3) 
19/47 8196 7.2 (2.8 - 18.3) 
36/89 16/1663.8 (1.6 - 9.3) 
37/165 15/1462.3 (1.2 - 4.5) 
Heterogeneity between studies was tested to determine whether one pooled OR 
might be assumed for all studies. Homogeneity behl'een studies is assmned when the 
p - value exceeds 0.05. 
9.3 RESULTS 
9.3.1 STUDY IDENTIFICATION 
From 30 identified publications investigating the outcome of RSV bronchiolitis, 
only four articles fully met the selection criteria (Table 9.1) 12.15. These were included for 
analysis. Two studies included also infants ·with viral agents other than RSV, but 
performed a subanalysis in which only the RSV (+) infants were compared with the 
conh'ols 16,17. TIlese nUlllbers were used for analysis, Four other studies satisfied all 
criteria except for the presence of a control group 1S-21. 
Data on the munber of children with one or more of the outcomes of interest studied 
were easily reh'ievable. SOllle difficulties occurred for ,vheezing either one or two years 
before follow-up with the studies by Sims and Murray 12,l7. For Sims eI ai, the ntlllber of 
children with current wheezing was calculated by 18 (cumulative wheezing) minus 
10 not experiencing wheezing episodes in the last two years before follow-up. The 
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number of RSV positive patients with wheezing in the study by Murray el al was 
calculated as follows: 39.5% for 42 RSV positive children available for analysis equals 
17. For recurrellt wheezillg, only the ntlUlber on asthma was used from the study by 
Sigurs et III since recurrent wheezing in their study yielded it not being verified by a 
physician 14. 
9.3.2 WHEEZING 
TIle percentage of children with wheezing after RSV bronchiolitis in infancy declined 
with increasing years of follow-up. In the first five years after RSV bronchiolitis in 
infancy, 40% of the children experienced wheezing against 11 % in the conh'ol group 
(OR 3.8, 95% CI 1.6 - 9.3 (p < 0.001». At five to ten years of follow-up, the odds ratio 
decreased to 2.3 (95% CI 1.2 - 4.5, P = 0.004) (Figure 9.1). For the pooled OR's, no 
heterogeneity was observed. 
All ntunbers presented represented II cUl'l'enf' wheezing: wheezing episodes either 
one or two years before follow-up. 
9.3.3 RECURRENT WHEEZING 
When investigating the percentage of patients 'with recurrent wheezing, in the first 
Figure 9.2 Relatiollship lletwet'll RSV brollchiolitis ill illfallcy alld recurrent wheezillg dllrillg (early) childl/Ood. 
The thick l.lerticnllille represellts tile odds mtio, flie small verticnllillt's represent tile 95% collfidence interval of 
tlie odds ratio. For the pooled OR, 110 heterogeneity was observed. YFU: years of follOW-lip. 
First Years of 
author follow-up 
Pullan 13 8 - 10 
Mok 16 7 
8igurs 12 3 
Osundwa 15 2 
::; 5 years 
> 5 years 
Favours no association OR = 1 
-1-· 
f-I 
1 
---; 
Favours association 
RSV Control OR (95 % CI) 
7/130 5111 1.4 (0.4 - 4.4) 
6/100 5/200 2.5 (0.7 - 8.4) 
i 11/47 1193 28.8 (3.5 -225.7) 
31nO 9/70 8.0 (3.5 - 18.5) 
421117 10/163 5.5 (2.4 - 12.6) 
14/230 10/321 2.4 (0.7 - 8.4) 
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Figure 9.3 Relatiollsllip /Ietweell RSV bronchiolitis ill illfilllcy mid a persolla/llistory of atopy. Tile tliick 
vertical line represellts the odds mtio, tlie slIIalll1erfical lillI's reprcsent the 95% confidt'llce init>n'(ll of tlte odds 
mtio. For the Jlooled OR, 110 lteteroge1leity was ol/servcd. YFLl: years of follow-lip. 
First author RSV Control OR (95 % CI) 
Sims 12 
--+-1- 5/32 2126 1.3 (0.5 - 3.4) 
Pullan 13 25/13033/11 0.6 (0.3 -1.0) 
Sigurs 14 9/47 14/93 1.3 (0.5 - 3.4) 
Poole'd -1-1 31/21240/2390.7 (0.4 - 1.1) . 
Favours no association OR = 1 Favours association 
Figure 9.4 Rel(ltiolls/Jip between RSV brollclliolitis ill illfilllcy alld a positive falllily history of (lstllllm and/ 
or atopy. T1/C thick vertical lille represents the odds mtio, tlte small vertical lim's represent the 95% confidel/ce 
illterml of tlte odds mtio. For flit' pooled OR 110 heterogeneity was observed. YFLl: years of follOW-lip. 
First author RSV Control OR (95 % CI) 
Sims 12 1- 5/32 2/26 1.3 (0.5 - 3.4) 
Pullan 13 25/130 33/11 0.6 (0.3 - 1.0) 
Sigur$ 14 9/47 14/93 1.3 (0.5 - 3.4) 
Pooled i 1 ! 31/21240/2390.7 (0.4 - 1.1) 
Favours no aSSociation OR = 1 Favours association 
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five years after the initial illness a significant difference was observed between the 
RSV bronchiolitis and the conh·ol group (45% in the bronchiolitis group as compared 
to 13% for the control group, p < 0.001). By five years of follow-up or more, there was no 
clear difference in the prevalence of recmrent wheezing in the RSV bronchiolitis group 
and in the conh·ol group (Figure 9.2). For the pooled OR's, no heterogeneity was 
observed. 
Ntunbers frot11 the studies by Osw1dwa and Sigurs represent cllIl1ulative numbers 
at two or tlu·ee years of follow-up. 11,e munbers from the studies by Mok and Pullan 
represent current recurrent,vheezing at seven and eight to ten years of fonow-up. 
9.3.3 PERSONAL ATOPY 
Figures 9.3 describes the relation between RSVbronchiolitis and personal history 
of atopy at the time of follow-up. Four studies investigated the relationship between 
the presence of a personal history of atopy and RSV bronchiolitis 12.14.16. One group 
found no relationship behveen RSV bronchiolitis and atopy, but gave no actual 
figures 16. The study by Sigurs et al investigated the munber of infants with atopy prior 
to the bronchiolitis, whereas the shldies by Pullan eI al and by Sims et al defined a 
personal history of atopy by either atopic dermatitis, allergic rhinitis or a history of 
allergy up to the age of eight or ten years. 
ll1e occurrence of a personal histOlY of atopy was not significantly different behveen 
the RSV bronchiolitis and the conh·ol group (15% as compared to 12% for the control 
group). 
No conclusion could be drawn about the relationship between RSV bronchiolitis 
in infancy and the number of positive SPT's at follow-up since the homogeneity test 
yielded a p - value < 0.05. Tlus indicated that the results of the studies demonshated 
heterogeneity and thus cannot be combined. 
9.3.4 FAMILY HISTORY OF ASTHMA AND ATOPY 
Significant differences between the RSV bronchiolitis and the control group were 
neither observed with respect to the presence of a family lustory of atopy and/or 
astlmla (Figure 9.4). For all pooled OR's, no heterogeneity was observed. 
A secondary analysis 'was performed, adding four studies lacking a control group 
but fullfilling all other criteria 1~21. The outcome of tIus analysis was comparable (data 
not shown) with regard to '\vheezing, recurrent wheezing, personal history of atopy 
and a positive family Ius tory of atopy and/or astIuna. 
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9.4 D,SCUSS,ON 
In this quantitative revie\v the course and development of (reclUTent) wheezing 
was described in infants with RSV. Wheezing episodes persisted for five to ten years of 
follow-up. The percentage of patients with reCllrrel1t wheezing decreased with increasing 
years of follow-up. After five years of follow-up there was no significant difference 
between the RSV bronchiolitis group and the control group. No significant difference 
between the RSV bronchiolitis and the control group regarding a personal history of 
atopy was observed. No association behveen RSV bronchiolitis in infancy and a fanmy 
history of asthma and/or atopy ·was observed. 
Several studies investigated the relationship between RSV bronchiolitis and long 
tenn effects such as wheezing and the developlnent of recurrent wheezing or astluna 
in later life. Unforttulately, ll1ethodological differences, such as differences in duration 
of follow-up and lack of a conhul group, between various shldies cOlnplicated the 
perfonnance of a straightforward meta-analysis. TIlerefore, the tenn quantitative ,vas 
introduced so that the prevalence of lower respiratory tract symptoms after RSV 
bronchiolitis in infancy and h'ends in outcOlne pm'anleters over titne could be exatnined 
by this method ". 
This analysis demonstrated that wheezing is a feature after RSV bronchiolitis in 
infancy and that it may persist for five or more years of follow-up. At eight to ten years 
of follow-up a non-significant difference between the RSV bronchiolitis and the control 
group was observed by one group 13. TI,e cause of wheezing due to RSV bronchiolitis 
may be multifactorial. Many factors may explain wheezing after RSV bronchiolitis as 
\vas extensively reviewed by Balfour-LYlul 23. It relnains to be detennined which of 
these factors are responsible for ·wheezing after viral bronchiolitis in infancy. 
TI,e pre"alence of rectu'rent wheezing after RSV bronchiolitis in infancy decreased 
,vith increasing years of follmv-up. At five years of follow-up, no clear difference 
behveen cases atld controls 'vas f01Uld. Recurrent \vheezing was defined as tlu'ee or 
more episodes of wheezing verified by a physician 01' the use ofbronchodilators in the 
year preceding follow-up. TItis defittition may also apply for the defutition of astIuna. 
I-Iowever, there is increasing debate about the definition of astluna 2-1,. It is understood 
that there are differentwheezitlg phenotypes. hl some ciilldren wheezitlg duritlg infancy 
resolves in the em'ly school years. TIlese ·wheezing episodes do not seelll to be associated 
with increased 19E levels. In other children with persistent wheezing 01' cltildren itl 
\VhOl11 the respiratOlY symptOlns occur for the first titne aroluld five years of age, these 
symptoms may be the first manifestation of astIuna. TItis wheezing may be an 19E 
Inediated reaction 10,24-26. 
Children are predisposed to develop" classic" astlulla - to be called atopic astIulla 
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- when there are signs of atopy - defined by a positive history for eczema, increased 
sermll IgE levels, eosinophilia and/or positive skin prick tests - and a genetic 
predisposition (a positive family history for astluna) 1l,2j. This analysis denlonstrated 
that there was no difference between the RSV bronchiolitis group and the control 
group regarding the presence of a personal history of atopy and that there ,vas no clear 
association between RSV bronchiolitis in infancy and a positive faillily history of 
atopy and/ or astluna. This indicates that children with a history of RSV bronchiolitis 
in infancy are not lllore predisposed to develop atopic asthma than children without 
such a history, 
It has been observed that RSV infection may result in allergic sensitization to food 
or inhalant allergens. TI,e study by Sigurs ef nl provided evidence for an increased 
allergic sensitization as rneasured by an increased number of positive SPT's to inhalant 
allergens 14. A later study by this group demonstrated that this allergic sensitization 
was associated with higher anti-RSV IgA titres 27. Further evidence for allergic 
sensitization was found in the animal model. A possible explanation may be the 
induction of allergen-specific IL-2 responsiveness of lymphocytes after RSV 
infection 28, However, others provided conflicting results 29. It ·was concluded that 
only during the first year of life RSV infections slightly promoted aeroallergen 
sensitization in non-hospitalised children, though no clinical 11lanifestations were 
apparent. Nonetheless, this possible allergic sensitization of children with a histOlY of 
RSV bronchiolitis during infancy requires fmther study. 
111is study provides further evidence to the long tenn rnorbidity associated with 
RSV. However, many aspects on RSV remains mlknown, For instance, it is still unknown 
as to how RSVbronchiolitis during infancy causes wheezingduring(early) childhood. 
Identification of inflammatory markers produced dming the acute illness that may be 
found in children ·with recurrent wheezing rnay provide sonle elucidating evidence. 
FmthermOl'e, just foUl' stuclies from all 30 identified used a conhul group. This inclicates 
that in fact there are just a few studies from which the long time prognosis of RSV 
bronchiolitis in infancy can be estimated. 
The interpretation of this analysis may be complicated by several factors. Studies 
used for analysis are heterogenous and cases and controls rna)' vary in different 
characteristics. It was attempted to minimize these c1ifferences by defining a number of 
inclusion criteria prior to the screening of the literature, Furthermore, only a slllall 
lllunber of suitable shlclies were identified using many c1ifferent definitions of outcome 
variables. The study by Sigurs eI nl was the only one to use a prospectively followed 
control group whereas the others used a retrospective control group. The use of a 
prospectively followed control group is preferable, because then the h'ue development 
of lovvel' respira.tory h'act syrnpt01ns can be estilnated. 
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Since is was notpossible to exh'act clear definitions of wheezing from the included 
studies} the definition used by the various authors was adapted in order to avoid the 
elimination of studies that could conh'ibute to this quantitative review. Characteristics 
not available for this analysis since they were not (frequently) mentioned in included 
studies Inay be confolU1dingvariables. For instance} socio-econOluic status and parental 
smoking are risk factors for wheezing in later life 3001. Only published studies reh'ieved 
through a MEDLINE/PubMed search ·were used in this quantitative review. This Ina), 
implicate a publication bias. It may be possible that negative shldies on the relationship 
between RSV bronchiolitis and asthma in later life may have not been published. 
The analysis was restricted to infants hospitalised for RSV bronchiolitis, since it 
,"vas assmned that only cases of bronchiolitis ·with lower respiratoIY tract involvem.ent 
demonsh'ate pulmonary problems which may result in long term morbidity. Infection 
in children with a mild disease course is 1110st likely resh'icted to upper respiratory 
h'act involvelnent only. 
III couclusioH, the outCOlne of this quantative review denlonstrated that children 
continued to wheeze after RSV bronchiolitis in the first year of life. TIus wheezing 
persisted for up to five years of follow-up or Inore. However, after five years of follow-
up, no difference in recurrent wheezing between the RSV broncluolitis and the control 
group was observed. No clear relationship was fotmd between RSV bronchiolitis and 
the presence of a personal Ius tory of atopy. Also, no significant association was found 
regarding a family histOlY of atopy or asthma between the broncluolitis and conh'ol 
group. TIlerefore it seems unlikely that the occurrence of RSV bronchiolitis in the first 
year of life is a cause of atopic astluna in later life. 
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10.1 INTRODUCTION 
Respiratory syncytial virus (RSV) is the most important cause of viral respiratory 
tract infections in infants and yOlmg children. This thesis describcs the results of 
epidemiological and clinical studies on infections by RSV. The investigations were 
carried out at the Sophia Children's Hospital (SCI-I), Rotterdam, a university hospital 
with secondary and tertiary care nmctions. Between 1992 -1995, 266 children younger 
than 12 months of age diagnosed with virologically confirmed RSV infections 
("Rotterdam database") were included in the reports described in this thesis. TIlirty-
foUl' of these 266 children had a nosocomial RSV infection. 185 of the 232 c1lildren 
with community acquired infections by RSV were adnlitted to the SCH. The data 
collection included demograpllical, clitlical and laboratory parameters, as well as 
characteristics of hospitalisation. 
In Chapters 1 and 2, pathophysiological and clinical characteristics of RSV 
infection are reviewed. TI,e pathogenesis of RSV infection is complex and itilluenced 
by both htllllOral and cellular inUlltlllC responses. Studies in luunans and animals 
have shown that both CD8 positive cytotoxic T cells as well as CD4 positive T helper 
cells are involved itl the elimitlation of RSV. Two major subsets can be identified 
withitl the T helper cells: TH-l and TH-2 cells. T H-1 cells take part itl the cellular itmnune 
response ,vhereas TH -2 cells are associated with the production of inununoglobulins 
and the itlduction of eosinophilia. Both subsets are activated in children with RSV 
infections. In addition, T-cells Ina1' also contribute to the developlnent of 
immunopathology. Other cells that are involved in the inunlule response include 
neutrophils, eosinophils and nlast cells with subsequent production of various 
ittila11unatory mediators. A hypothetical model of the complex pathogenesis of RSV 
infections is presented in Chapter 2 (page 28). 
Further research on the pathophysiology of RSV ittiections is required itl order to 
provide a better understanding of the disease and its clinical presentations. A 
longitudinal cohort study l11ay reveal whether infants are prone for a TH 1- response or 
a Til 2- response once itlfection by RSV OCClli·S. It would be interestitlg to itwestigate 
whether a genetic predisposition for either one of these two responses mal' be identified. 
Genetic polymorphisms have already been elucidated as important detennitlants in 
the susceptibility and severity of other ittiectious diseases. For instance, a polymorphism 
in the promotor region of the gene encoditlg for plasmitl0gen activator itulibitor (PAI)-
1 has recently been associated with outcmne in children vdth meningococcal sepsis 1. 
Polymorphisms in cytokine genes or other components involved in the extent of the 
inf1anullatolY process in infections by RSV may co-determine the outcmne of disease. 
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10.2 SUBGROUP VARIATION IN INFECTIONS BY RSV 
Two subtypes of RSV can be identified by the use of monoclonal antibodies on the 
basis of differences in the G-protein. These subtypes, A and B, can cocirculate but may 
also circulate independently from each other dming an epidemic. Several investigators 
have studied the presence of a possible relationship behveen the clinical severity of 
infections by RSV and the subtype. The results of the Rotterdam study on the 
relationship between the clinical severity of infections by RSV and subtype A or Bare 
described in Chapter 3. Between 1992 and 1995, the majority of RSV infections (64.7%) 
was caused by subtype A whereas 35.3% of the infections was due to subtype B. We 
could not detect a relationship between the clinical severity of infections by RSV and 
the subtype. One may therefore conclude that new vaccines need to protect against 
subtype A as well as against subtype B. TI,e F-protein may be used as a target for 
fmther vaccines because of the great degree of homology of this protein in the two 
subtypes. 
TI,e results of am shldy are compared with those of20 other studies (Table 10.1). In 
eleven studies no relationship was detected behveen the clinical severity and subtype 
A or B, whereas the results of eight investigations suggest that subtype A is associated 
Table 10.1 Studies 011 the relatiollship between clinical seuerity of infectiolls by RSV (Illd subtype A or B 
Study First author Study period Country Number of Methods1 Results2 
number (reference} isolates (AlB) 
1 Hendry 42 82-82 USA 51134 RIND 
2 Mufson 4) 81 -86 USA 155151 RID A 
3 Hendry4-i 83-85 USA 125192 RIND 
4 Taylor 4, 74-88 UK 3281169 RID A 
5 Monto ~, 65-71 USA 64129 RIND 
6 McConnochie 41 76 -81 USA 95162 PIDIMV A 
7 Mcintosh ~3 85-87 Austrialia 3371107 PID 
8 Hall ~'J 89 - 91 USA 8581351 RID A 
9 Wi1son~ 87-88 Canada 45124 RID 
10 Wang 51 93 Canada 1021250 PIDIMV 
11 Salomon 02 87-88 Argentina 23193 RND A 
12 Tsutsumi 53 80 - 89 Japan 77152 RIND 
13 Heikkinen ~-I 87-92 Finland 1921134 PID A 
14 Russi 05 85-87 Uruguay 19122 PID 
15 Walsh o~ 88-91 USA 1341131 PIDIMV A 
16 Mufson :i1 78-88 USA 319186 RID A 
17 Stark oa 85-88 USA 176121 RID 
18 Mlinaric,9 91 USA 8110 RID 
19 Straliotto <-) 90 Brazil 2217 RID B 
20 Hornsleth 61 93-95 Danmark 31154 PID B 
21 Kne~ber 92 95 Netherlands 150182 R1DIMV 
1 R illdicates retrospective study, P indicates prospective stlldy; ND i1ldicates tilat the illdicators for severity and/ 
or a scorillg model were /lot described, whereas D indicates that they were dOCIIl1lented 
2 A indicates sllbtype A more St'l.'ere, whereas B indicates slIbtype B more severe and "=" indicates //0 differellce i1l 
severity 
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with a lnore severe disease course. For instance, studies I, 8 Elnd 13 found lllore cases 
of bronchiolitis, a larger nunlber of patients with intensive care adlllission and an 
increased risk for wheezing and oxygen therapy associated with subtype A. Studies 7, 
10 and 17 did not find a difference between subtype A and B in important estimates of 
disease severity such as mechanical ventilation and supplemental oxygen. Study 14 
did not provide details on mechanical ventilation or oxygen supplementation but also 
fotmd no relationship between the clinical severity and subtype A or B. 
In OlU' opinion, conclusions about a possible relationship between severity of 
infection and RSV subtype A or B may only be drawn based on objective outcome 
variables and 111lutivariate analysis. Confounding variables Inay be identified and 
reliable conclusions about independent vm'iables may be detected. Only foUl' studies 
including the one presented in Chapter 3 used inultivm'iate analysis. Two of these 
studies (6 and 15) which were performed in the smne population concluded that 
subtype A ·was associated ·with lllore severe disease. In study 10 and in our study no 
relationship could be fotUld between subtype A or B and severity of RSV infections. 
TI,e results of meta-analyses on the relationship between the severity of infections 
by RSV mld subtypes A or B are presented in Figures 10.1 mld 10.2. Studies were 
included if they met the following criteria: (i) age below 24 months of age mld (ii) 
virological confirmation of the RSV infection (Table 10.2). Outcome parameters of interest 
were Q)''Ygen supplementation mld mechanical ventilation. The Mantel-Haenzel pooled 
odds ratio and 95% confidence intelval for oxygen supplementation was 1.2 (0.8 -1.8) 
Table 10.2 Characteristics of studics iucluded for mt'fl1-allalyscs 011 thc relationship bt'fweell thc clinical severity of 
RSV infections alld the subtypc 
First author Number of Population Ageo! Outcomes 
isolates (NB) inclusion studiedl 
Walsh 07 134/131 Hospital < 24 months MV 
Straliotto 61 2217 Hospital < 12 months °2,MV 
Stark o? 101/16 Hospital Unknown 0Z1 MV 
McConnochie 43 95/62 Hospital < 24 months MV 
Mcintosh 41 337/107 Hospital Unknown 0 21 MV 
Heikkinen 55 1921134 Hospital and outpatfent Unknown a"MV 
Taylor 46 328/169 Unknown Unknown 0 21 MV 
Kneyber 150/82 Hospital and outpatient < 12 months °2,MV 
102 oxygcn sllpplel1lClltatioll, lVIV mechanical ventilation 
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Straliollo 
1 -+ 
Stark 
Mcintosh 
Heikkinen 
Taylor 
Kneyber 
Pooled 
Favours subtype B 
1- 1 
'-, I~ 
-I 
1-1 
i 1 
OR = 1 Favours subtype A 
Summary and col/clusiolls 
OR (95% GI) 
0.1 (0.1 -1.4) 
2.4 (0.5 - 11.4) 
1.2 (0.8 - 1.9) 
2.0 (1.2 - 3.2) 
1.5 (1.0 - 2.2) 
2.0 (1.0 - 3.4) 
1.2 (0.8 - 1.8) 
Figure 10.1 Results from a mela-allalysis on lhe relatioH betweell clillical severity of RSV illfectioll and subtype 
with oxygell supplemelltatioll as outcome pammeter. OR Odds mtio. For references of the iI/eluded studies, see 
Table 10.2 
I 
OR (95% GI) 
Straliollo I 0.3 (0.1 - 2.2) 
Stark 1.1 (0.1 - 9.7) 
McConnochie 8.8(1.1 - 69.7) 
Mcintosh 1.2 (0.5 - 2.6) 
Heikkinen 0.3 (0.0 - 3.9) 
Taylor I 6.4 (0.8 - 49.5) I 
Walsh -1--1 2.4 (1.0 - 6.0) 
Kneyber f--
-I 1.7 (0.7 - 4.3) 
Pooled 
-1- 1.5 (0.4 - 5.0) 
Favours subtype B OR~1 Favours subtype A 
Figure 10.2 Results from a meta-(//wiysis all fhe relatioll betweell clil/ical severity of RSV illfection alld 
sl/btype with mechanical velltilatiol/ (/S outcome p(/rflmeter. OR Odds mfio. For references of tl/C iI/eluded 
studies, see Table 10.2 
(Figure 10.1). This indicates the absence of an association between oxygen 
supplementation and subtype A or B. The same conclusion could be drawn with 
respect to mecllanical ventilation (OR 1.5, 95% CI 0.4 -5.0, Figure 10.2). No heterogeneity 
was observed for both analyses. 
The data presented above conclude that there is no relationship between the clinical 
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severity of infections by RSV and subtype A or B. 
10.3 APNOEA IN INFECTIONS BY RSV 
Apnoea may be the first sign of disease in children with infections by RSV. The 
results of a study on risk factors for RSV associated apnoea in a hospitalised population, 
on risk factors for mechanical ventilation once RSV associated apnoea occurred and 
the risk for recurrent apnoea are presented in Chapter 4. Apnoea at adnussion was 
defined as a history of respiTatory arrest with cyanosis, or an observation in the 
paediah'ic enlergency r0O111 of respiratory arrest for a period longer than 20 seconds 
and/or bradycardia with accompanying cyanosis 01' oxygen desaturation belmv 90%. 
Twenty-one percent of the patients hospitalised with RSV infections presented 
-with apnoea. TIlese children "'ere significantly YOllllger, had a lmver body telnperature, 
higher peo, and more often atelectasis on chest radiographs than patients without 
apnoea. Apnoea at admission increased the risk for recurrent apnoea by ahnost 12 
tinles. The OCClUTence of recurrent apnoea increased the risk for mechanical ventilation 
by nearly seven times. The great Inajority of recurrent apnoea occtU'red -within 24 to 48 
hOlu's after adnussion. Logistic regression analysis sho-wed that YOlUlg age - especially 
in infants below two months - was the only independent predictor for RSV associated 
apnoea, Hence, cardiorespiratory lllonitoring of infants with RSV infection seems 
warranted during the first 48 hours of adlnission. Hu\vever, well-defined criteria are 
necessary in order to prevent excessive use of lllonitoring and the induction of 
Ululecessaryparental fears associated with monitoring 2, We conclude fron1 our study 
that apnoea at adnussion and age s 2 Inonths necessitate cardiorespiratolY lllonitoring 
in children with infections by RSV. Further support for the age criteritun is provided 
by the observation that in our database all children with a first episode of apnoea 
occurring during hospitalisation \vere S 2 11lonths of age. Previous shldies suggest 
that premahtrely born infants - especially those born with a gestational age of below 
32 weeks - are also candidates for cardiorespiratory monitoring H. Table 10.3 
slilllIDarizes the ntunbel' of patients \vithout apnoea at admission that have to be 
monitored (the Ntunber Needed to Treat, NNT) in order to detect one patient with a 
first episode of apnoea occmring during hospitalisation. TI,e NNT is calculated as 
follows: 100/[Ntunber of apnoea's in a certain population (%) - number of apnoea's 
one allows to Iniss, -which is usually 0%]. For instance, in our study population the 
munber of first apnoea during hospitalisation is 6 (4.1%). TI,e NNT would then be 
100/4.1% equals 25 patients. This indicates that 25 patients have to undergo 
cardiorespiratory monitoring in order to detect one patient with a first episode ofRSV 
associated apnoea during hospitalisation. Two from the six patients with a first RSV 
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Table 10.3 Efjlcacy oj cardioYt':;pimfory mOllitorillg ill rcspimtory sYllcytial virus illjectioll 
Number of infants with RSV associated apnoea at admission 38/185 
Number of infants with RSV associaled apnoea during hospitalisation 24/185 
Number of infants with apnoea at admission and during hospitalisation 18/185 
Number of infants with first episode of apnoea occulring during hospitalisation 6/185 
Monitor indication Apnoea! Missed apnoea's when NNT 
group size indication applied 
All infants without apnoe at admission 61147 0 25 
Age :-0;2 months and/or gestational age ~ 32 weeks 6/115 0 19 
Age :-0;2 months and/or gestational age ~ 34 weeks 6/118 0 20 
Age !>2 months and/or gestational age ~ 37 weeks 6/126 0 21 
Age ~2 months 6/101 0 17 
Gestational age ~ 37 weeks 3/50 3 17 
Gestational age ~ 34 weeks 2/21 3 11 
NNT: lIulIIlJer-IIt't'dcd-fo-frt'lIf 
associated apnoea during hospitalisation required nlechanical ventilation. 
TI,e cause of RSV associated apnoea remains tmelear. In om study, only )'otUlg age 
was independently associated with RSV associated apnoea. We therefore suggest that 
tmderlying immatmity of the respiratory system is a major risk factor in RSV associated 
apnoea. Severe lower respiratory tract illness does not predispose to RSV associated 
apnoea. RSV may alter lalyngeal CheI1l0receptors as has been described in htnnans 7. 
Apnoea Inay then OCClU' 'ivhen these receptors arc stiInulated. Pickens and cO-'ivorkers 
described a mixed character of RSV-associated apnoea (being both obsh'uctive and of 
central origin) 8. They observed that apnoea coincided with swallowing and coughing 
and therefore suggested that airway protective reflexes may suppres the ventilatory 
drive. 
Continuation of the characterisation of RSV associated apnoea with 
polysomnographic studies in a hospitalised population is warranted to identify type, 
pathophysiology and recovelY from RSV associated apnoea. Also, a fuhu'e large multi-
center study is necessary to provide additional data on criteria for cardiorespiratory 
monitoring in children with infections by RSV. 
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10.4 CHEST RADIOGRAPHY IN INFECTIONS BY RSV 
Chest radiographs are performed in approximately 70% of hospitalised children 
with infections by RSV '. Hyperinflation, atelectasis and pulmonary infiltrates are 
cOllunonly seen. However, no correlation has been found behveen roentgenographic 
findings and severity of illness 10. The results of a study of predictors for a normal 
chest radiograph are presented in Chapter 5. Using these predictors, a subgroup of 
patients with a high probability for a normal chest radiograph - defined as the 
abscence of atelectasis, hyperinflation or pulmonary infiltrate - may be identified. In 
202 patients, a chest radiograph was performed. Seventy-five of these children had a 
normal chest radiograph. The prediction model for a normal chest radiograph 
cOIllprised increasing age, increasing birthweight presence of rhinitis, abscence of 
reh'actions and increasing Saar TIle area under the Receiver Operating Characteristic 
(ROq-curve was 0.80, indicating good discrimination of the model between normal 
and abnormal chest radiographs. TIle prediction lllodel \-vas h'ansfel'l'ed into a score 
chart to facilitate assessment of the probability for a normal chest radiograph. 
What are the indications for chest radiography in infections by RSV? Dawson and 
cO-Vo.Torkers suggested that intensive care admission, unexpected deterioration in the 
patient's condition or the presence of tmderlying pulmonary or cardiac disorders 
were good indicators to perform a chest radiograph ll. Eriksson and co-workers 
suggested that the presence of atelectasis is strongly suggestive of a bacterial 
superinfection by StreptocoCClIs p"wlllo"iae and Haelllopilillls i"fl"e"zae. Careful 
examination of their data leads to the conclusion that these indications apply especially 
to patients older than 12 months of age ". We suggest to perform chest radiographs 
in patients with a sum score less than 52 as can be calculated by our prediction model, 
and in patients with tmexpected clinical deterioration. With these indications, the 
number of chest radiographs may be significantly reduced. Prospective validation is 
required in order to establish h'ue applicability and generalizability of our model to 
other populations. 
ill mtiversity and general hospitals in The Netherlands chest radiographs are often 
performed in cltildren with infections by RSV. However, the results of our shtdy 
show that performance of a chest radiograph in children with infections by RSV is 
only indicated in selected patients. 
10.5 NOSOCOMIAL INFECTIONS BY RSV 
RSV has been identified as an important nosocomial pathogen leading to an 
increased morbidity and mortality especially in vetyyoung children. Approximately 
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4% to 7% of all hospitalised children will develop a nosocomial infection by RSV 15. 
TIle increased lllorbidity is reflected by an increase in the OCClu'rence of bronchiolitisl 
prolonged hospitalisation and an increased mortality among patients with underlying 
diseases such as congenital heart disease (CHD), bronchopulmonary dysplasia and 
prematurity 13.1'. Especially children with CHD have a significantly increased risk for 
mortality after acquisition of a nosocomial infection by RSV 15. 
Chapter 6 presents the results from a shidy on nosocomial infections by RSV 
(NA-RSV). TI,e munber of NA-RSV was investigated and characteristics ofNA-RSV 
were compared with commwuty acquired RSV infections (CA-RSV). TI,e percentage of 
nosocomial infections by RSV (munberofchildren withNA-RSV divided bythemunber 
of hospitalised children yOlmger than 12 months of age dming the RSV seasons in the 
three year shldy period) was 2.7%. The number of nosocomial infections by RSV 
decreased over the tlu-ee years. Tlus is probably a result of the appropriate use of 
guidelines on prevention of nosoc01uial infections by RSV in our hospital. TIlese 
guidelines include handwashing by hospital persolmel and the isolation of RSV-
positive patients or cohort-caring of these patients. The risk for the acquisition of a 
nosocomial infection by RSV was correlated with the dtuation of hospitalisation for 
any IU1derlying disease (Figure 10.3). 
TI,e cmucal pic hIre of patients with nosocomial infections by RSV was comparable 
Figure 10.3 NUII/ller of nosocolllial illfections by RSV compared with the dlfmtioJl of hospitalisation for allY 
ullderlying disease 
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with that of community acquired infections by I~SV. The significant differences in 
mean birth weight and impaired feeding between NA-RSV and CA-RSV were in our 
opinion a reflection of the specific population of our hospital and not due to a more 
severe disease Course in patients with NA-RSV. Other characteristics of the clinical 
presentation and hospitalisation were comparable between children with NA-RSV 
mld those with CA-RSV. All four children with BPD and NA-RSV requiredmechmlical 
ventilation. We conclude that with the exception of patients with BPO, nosocomial 
RSV infections in this study are not characterised by a l110re severe disease COluse 
,""hen cOlnpared to COllllllunity acquired RSV infections. 
10.6 DURATION OF HOSPiTALISATiON iN CHiLDREN WiTH iNFECTIONS BY RSV 
EstiInation of disease severity in infections by RSV lnay aid physicians to decide 
,.vhen to initiate specific therapies, or identifies patients prone for a severe disease 
course so that they may be subjects for preventive approaches. Moler and Olunit have 
recently developed a prediction model for the dmation of hospitalisation in RSV 
infection. The lllodel showed good discrimination as assessed by the area under the 
ROC-curve 16. TIley hypothesized that prolonged hospitalisation ~ 7 days would 
discriminate the lllOst severe infections with a lnean duration of hospitalisation in 
their database of four days. TI,e model predicted a hospital stay ~ 7 days by weight, 
presence of congenital heart disease, presence of failure to thrive, premahlrity, presence 
of BPD, presence of other pulnlonary diseases, lniscellaneous conditions, early 
tnechanical ventilation and early ribavirin. Their l1lodel ,.vas validated on OlU' database 
set. TI,e results of this study are described in Chapter 6. TI,e validation demonstrated 
that the model could not adequately predict a prolonged hospital stay ~ 7 days as 
determined by the combination of a high sensitivity mld a low false positive rate (FPR). 
FUl'thennore, it ,vas argued that for OlU' institution a cut-off at seven days would not 
necessarily provide a good discrimination bet-ween less severe and severe infections 
given the two-fold longer duration of hospitalisation for our patients cOlnpared with 
the Miclligan-database. A good discrimination may be better represented by the median. 
Thus, a prediction model for prolonged hospitalisation ~ 9 days (which represented 
the 111edian in our database) Was constructed. Independent predictors were weight 
mld need for oxygen supplementation. The ROC of the model was low (0.65). When 
validated on a single RSV season, the prediction of duration of hospitalisation proved 
inadequate. We conclude from these data that a reliable prediction of duration of 
hospitalisation is currently impossible and hence may not adequately represent the 
severity of RSV infectio~ls. This observation has iInportant iInplications since many 
ll1ulticenter trials used dlu'ation of hospitalisation as an outcomeparanletel' for clinical 
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response. 
10.7 TREATMENT AND PREVENTION OF INFECTIONS BY RSV 
10.7.1 TREATMENT OF INFECTIONS ByRSV 
Research on the Ii'eahnent ofRSV infections has focused on the use ofcorticosteroids, 
bronchodilators and antiviral drugs. 
Corticosteroids would seem attractive agents in the treatment of infections by RSV 
because of the increasing evidence that RSV associated disease is an 
inununopathological process. Hmvever~ various studies failed to deillonsh'ate efficacy 
of corticosteroids in the treahnent of irifections by RSV 17. Furthermore, corticosteroids 
do not prevent recurrent wheezing after RSV bronchiolitis. Hence~ the use of 
corticosteroids is not "\vmTanted. 
Bronchodilators are commonly used in patients with infections by RSV due to 
sinillarity in clinical features between RSV bronchiolitis and astluna. TIle results from 
several studies m'e conflicting 18. There is no conclusive evidence to support the efficacy 
of bronchodilators 19. At this moment, it would seenl that an initial h'eahnent with 
bronchodilators tnay be considered in the individual patient. "\IVhen the patient shows 
clinical iInprovelnent, continuation of bronchodilators lnay be considered. 
Ribavirin currently remains the only antiviral drug for RSV infection. Controversy 
about its use has arisen since promising results fr01n early studies perfonned in the 
'80s were contradicted by results from recent, methodologically more sound studies. 
High costs and possible teratogenic and carcinogenic side-effects fmther contribute to 
this controversy. Hence, ribavirinis seldOlllly used nowadays 20. Prescription of ribavirin 
should only be considered in the immunocompromised patient (T-cell 
inllllunodeficiency) with a severe disease course. RSV illUl1lUle globulin should not be 
used for the treatment of RSV infections IS. The occurrence of secondary bacterial 
infections is low 21 As a consequence, therapeutic h'ials failed to identify any benefit of 
antibiotics 22,2\ Therefore, routine use of antibiotics is not warranted. 
10.7.2 PREVENTION OF INFECTIONS BY RSV 
Prevention of RSV infections Inay be achieved tluough active and passive 
inununisation. Vaccination trials with fonnalin-inactived, alUln precipitated RSV vaccin 
carried out in the '60s were complicated by serious side-effects. Vaccinees developed 
severe disease with increased mortality rates on subsequent challenge by wild type 
RSV. Nevertheless, continued research on novel vaccines has yielded several (potential) 
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candidate vaccines such a BBG2Na, Purified Fusion Protein (PFP)-2 vaccine and 
attenuated cold-passaged, temperature sensitive mutants such as cpts-248, cpts-248/ 
404 and cpts-530/1009. The immunogenicity of these candidate vaccines has been 
dernonstrated in the animal 11lodel 2.t~26, PFP-2 has been tested in humans and 'was 
found not to reduce RSV associated respiratory h'act illness 27,28, Cpts-vaccines were 
effective in children over 6rnonths of age, but caused nasal congestion in one and hvo 
month old infants 29. TIle development of a vaccine against RSV may be hindered by 
the presence of maternal antibodies '\vhich Inay depress the infanfs imnlune response, 
and the low ability of yOlmg infants to respond to viral surface glycoproteins. 
Research on passive immunisation has produced hvo licensed drugs: RSV inuntU1e 
globulin (RSV-IVIG) and humanised monoclonal antibodies directed against the F 
protein (Palivizmnab). The PREVENT-study included prematurely born infants mld 
children with BPD for treatment with RSV -IVIG or placebo. TIle study demonstrated a 
41% reduction of RSV-hospitalisation and a 53% reduction in total days of RSV 
hospitalisation associated with RSV-lVIG 30. The use of Palivizumab in children 
YOlmger than 24 months of age with BPD and infants YOlmger than six months of age 
with a history of a prematme birth (0) 35 weeks) resulted in a 55% reduction in RSV 
hospitalisations in a high risk population (a 78% reduction for the prematurely born 
infants and a 39% reduction in the BPD group). A reduction of 47% of RSV-
hospitalisations was observed for infants born before a gestational age of 32 weeks, 
'\vhereas a reduction of 80% was observed for infants with a gestational age behveen 
32 and 35 weeks. ntis latter group constitutes the greatest portion of prematmely born 
infmlts with a gestational age below 37 weeks. The use of palivizmnab did not alter the 
ntunber of infants requiring Inechanical ventilation, 
Indications for administration of Palivizmnab may be influenced by regional or 
(inter)national differences in RSV associated disease bmden. These differences include 
number of prenlahlrely born infants with or without clu'onic lung disease, severity of 
RSV associated disease and rehospitalisation rate for high-risk patients. 
Rehospitalisation rates Inay vary between 3% and 25% 31, Limitations of a widespread 
use of RSV-IVIG include high costs mld intravenous administration. A benefit of 
Palivizumab over RSV -IVIG is the inh'anluscularly route of administration, The lise of 
RSV-lVIG seems to be outdated with the availability of Palivizumab. However, cost-
effectiveness analyses have to be performed in order to generate appropiate indications 
for the use of Palivizumab. These analyses may result in the appropiate Number 
Needed to Treat acceptable for patients and doctors in relation to the costs and bmden 
of treahnent. 
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10.8 LONG TERM EFFECTS OF RSV INFECTION 
Over the past decades/ the presence of a relationship behveen RSV infection in 
early childhood and asthma in later life has been studied extensively. 11,is issue is still 
subject of intensive debate. Two hypotheses prevail: (i) RSV bronchiolitis and astluna 
are two different. entities with comparable clinical manifestations, and (ii) RSV 
bronchiolitis identifies the predisposed host who subsequently develops asthma after 
bronchiolitis in early childhood. We performed a quantitative review to investigate the 
association between a preceding RSV bronchiolitis and the development of reClll'rent 
wheezing in children in time (Chapter 9). Controlled studies in hospitalised patients 
younger than 12 months of age with vil'Ologically proven RSV bronchiolitis were 
identified tluough a Medline search of prospective and retrospective case control or 
longitudinal cohort studies published between January 1978 and December 1998. 
TIlirthy publications were identified/ of 'which only six lllet all inclusion criteria. 
The odds ratio for wheezing decreased from 3.8 (95% CI 1.6 - 9.3, P < 0.001) in the 
first five years after RSV bronchiolitis in infancy to 2.3 (95% CI 1.2 - 4.5, P = 0.004) at 
five to ten years of follow-up. Reclll'rentwheezing - defined as tluee or more episodes 
of 'wheezing verified by a physician, or the use ofbrondlodilators in the year preceeding 
follow-up - was not associated with RSV bronchiolitis in infancy at five or l1l0re years 
of follow-up (OR 2.4, 95% CI 0.7 - 8.4). No association between RSV bronchiolitis and 
the occurrence of a personal history of atopy or a family history of atopy and/or 
asthma was found. Hence, it was concluded that the OCClll'rence of RSV bronchiolitis 
in the first year of life is not a cause of atopic astlmla in later life. 
The results of OlU' quantitive revie,,, are supported by an increased lUlderstanding 
of the pathogenesis of RSV infections. Characteristics of asthma and bronchiolitis are 
presented in Table 10.4. Whereas in asthma CD4 positive T cells are the predominant 
lymphocytes, an ablUldance of CD8 positive T cells is observed in RSV bronchiolitis ". 
Also, eosinophils are important in the pathogenesis of asthma, but these cells may 
Table lOA Compariso1l liefweel1 RSV brollclIiolitis I1Ild asf11JJ1I1 
RSV bronchiolitis Asthma 
T - cells CDB(+) CD4 (+) 
T·helper subset 
Role of eosinophils + +++ 
Personal history of atopy +++ 
Family history of atopy and/or asthma + 
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only playa conh'ibutary role in the pathogenesis of RSV bronchiolitis ", Furthermore, 
'ivhereas in astluna a dysbalance in the TII-ljTH-2 paradigll1 is found in favour of TH-
2 lymphocytes, RSV also induces a T H-1 response. 
IgE plays an important role in the pathogenesis of asthma "'. However, senun IgE is 
not elevated after RSV bronchiolitis 35, Although RSV-specific IgE may be found in 
nasopharyngeal secretions or HAL srunples during the acute infection, the appearrulce 
of RSV-specific IgE was fOlmd not to be related to recurrent wheezing at the age of 
seven to eight years 36. A sinillarity between the two clinical entities is the observation 
of increased concentrations of eosinophilic cationic protein (ECP). However, the 
measurement of ECP during RSV bronchiolitis does not conh'ibute to the prediction 
whether children ,vill develop bronchial obstruction or astluna 37. Other viral infections 
may also induce increased ECP levels 3S. 
The pulmonary function after RSV bronchiolitis including FVC, FRC, inspiratory 
airway resistance, peak expiratory flow resistance and respiratory systenl cOlnpliance, 
were not decreased 'when cOlnpru'ed to controls n4D. However, it'ivas found that infrults 
who develop bronchiolitis had evidence for pre-existing diminished itmg function '1. 
These pre~existing abnornlalities in lung nUlction may function as a risk factor for 
wheezing associated lower respiratory tract illnesses during the first year of life ".". 
Children with RSV bronchiolitis should be followed for at least ten years in order to 
investigate which inflanunatol'Y markers that are produced during the acute illness -
111easured in nasopharyngeal \vashings -lnay be responsible for (recLUTent) ·wheezing. 
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SAMENVATTING EN CONCLUSIES 
C"apter 11 
11.1 INTRODUCTlE 
Het respiratoir syncytieel virus (RSV) is de belangrijkste verwekker van virale 
luchtweginfecties bij zuigelingen en jonge kinderen. In dit proefschrift worden de 
resultaten van klinisch-epidemiologisch onderzoek naar RSV infecties bij jonge 
kinderen besclu·even. Het onderzoek \verd verricht inhet Sophia Kinderziekenhuis te 
Rotterdam, een academ.isch kinderziekenhuis lllet zowel sectllldaire als tertiaire zorg. 
De shldieperiode liep van 1992 tot en met 1996 ("Rotterdam database"). 266 kinderen 
jonger dan 12 Inaanden ,"verden gediagnostiseerd lllet een virologisch bewezen RSV 
infectie. Van deze kinderen hadden 34 een nosocomiale RSV infectie. Van de 232 
kinderen lllet een buiten het ziekenhuis verworven RSV infectie ,"verden er 185 
opgenOlnen in het ziekenhuis. Demografische en klinische paratneters werden 
verkregen uit de medische status. 
In Hoofdshlk 1 en 2 worden de klinische en pathofysiologische aspecten van 
RSV infecties beschreven. De pathogenese van een RSV infectie is complex en wordt 
bei'nvloed door zowel de humorale als de cellulai!'e immuniteit. Vit onderzoek verricht 
bij mens en cliervolgen aanwijzingen dat zowel CD8 positive cytotoxische T1ymfocyten 
als CD4 positive T helper cellen betrokken zijn bij het elimineren van RSV. Bhmen 
deze T helper cellen ktmnen twee subgroepen onderscheiden worden: TH-l en T H-2 
cellen. TH-l zijn betrokken bij de cellulaire hmnuumespons, T H -2 cellen zijn betrokken 
bij de produktie van antilichamen en de inductie van eoshlofilie. Beide subgroepen 
zijn geactiveerd hl khlderenmet een infectie door RSV. De T-cellen kmmen echter ook 
bijdragen aan het ontstaan van inulluunpathologie. Neutrofiele granulocyten, 
eosinofiele gratltdocyten en lllestcellen worden eveneens geactiveerd en produceren 
ontstekingslnediatoren. Een hypothetische grafische \veergave van de cOfllplexe 
pathogenese in RSV huecties kan gevonden worden in hoofdstuk 2 (paghla 28). 
am het ziekteproces betel' te kurulen begrijpen is uitgebreid onderzoek naar de 
paUlOfysiologie gewenst. Een longitudinale cohort studie kan inzicht verschaffen welke 
kinderen genetisch gepredisponeerd zijn voor een T H-1 respolls en welke voor een TH-
2 respons wanneel' een RSV infectie zich voordoet. Zogenaatnde genetische 
polymorfismen zijn belangrijk hl het bepalen van gastheer vatbaarheid en ernst van 
een huectieziekte. Zo is recent aangetoond dat een polymorfisme hl de promotorregio 
van het gen dat codeert voor PlasmhlOgeen Activitor Inhibitor (P AI)-l de overlevhlg 
van kinderen lllet een rneningococcensepsis bepault 1. PolYl1l0rfismen in genen \velke 
voor cytokilles coderen of voor andere onderdelen van het ontstekhlgsproces in RSV 
tiuecties bepalen mogelijk mede de ernst van het beloop van de ziekte. 
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11.2 SUBTYPE VARIAllE 
Met behulp van monoclonale antilichamen kunnen twee subtypes van RSV 
onderscheiden ·worden: A en B. Antigene variatie in met nanle het G-eiwit is hiervoor 
verantwool"delijk. Beide subtypes circuleren zowel onafhankelijk als gezamenlijk 
gedurende een epidemie. De ontdekking van de twee subtypes heeft geleid tot diverse 
studies waarin een tl10gelijke relatie tussen subtype van het Vil'llS en de klinische ernst 
van de infectie 'iverd onderzocht. De resultaten van een studie naar een dergelijke 
relatie worden besclu'even in Hoofdstuk 3. Subtype A kwam vakel" voor dan subtype 
B (subtype A 150 (64.7%) vs 82 (35.3%) subtype B). Wij vonden geen relatie tussen de 
klinische ernst van de RSV infectie en subtype. Derhalve concludeerden wij dat nieuwe 
vaccins dienen te beschermen tegen zowel subtype A als subtype B. Het F-eiwit is voor 
een zeer groot deel gelijk in beide subtypen. Zodoende komt dit eiwit in aamnerking 
als antigene determinant van een vaccin. 
De l'esultaten van onze studie en van twintig andere studies zijn smnengevat in 
Tabel 10.1. Vit elf onderzoekingen bleek geen verschil in de klinische ernst tussen 
beide subtypen. Daarentegen bleek uit acht studies dat een ernstiger verloop van de 
infectie geassocieerd is met subtype A. Zo bleek bijvoorbeeld in de stueties 1, 8 en 13 dat 
Tabelll.1 Sfudies ,war dc relatil' fusscII k/illischc ernst Vall fell RSV infccfie ell subtype A of B 
Studie Eerste auteur Studie Land Aantal Methoden1 Resultalen 2 
nummer (referentie) I;l:eriode isolaten AlB} 
1 Hendry 4l 82 82 VS 51/34 RlNB 
2 Mufson 44 81 -86 VS 155/51 RIB A 
3 Hendry 45 83-85 VS 125/92 R/NB 
4 Taylor ~6 74-88 GB 328/169 RIB A 
5 Manto 41 65 -71 VS 64129 RlNB 
6 McConnochie 4' 76- 81 VS 95/62 P/B/MV A 
7 Mcintosh H 85-87 Australis 337/107 P/B 
8 Hall ~] 89 - 91 VS 858/351 RIB A 
9 Wilson 51 87-88 Canada 45/24 RIB = 
10 Wang ,2 93 Canada 1021250 P/B/MV 
11 Salomon 53 87 88 Argentln,iS 23/93 RlNB A 
12 Tsutsumi E4 80 89 Japan 77/52 RlNB 
13 Heikkinen ~ 87 92 Finland 1921134 P/B A 
14 Russi Yo; 85 87 Uruguay 19/22 PIB 
15 Walsh 57 88 91 VS 134/131 P/B/MV A 
16 Mufson 58 78 88 VS 319/86 RIB A 
17 Stark 59 85 88 VS 176/21 RIB 
18 Mlinaric w 91 VS 8/10 RIB 
19 Straliolto 61 90 Brazilie 2217 RIB B 
20 Hornsleth 62 93-95 Denemarken 31/54 PIB B 
21 Kne~ber 92- 95 Nederland 150/82 RlB/MV 
I R: retrospectieve studie, P: prospectieve stadie; NB geeft mm dal de parametcrs 7.1001' emst vall ziekle I'll/of eellS 
scorillgs1II0dellliet zijll bescllrevell, lerwijf B weergeeft dat dac parameters wei zijll bescllrClIell 
1 A geeft allJl dat subtype A met CCIl ernsfiger ziekteilt'loop was geassocil!erd, terwijI B IIm/geeft dat dit vaor sulltype 
B geldt ell no=." geeft 11a11 daf er gl!ell verschil ill klillische cmst tUssell bdde subtypes werd gevolldeJl 
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bronchiolitis, intensive care opnarne, \vheezing en zuurstofbehoefte significant vaker 
geassocieerd waren met subtype A. In de studies 7, 10 en 17 werd geen versehil 
gevonden in belangdjke parameters van ziekte zoals beademing en zuurstofsuppletie 
tussen patienten met een infeetie door subtype A of subtype B. De autelll'S van studie 
14 besclu'evenniet in getal de bestudeerde paralneters van ziekte. Er \verd geen verschil 
in de klinisehe ernst tussen subtype A en subtype B gevonden. 
Ons inziens ktmnen eonclusies over een mogelijke relatie h,ssen RSV subtype en 
ernst van een infectie aileen getrokken worden indien objectieve pararneters van ziekte 
geanalyseerd zijn. Daarnaast dient een ruultivariate analyse toegepast te worden 0111 
het effect van verstorende variablen uit te sluiten. Slechts vier studies hebben een 
dergelijke analyse toegepast, waaronder onze stu die besclu:ev~n in hoofdstuk 3. Twee 
van deze vier studies (studie 6 en 15) waren gebaseerd op dezelfde patientenpopulatie. 
Hiedn werd geconcludeerd dat subtype A geassocieerd is met een ernstiger vedoop. In 
studie 10 en onze eigen stu die bleek er geen relatie aanwezig te zijn tussen subtypes A 
en B en ernst van de RSV infectie. 
De resultaten van de rueta-analyses naar de relatie tussen klinische ernst van een 
RSV infeelie en het subtype vanhet virus worden weergegeven in figuur 11.1 en figuur 
11.2. Studies werden ge'includeerd inclien aan de volgende voonvaarden ,vas voldaan: 
(i) leeftijd jonger dan 24 maanden en (ii) de diagnose RSV infeetie was virologiseh 
bevestigd (tabell0.2). De uitkomst parameters waren zUlll'stofsuppletie en beadell1.ing. 
De Mantel-Haenzel gepoolde odds ratio en het 95% betrouwbaarheidsinterval voor 
zuurstofsuppletie bedroeg 1.2 (0.8 -1.8) (figuur 10.1). Dit houdt in dat er geen verband 
bestaat tussen RSV subtype en de behoefte tot zuurstofsuppletie. Een vergelijkbare 
Tabelll.2 Karaklcrisfickcll vall de studie gCi'llcludecrd ,Ioor de lIIcfa-mllllyst's mUIr de re/atit' fUS5ell klillisclie crt/st 
vall 1'1'11 RSV illfcelic ell subtype A of B 
Eerste auteur Aantal isolaten (AlB) Populatie Leeftijdscrilerium Uitkomsten 1 
Walsh 134/131 KlinisGh < 24 maanden B 
Straliotto 2217 Klinisch < 12 maanden O2) B 
Stark 101/16 Klinisch Onbekend O2) B 
McConnochie 95162 Klinisch < 24 maanden B 
Mcintosh 337/107 Klinisch Onbekend O2) B 
Heikkinen 1921134 Klinisch en poliklinisch Onbekend 0 21 B 
Taylor 328/169 Onbekend Onbekend 02)B 
Kneyber 150/82 Klinisch en poliklinisch < 12 maanden O2 ) B 
'B: bt'adcmillg, 02: ZlIlIrstofsllpplctic 
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OR (95% 81) 
Straliotto 0.1 (0.1 -1.4) 
Stark -----
-I 2.4 (0.5 - 11.4) 
Mcintosh 1 1.2 (0.8 - 1.9) 
Heikkinen 1 
2.0 (1.2 - 3.2) 
Taylor 
---I 1.5 (1.0 - 2.2) 
Kneyber 1 2.0 (1.0 - 3.4) 
Pooled 1.2 (0.8 - 1.8) 
Ten voorde[e van subtype B OR = 1 Ten voordele van subtype A 
Figutrr 11.1 ReslI/tatell vall dc meta-al/alysc lIaar de rclatie tUSSeIl de klillisc1/C ems! Va/I WI RSV ill/ectie ell 
sulltype A 0/ H, l1Iet Ills lIitkolllSt tlllmmeter ZllIlrsto/sllppletic, OR: Odds mHo. Voor referellties Villi de 
gebmikte studies wordt verwezw IlIlllr Tnllel 11.2 
Straliotto 
Stark 
McConnochie 
McIntosh 
Heikkinen 
Taylor 
Walsh 
Kneyber 
Pooled 
1 
i------II---_ 
1 
-----1- ----
1---
1--
OR (95% 81) 
0.3 (0.1 - 2.2) 
1.1 (0.1 - 9.7) 
8.8(1.1-69.7) 
1.2 (0.5 - 2.6) 
0.3 (0.0 - 3.9) 
6.4 (0.8 - 49.5) 
2.4 (1.0 - 6.0) 
1.7 (0.7 - 4.3) 
1.5 (0.4 - 5.0) 
Ten voordele van subtype B OR = 1 Ten voordele van subtype A 
Figutrr 11,2 RcslIltatell Va/I de mefll-llIlIllyse IIllar de rdlltie fUSSell de klillische erllst vml Cell RSV ill/celie ell 
sl/Mype A 0/ H, met Ills uitkolllsf parameter hcadclI/illg. OR Odds mtio. Vaor rc/erellfies VillI de gchmikte studies 
wordt verwezell IInal" Tnllel 11.2 
conc1usie kon worden getrokken met beh·ekking tot beademing (OR 1.5, 95% CI 0.4-
5.0, figuur 10.2). In beide analyses werd geen heterogeniteit gevonden. 
De hierboven genoemde gegevens geven sterke aanwijzingen op dat er geen relatie 
bestaat tussen klinische ernst van een RSV infectie en subtype A of B. 
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11.3 APNOE IN RSV INFECTIE 
Het optreden van een apnoe - gedefinieerd als een ademstilstand met een tijdsduur 
van 20 seconden of langer en/ of een bradycardie met cyanose - kan het eerste teken 
zijn van een RSV infectie. De resllitaten van een studie naar risicofactoren voor apnoe 
bij een RSV infectie in een gehospitaliseerde populatie, het risico op beademing indien 
een apnoe optreedt en het fisico op een recidief apnoe ,vorden beschreven in 
Hoofdstuk 4. Van alle opgenomen kinderen presenteerde 21 % zich met een apnoe. 
Deze kinderen ·waren significant jonger, hadden een lagere lichaaIllsternperatulu', 
hogere pCO, en vaker atelectase op de thoraxfoto vergeleken met kinderen zonder een 
apnoe. Een apnoe bij binnenkorllst confereerde een bijna twaalfvoudig verhoogd fisico 
op een recidief apnoe. Het optreden VaIl een recidief apnoe resulteerde in een ruitn 
zesmaal verhoogd risico op beademing. Het meerendeel van de apnoes trad 24 tot 48 
mu' na ziekenhuisopname op. Na logistische regressie analyse bleek leeftijd, met name 
S 21naanden, de enige onafhankelijke risicofactor voor het optreden van eell apnoe bij 
patienten met een RSV infectie. Carcliorespiratoire bewaking van deze kinderen is dan 
ook ge'indiceerd gedurende de eerste 48 lUll' na ziekenhuisopnaIne. Om nledische 
overconswnptie te voorkomen dienen sh'ikte criteria voor bewakingopgesteld te worden 
'. Vit onze studie kan worden geconcludeerd worden dat dit de volgende criteria 
betreft: apnoe bij bitmenkomst in het ziekenhuis en/ of leeftijd <; 2 maanden. Ook bleek 
dat de kinderen die zich niet presenteerden met een apnoe, doch itlhet ziekenhuis hun 
eerste episode VaIl apnoe doornlaakten, allen s 2 rnaaIlden oud waren, Op basis van 
de literatuur kan ook prematmiteit (met name een zwangerschapsduur <; 32 weken) 
als criterium toegevoegd worden "'.In tabell1.3 wordt het aantal kinderen aangegeven 
dat cardiorespiratoir bewaakt dient te worden om een eerste apnoe tijdens 
ziekenhuisopname (dus geen apnoe bij binnenkomst) te voorkomen. Deze Ntunber 
Needed to Treat (NNT) analyse wordt als voIgt berekend: 100/[het aantal apnoes itl 
een bepaalde populatie (%) - het aantal apnoes dat men zich veraodooft om te missen, 
(dit is 0%)]. Zes (4.1%) kitlderen maakten itl het ziekenhuis hun eerste apnoe door. De 
NNT bedraagt dan 100/4.1% is 25 kinderen. Dit betekent dat 25 kinderen 
cardiorespiratoir be\vaakt dienen te worden 0111 bij een patient een eerste apnoe te 
ontdekken. Twee van de zes patienten Inet een eerste apnoe tijdens ziekenhuisopnaIne 
behoefden beademing. 
De oorzaak van een apnoe bij patienten filet een RSV infectie is vooralsnog 
onduidelijk. Gesteld kan worden dat onderliggende onrijpheid van het 
ademhalingscenh'ull1 een belaIlgrijke risicofactor vornlt voor een apnoe tijdens een 
RSV infectie. Dit gegeven is gebaseerd op onze bevinding dat aileen leeftijd 
onafhankelijk geassocieerd is met eell apnoe. Een ernstig verloop van de ituectie geeft 
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Tabelll.3 Effect vall CIlrdiorespirafoire be-wakillg ill RSV in/celies 
Aantal kinderen met een RSV infectie mel een apnee bij opname 381185 
Aantal kinderen met een RSV infectie met een apnoe gedurende ziekenhuisepname 241185 
Aantal kinderen met een RSV infectie mel een apnee bij opname en gedurende opname 181185 
Aantal kinderen met een RSV infectie en aileen een apnoe gedurende ziekenhuisopname 6/185 
Monilor indicalie Apnoel Aanlal gemisle apnoes wanneer NNT 
Graeps-grootte indicatie niel toegepast 
AUe kinderen z~nder apnoe bij 6/147 o 25 
opname 
Leeftijd ~ 2 maanden en/of 6/115 o 19 
zwangerschapsduur ~ 32 weeks 
Leeftijd ~ 2 maanden en/of 61118 o 20 
zwangerschapsduur ~ 34 weeks 
Leeftijd ~ 2 maanden en/of 6/126 o 21 
zwangerschapsduur ~ 37 weeks 
Leeftijd .$ 2 maanden 6/101 o 17 
Zwangerschapsduur ~ 37 weken 3150 3 17 
Zwangerschapsduur ~ 34 weken 2121 3 11 
NNT: IIIl1llbcr-IIceded-to-lreat 
geen aanleiding tot het optreden van een apnoe tijdens een RSV infectie . Bij de mens is 
aangetoond dat verandering van chelnoreceptoren in de larynx kan resulteren in een 
versterkte respons en tot een apnoe watmeer deze receptoren worden gestillltlleerd 7. 
Pickens en collega's beschreven het karakel' van een apnoe)n een RSV infectie als 
gecombineerd (zowel cenh'aal als obsh-uctiei) 8. Zij observeerden dat een apnoe gepaard 
ging filet slikken en 11Oesten, en conc1udeerden hieruit dat beschennende reflexen in 
de luchtwegen de ademhaling onderdrukken. 
Het verdeI' kal'akteriseren door lniddel Vatl polysOlnnografie van een apnoe tijdens 
een RSV infectie is noodzakelijk am meer inzicht in de pathofysiologie van dit proces 
te verkrijgen. Een grote 111ulticentrlsche stu die is nodig onl aanvuHende criteria voor 
cardiorespiratoire bewaking op te ktumen stell en. 
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11.4 THORAXFOTO'S BIJ PATIENTEN MET RSV INFECTIES 
Bij ruim 70% van aile kinderen die worden opgenomen inhet ziekenhuis in verband 
met een RSV infeelie wordt een thoraxfoto gemaakt '. Hyperinflatie, atelectasen en/ of 
infiltraten zijn frequente bevindingen. Er bestaat eehter geen relatie tussen deze 
bevindingen en het klinisch beeld 10 De rcsllltaten van een studie naar voorspellcrs 
voor een nonnale thoraxfoto bij patienten Inet een RSV infcctie worden besclu'even in 
Hoofdstuk 5. Een groep van patienten met een hoge waarschijnlijkhcid op een nonnale 
thoraxfoto -gedefinieerd aIs de afwezigheid vanhyperinflatie, atelectascn en infiltraten 
- kan met behulp van dit voorspellingstnodel onderscheiden worden. 
In onze popniatie werd bij 202 kinderen ecn thoraxfoto getnaakt. Hiervan waren er 
75 niet afwijkend, Een nonnale thoraxfoto kon voorspeld worden op basis van een 
toenan1e in leeftijd en gcboortege'ivicht, de aanwezigheid van rhinitis, de afwczigheid 
van inh'ekk41gcn en een toename in Sa02• Bet oppervlak onder de Receiver Operating 
Characteristic (ROC) curve was 0.80, hetgeen aangeeft dat het model een goed 
onderscheid biedt heeft tussen nonnale en abnonnale thoraxfoto's. Het tnodel 'iverd 
geh'm1sfonneerd naar een score kaart OIn de berekening van de waarschijnlijkheid op 
een normale tharaxfoto te vergemakkelijken. 
Menkan zich afvragen 'ivat de indica ties zijn O1l1een thoraxfoto te 111aken bij kinderen 
Inet RSV infecties. Da'ivson en collega's noetnden intensive cm'e opnatne, aanwezigheid 
van onderliggend hart- of longlijden en een onverwachte achteruitgang in de klinische 
conditie van de patient 11, Eriksson en coUega's suggereerden dat de aanwezigheid 
van atelectasen zeer suggestief is vooreen RSV infectie in combinatie tnet een bacteriele 
sllperinfectie met pathogenen zoals Streptococcus p"eulIloliae en Haelllopliilus illfluellzae, 
zodat een thoraxfoto noodzakclijk ZOll zijn 12. Ed1ter, dit geldt met natne voor patienten 
ouder dan 12tnaanden. Wij stellen voor een thoraxfoto te Inaken bij patienten 111et een 
SOlnscore lager dan 52, of indien er een onvenvachte achteruitgm1g is in de klinische 
conditie van de patient. Bet aantal thoraxfoto's kan significant gereduceerd worden 
Inet deze criteria, Prospectieve validatie van het tnodel is noodzakelijk 0111 de 
toepasbaarheid op andere locaties te toetsen, 
In kinderafdelingen in Nederland worden vaak tharaxfoto's gemaakt bij zuigelingen 
en peuters tl1et een RSV infectie. De resultaten van onze studie geven echter aan dat dit 
slechts geYndiceerd is in een bepcrkt aantal patienten, 
11.5 NOSOCOMIALE RSV INFECTIES 
RSV wordt beschouwd ais een belm1grijke verwekker van nosocOIniale infecties. 
Deze kmu1en lciden tot een toename in 1110rbiditeit en sterfte onder ll1Ct na1l1e jonge 
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kinderen. Ongeveer 4% tot 7% van aIle gehospitalisecrde kinderen rnaakt een 
nosocOlniale RSV infectie door 15. Een nosocOlniale infectie door RSV zou vaker 
aanleiding geven tot een bronchiolitis en/ of pneurllonien of een verlengde opnanleduuf. 
Een toegenOlnen rnortaliteit ,vordt gezien onder kinderen Inet een congenitale 
hartziekte, bronchopulrnonale dysplasie of prelnaturiteit 1:\14. :Met narne de cOlnbinatie 
van een congenitale hartziekte en een nosocomiale RSV infectie geeft aanleiding tot 
een verhoogde sterftekans 15. 
hl Hoo£dstuk 6 ""vorden de resultaten beschreven vaneen studie naar nosocomiale 
RSV infecties (NA-RSV). Het aanta! NA-RSV werd bestudeerd en karakteristieken 
,verden vergeleken Inet die bij zuigelingen nlet een buiten het ziekenhuis venvorven 
RSV infectie (CA-RSV). Het percentage patienten met een NA-RSV (het aantal kinderen 
met een NA-RSV gedeeld door het totaal aantal opgenomen kinderen jonger dan 12 
maanden gedtu'cnde het RSV seizoen) bedroeg 2.7% en vertoonde per seizoen een 
dalende tendens. Deze daling is waarschijnlijk een gevolg van de toepassing van 
specifieke richtlijnen tel' preventie van nosocOlniale RSV infecties in ons ziekenhuis. 
Deze richtlijnen Olllvatten handenwassen door ziekenhuispersoneel en de isola tie 
van RSV gelnfecteerde patienten. Het risico op het verkrijgen van een NA-RSV 
gerelateerd aan de dutu' van opnrune voor onderliggend lijden is weergegeven in figuur 
11.3. 
Het klinisch beeld van patienten met NA-RSVbleek vergelijkbaar met dat van CA-
FignUT 11.3 Aallfalllosoco1lliaie RSV illfixties vl.'rseiekell met de dllllr vall 0pl/allle (loor oJ1dcrliggclld lijdcll 
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RSV. Het significante verschil tussen beide groepenmet beh'ckking tot geboortegewicht 
lijkt het gevolg van de algemene zickenhl1ispopl1latie van ons ziekenhuis in plaats 
van een wcrkelijk gevolg van NA-RSV. De karakteristieken van ziekenhl1isopname 
waren ook vergelijkbaar tussen NA-RSV en CA-RSV. Aile kinderen (n ~ 4) met 
bronchopl1lmonale dysplasie (BPD) en een NA-RSV werden beademend. Dit in 
tegenstelling tot kinderen met BPD en een bl1i ten het ziekenhuis verworven RSV infectie, 
waarvan er slechts twee beademingsbehoeftig waren. Wij concllldeerden dat Inet 
uitzondering van patienten tllet BPD en een nosocOlniale RSV infectie, nosocomiale 
RSV infecties in onze shIdie niet gepaal'd gaan tnet een ernstiger ziekteverloop dan 
buiten het ziekenhuis venVOl'ven RSV infecties. 
11.6 OPNAMEDUUR IN RSV INFECTIE 
Het gebruik van een voorspellingsmodel kan helpen bij de beslissing wanneer 
bepaalde therapien voorgeschreven nloeten worden. Oak kllnnen patienten 
ge'identificeel'd worden die in arunerking kOlnen voor preventieve lnaah'egelen, Recent 
hebben Moler en Ohmit een t110del onhvikkeld waru'J1lee de opnmneduul' voor patienten 
tnet een RSV infectie voorspeld kon worden 16. Zij veronderstelden dat aan de hand 
van een opnanleduur ~ 7 dagen een onderscheid genlaakt kon worden 'was tussen 
ernstige en niet ernstige infecties. De gemiddelde opnameduur in hun stu die bedroeg 
vier dagen. Vom'spellers voor een opnmlledllUl' ~ 7 dagen waren gewicht, congenitaal 
hartlijden, failure to thrive, prematuriteit, bronchopulmonale dysplasie, longlijden 
andel's dml BPD, diverse ziekten, vroege noodzaak tot beademing en vroege start van 
ribavirine. Het model had een goed onderscheidend vennogen zoals bepaald door het 
oppervlak onder de ROC curve. Het model werd gevalideerd op onze popl1latie. De 
resultaten hiervan zijn besclu'even in HoofdshIk 7. Het model bleek een slechte 
voorspeller amlgezien er geen goede balans ,vas tussen de sensitiviteit en het aantal 
vals positieven. De gemiddelde opnamedulu' in onze studie was twee keel' zo groat als 
die van het Michigan databestand, zodat wellicht geldt dat een drempel van zeven 
dagen gcen goed onderscheid mogelijk maakt tussen ernstige en niet ernstige infecties. 
De lllediaan is dan ,vellicht een betere pru'ameter. Derhalve ,verd een t110del onhvikkeld 
·waannee een opnameduur ~ 9 dagen (de 111ediaan in onze populatie) kon worden 
voorspeld. OnafhatIkelijke variabelen waren gewicht en zuurstofsl1ppletie. Echter, 
. het oppervlak onder de ROC curve bedroeg slechts 0.65. Uit de valida tie bleek dat het 
een slecht voorspellend l1l0del was. Wij concludeerden dat de opnmneduur van 
kinderen I1let een RSV infectie niet te voorspellen is en niet de ernst van een infectie 
weerspiegelt. Deze bevinding heeft belangrijke implicaties aangezien in veel 
t11ulticenh'isch onderzoek de opnm11eduur ais llitkm11st parm11eter werd gebruikt 0111 
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de klinische respons te bepalen. 
11.7 BEHANDELING EN PREVENTIE VAN RSV INFECTIES 
11.7.1 BEHANDELfNG VAN RSV INFECTIES 
Onderzoek naar de behandeling van RSV infecties heeft zich gericht op de 
toepassing van corticosteroiden, bronchodllatoren en antivirale lnedicatie. 
Gezien het toenelllende inzicht dat bronchiolitis een imlllUlUlpathofysiologisch 
proces is, lijkt het gebruik van corticosteroiden voor de hand liggend. De effectiviteit 
van corticosteroj'den is echter niet aangetoond 17. Ook zijn corticosteroj'den onwerkZaaIll 
als profylactictun tegen het herhaald wheezing dat vaak optreedt aansluitend aan een 
RSV bronchiolitis. Derhalve wordt het gebruik van corticosteroiden afgeraden. 
VaIHvege de klinische overeenkOlllsten ll1et astnla ,vaarbij bronchodilatoren zeel' 
effectief zijn, worden bronchoclilatoren frequent gebruikt bij kinderen met een RSV 
infectie. De resultaten van diverse studies zijn tegenstrijdig en leveren geen bewijs 
VOOl' het effect van bronchodilatol'en 18,19. Bij de individuele patient kan een 
proefbehandeling worden overwogen. Bij voldoende effect kan de therapie zonodig 
gecontinueerd ·worden. 
Ribavirine is het enige antivirale middel dat geregistreerd is voor het gebl'llik onder 
kinderen rllet RSV infecties. Contl'ovel'se over het gebl'uik is ontstaan nadat de 
aanvmlk:elijk gllllstige resultaten VaIl studies uit de jal'en '70 en '80 werden ,veersproken 
door negatieve resultaten uit recente studies. Bovendien waren de studies lut de jaren 
'70 en '80 lllethodologisch niet sterk. Hoge kosten en mogelijke teratogene en 
cal"Cinogene bij,verkingen VaIl ribavil'ine hebben eveneens bijgedragen aan de nog 
steeds bestaande controverse. Ribavirine wordt tegenwoordig nauwelijks llleer 
gebruikt 20. Het gebruik dient aileen overwogen te worden bij de immuun-
gecolllpromitteel'de patient met een ernstig ziekte verloop. 
RSV immuunglobuline heeft geen therapeutische waarde 18. Een bacterii;Je 
superinfectie kOlllt zelden voor 21. Er ,verd geen therapeutisch effect gevonden VaIl het 
1'0utinelllatig gebruik van antibiotica tel' preventie van een superinfectie 22,23. 
11.7.2 PREVENTIE VAN RSV INFECTIES 
Preventie VaIl RSV infecties kan door rniddel VaIl actieve en passieve inulllullsatie. 
In de jaren '60 had vaccinatie 11let een fonnaline gej'nactiveerd vaccin dl'anlatische 
gevolgen. Kinderen die het vaccin kregen, ontwikkeldenna infectie met wild type RSV 
een ernstiger ziektevel'loop lllet toenatne in sterfte. Op basis van jarenlang ondel'zoek 
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zijn recent een aantal interessante potentiele vaccins beschikbaal' gekOlnen zoais 
BBG2Na, PFP-2 vaccin en een verzwakt cold-passaged tell1peratlfre sel1sitive n1utantvaccin 
zeals cpts-248, cpts 248/404 en cpts-530 /1009. De ill1nnmogeniciteit van deze vaceins 
is in diermodellen aangetoond 2,1-26. PFP-2 vaccins zijn getest bij de Inens. Vaccinatie 
resulteerde niet in een reductie van hct aantal respiratoire ziekten door RSV 27,21:1, Cpts-
vaccins waren weI effectiefbij kinderen ouder dan zes n1aanden,lllaar veroorzaakten 
neusverstopping bij zuigelingen jonger dan twee maanden 29, De ont'ivikkeling van 
een vaccin tegen I~SV kan betlloeilijkt worden door de aanwezigheid van Inaternale 
antistoffen die de inunulinrespons van de zuigelingen kluu1en onderdrukken, en het 
verminderd vennogen van zuigelingen 0111 te reageren op virale glycoprotelnen in 
vaccins. 
Onderzoek naar de effectiviteit van passieve illllnunisatie heeft geleid tot de 
registratie van twee middelen: RSV ill1nnllmglobuline (RSV IVIG) en gehumaniseerde 
monoclonale antilichamen gericht tegen het F eiwit (palivizumab). In de PREVENT-
studie werden prematuur geboren kinderen en kinderen met BPD profylactisch 
behandeld met RSV -IYlG of placebo. Het gebruik van RSV -IVIG leidde tot een reductie 
van 41 % van het aantal RSV geassocieerde ziekenhuisopnmnes, evenals ecn reductie 
van 53% van het totaal aantal dagen in het ziekenhuis 30. Bet gebruik van palivizlln1ab 
bij kinderen jonger dan 24ll1aanden met BPD, en bij prematuur geboren (<; 35 weken) 
kinderen jonger dan 6 Inaanden resulteerde in een reductie van 55°,,{) van het aantal 
RSV geassocieerde ziekenhuisopnames (78% reductie in de gl'Oep prematuur geborenen 
en 39% reductie in de BPD gl'Oep). Een reductic van 47% werd gezien in het aantal RSV 
geassocieerde ziekenhuisopnames bij kindel'en geboren voor een zwangcrschapsduur 
van 32 weken, tenvijl bij kindcren geboren na een zwangerschapsduur van 32-35 
\veken een reductie van 80% werd gevonden. Deze laatste groep vonnt de grootste 
groep prematuur geboren kinderen Inet een zwangerschapsduur s 37 weken. Het 
gebruik \~an palivizlunab leidde niet tot een daling van het aantal kinderen dat 
beademing nodig had. 
De indica tics voor het gebl'uik van palivizumab worden sterk bei'nvloed door 
regionale en (inter)nationale verschillen in de gevolgen van infecties door RSV. 
Verschillen zijn bijvoorbedd het aantal prematuu!' geboren kinderen met of zonder 
clu'onisch longlijden, de ernst van de RSV infectie en het percentage risico-patienten 
dat opgenOlnen dient te worden. Dit percentage vaJ'ieertvan 3% in Uleer recente studies 
tot 25% in de oorspronkelijke publica ties 31. Toepassing van RSV -IVIG op grote schaal 
wordt beperkt door de hoge kosten en de intraveneuze toedieningsvorn1, Palivizltn1ab 
is daarentegen makkelijker toe te dienen (intra-musculail'). Het gebruik van RSV-IYlG 
lijkt achterhaald sinds het beschikbaal' komen van palivizlunab. Echter, kosten-baten 
analyses zijn noodzakelijk 0111 de juiste indicaties VOOl' het gebruik van palivizlunab 
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vast te stellen. Uit deze analyses voIgt de Number Needed to Treat die acceptabel is in 
relatie tot de kosten en nadelen van prophylaxe Vaal' zowel patienten als dokters. 
11.8 LANGE TERMIJN EFFECTEN VAN RSV INFECTIES 
De mogelijke aanwezigheid van een relatie tussen RSVbronchiolitis op jonge leeftijd 
en het ontstaan van ashna op latere leeftijd is intensief bestudeerd en het ondenverp 
van langdurig en hcftig debat. Twee hypothesen zijn voorgesteld: (i) RSV broncholitis 
en astma zijn twee verschillende entiteiten lllet een vergelijkbaar klinisch beeld, of (ii) 
RSV bronchiolitis identificeert de gepredisponeerde gastheer die na het doonnaken 
van de bronchiolitis ashna ontwikkeld. De resultaten van een kwantitatieve revie\v 
naar een 1110gelijke relatie worden besclU'even in Hoofdshtk 9. Gcconh'oleerde foIlow-
up studies met gehospitaliseerde patienten jonger dan 12 maanden met een virologisch 
be'wezcn RSV infectie, werden geanalyseerd. Met behulp van Medline werden 30 
retrospectieve en prospectieve case control of longitudinale cohort studies gevonden 
die gepubJiceerd waren tussen januari 1978 en december 1998. Slechts zes studies 
voldeden aan aIle inclusie criteria. 
De odds ratio voor wheezing daalde van 3.8 (95% CI1.6 - 9.3, P < 0.001) gedurende 
de eerste vijf jaar na een RSV bronchiolitis, naar 2.3 (95% CI 1.2 -4.5, P ~ 0.004) bij vijf 
tot tien jaar follow-up. Recurrent 'wheezing - gedefinieerd als drie of Ineel' episoden 
van wheezing vastgesteld door een arts of het gebruik van bronchodilatoren in het jaar 
voorafgaande aan follmv-up - was niet geassocieerd 111et RSV bronchiolitis op 
zuigelingenleeftijd na vijf of meer jaren follow-up (OR 2.4, 95% CI 0.7 - 8.4). Daarnaast 
werd geen associatie gevonden tussen RSV bronchiolitis op de zuigelingenleeftijd en 
het voorkOlnen van een positicve anamnese voor atopie of een positieve fanlilie-
anamnese voor atopie of astma. ''''ij concludcerden dat het doonnaken van een RSV 
bronchiolitis op de zuigelingenleeftijd geen oorzaak is van astma op latere leeftijd. 
Tabel11.4 VcrgelijkillS fliSSI'll RSV ll(olIcllioJitis ell flsflllf1 
RSV bronchiolitis Astma 
T - cellen COB (+) C04 (+) 
T-helper groepen 
Invloed van eosinofielen + +++ 
Atopie in de voorgeschiedenis +++ 
Fami1ie-anamnese positief voor atopie en/of astma + 
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De resultaten van onze k,vantitatieve revielV worden ondersteund door de 
toegenonlen kelmis over de pathogenese van RSV infecties. Karakteristieken van asnna 
en bronchiolitis worden samengevat in tabel 11.4. CD4 positieve T cellen zijn een 
belangrijke component bij ashna, terwijl bij infecties door RSV CDS positieve T cellen 
een belangrijke rol hebben ". Voorts vervullen in tegenstelling tot de situatie bij in 
ashna, eosinofielen in RSV bronchiolitis geen hoofdrol". Een dysbalans van het T H -1/ 
TH-2 pal'adigme in hetvoordeel van TH-2 ,vordt gezien bij kinderenlnet asnna, terwijl 
RSV ook een T H -lrespons induceert. 
IgE speelt een belangrijke rol in de pathogenese van ashna ". Het sermn IgE gehalte 
is echter niet verhoogd in RSV bronchiolitis ". Of schoon RSV-specifiek IgE werd 
gevonden in nasopharyngeaal spoelsels of bronchoalveolaire lavages gedurende de 
acute infectie, bleken de waarden hiervan niet voorspellend VOOl' het oph'eden van 
recurrent wheezing op de leeftijd van zeven tot 10 jaar 36, Ben overeenkOlnst tussen 
astma en RSV bronchiolitis betreft de verhoogde concentraties van eosinofiel cationic 
protein (ECP). Het bepalen ervan gedurende een RSV bronchiolitis blijkt niet 
voorspellend te zijn voor welke kinderen ,vel en welke kinderen niet broncho-
obsh'uctieve klachten op latere leeftijd ontwikkelen ". Andere virale infecties kmUlen 
ook aanleiding geven tot een verhoogde ECP concentratie ". 
De long funetie gemeten bij kinderen die een RSV bronchiolitis hadden 
doorgemaakt(zoals PVC, PRC, luchtwegresistentie, peak flow en compliance), bleek 
niet vernlinderd te zijn ten opzichte van controles 39,40, Wei werd aangetoond dat 
kinderen die een RSV bronchiolitis doonnaakten een initieel lagere longftmctie 
hadden 41, Deze pre-existente afwijkingen in longfunctie kunnen een risicofador zijn 
vaal' lagere luchtweginfecties lnet \vheezing gedtu'ende het eerste levensjaal' 3-l,.u, 
Kinderen die een RSV bronchiolitis doormaken dienen ten minste tien jam' gevolgd 
te worden onl daannee te onderzoeken ,velke ontstekingsnlediatoren die gedurende 
de acute ziekte geproduceerd worden (gemeten in neusspoelsels), vermltwoordelijk 
zijn voor (recmrent) wheezing na de RSV bronchiolitis. 
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